
•Title: A Randomized Double-Blind Phase 4 Study to Evaluate the Safety and Proportion of 
Subjects With Fistula Healing in 2 Dose Regimens of Entyvio (Vedolizumab IV) in the Treatment 
of Fistulizing Crohn’s Disease (ENTERPRISE)
Study ID: [REMOVED]
Protocol Approve Date: 20 April 2017
Certain information  within this protocol has been  redacted (ie,  specific content is masked irreversibly from 
view with a black/blue bar) to protect either personally identifiable information (PPD) or company 
confidential information (CCI). 
This may include, but is not limited to, redaction of the following: 
Named persons or organizations associated with the study.
Proprietary information, such as scales or coding systems, which are considered confidential  
information under prior agreements with license holder.
Other information as needed to protect confidentiality of Takeda or partners, personal  information, or 
to otherwise protect the integrity of the clinical study.
1.0 TITLE PAGE
PROTOCOL AMENDMENT 
A Randomized Double -Blind Phase 4 Study to Evaluate the Safety and Proportion of 
Subjects With Fistula Healing in 2 Dose Regimens of Entyvio (Vedolizumab IV) in the
Treatment of Fistulizing Crohn’s Disease (ENTERPRISE)
Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn’s Disease
Sponsor: Takeda Development Center Americas, Inc.
One Takeda Parkway
Deerfield, IL 60015
Takeda Development Centre Europe, Ltd.
61 Aldwych
London, WC2B 4AE
United Kingdom
Study Number: Vedolizumab -4003
IND Number: 009125 EudraCT Number: 2015 -000852-12
Compound: Vedolizumab IV
Date: 20April 2017 Amendment Number: 05
Amendment History : 
Date Amendment Number Amendment Type Region
02 September 2015 Initial Protocol, Version 1 Not applicable Global
29 February 2016 Amendment 01, Version 1 Substantial Global
06 May 2016 Amendment 02, Version 1 Non-substantial Global
11 May 2016 Amendment 03, Version 1 Non-substantial France
08 July 2016 Amendment 04, Version 1 Non-substantial France
20 April 201 7 Amendment 05, Version 1 Substantial Global
CONFIDENTIAL PROPERTY OF TAKEDA
This document is a confidential communication of Takeda. Acceptance of this document constitutes the agreement by 
the recipient that no information contained herein will be publ ished o r disclosed without written authorization from 
Takeda except to the extent necessary to obtain informed consent from those persons to whom the drug may be 
administered. Furthermore, the information is only meant for review and compliance by the reci pient, his or her staff, 
and applicable institutional review committee and regulatory agencies to enable conduct of the study.
Vedolizumab IV
Vedolizumab-4003 Page 2 of 130
Protocol Incorporating Amendment 05 20 April 2017
CONFIDENTIAL1.0 ADMINISTRATIVE INFORMATION 
1.1 Contacts 
A separate contact information list will be provided to each site.Takeda Development Center Americas, Inc. (TDC Americas) sponsored investigators per 
individual country requirements will be provided with emergency medical contact information 
cards to be carried by each subject.
General advice on protocol procedures should be obtained through the monitor assigned to the 
study site. Information on service providers is given in Section  3.1and relevant guidelines 
provided to the site.
Contact Type/RoleUnited States/Canada 
ContactEurope
Contact
Serious adverse event and pregnancy reporting
Medical Monitor(medical advice on protocoand compound)
Responsible Medical 
Officer 
(carries overall responsibility for the conduct of the study)PPD
Vedolizumab IV
Vedolizumab-4003 Page 3 of 130
Protocol Incorporating Amendment 05 20 April 2017
CONFIDENTIAL1.2 Approval 
REPRESENTATIVES OF TAKEDA This study will be conducted with the highest respect for the individual participants in accordance 
with the requirements of this study protocol  and also in accordance with the following:
!The ethical principles that have their origin in the Declaration of Helsinki.
!International Conference on Harmonisation E6 Good Clinical Practice: Consolidated 
Guideline.
!All applicable laws and regulations, including, without limitation, data privacy laws, clinical 
trial disclosure laws, and regulations.
SIGNATURES
The signature of the responsible Takeda medical officer can be found on the signature page.Electronic Signatures may be found on the last page of this document.
PPD
Vedolizumab IV
Vedolizumab -4003 Page 4of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL1.3 Protocol Amendment 05 Summary of Changes
Rationale for Amendment 05
This document describes the changes in reference to the Protocol Incorporating Amendment 5.
The primary  reasons for thi s amendment are to update the protocol to remove the eligibilit y 
requi rement for a seton to be placed before randomizat ion, to clarify  inclusi on and exclusio n 
criteria, to revi se the sample size calculat ion, to add a fut ility analysis, and to consolidate local 
country  (France) m odificati ons into a single global am endment. Other minor clarifications for 
procedures are included. Minor grammat ical, editorial, and formatting changes, for clarificat ion 
purposes only, are not listed below nor in Appendix K. For specific descript ions of text changes 
and where the changes are located, see Appendix K.
Changes in Amendment 05
1.Removed the requi rement for perianal seton placement as part of standard of care before 
rando mizat ion.
2.Change d the requirements for seton removal, if applicable, from 10 to 22 weeks after 
rando mizat ion to 6 to 14 weeks after randomizat ion.
3.Added a secondary endpo int to evaluate fistulas healed at both Week 22 and Week 30.
4.Modified inclusion criterion 6 such that both France- specific and global language is presented.
5.Modified inclusio n and exclusio n criteria to allow addit ional types of ant ibiotic to reduce the 
incidence of abscess.
6.Modified inclusio n criteria 10 and 11 per updated safet y language.
7.Modified exclusi on criteria 6 and 7 per updated safety  language.
8.Modified exclusio n criterion 17 to rem ove the option of 5 half lives as washout window.
9.Modified exclusio n criterion 19 to also exclude subjects with prior exposure to etrolizumab or 
anti-mucosal  addressin c ell adhesi on m olecule -1 therapy  therapy .
10.Reduced the study  sample size from  126 (63 per group) to 100 (50 per group).
11.Increased the number of study  sites from 30 to 40.
12.Added a stratificat ion factor f or seton or no seton at randomizat ion.
13.Added a fut ility analysis after 25 subjects complete the primary  endpoint assessment 
(Week 30).
14.Updated background information per the current Investigator’s Brochure.
15.Revised the rationale for the proposed study  given that perianal seton replacement no longer 
requi red.
16.Revised the benefit -risk assessment given that perianal seton replacement no longer required.
Vedolizumab IV
Vedolizumab -4003 Page 5of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL17.Modified the Schemat ic of Study  Design given the changes in this amendment.
18.Changed the maximum dose of oral corticosteroids fro m 30 to 20 m g/day  and clarified that
tapering schedule provided is an example of one schedule; allowed for return to baseline 
corticosteroi d dose.
19.Modified the criteria for discont inuat ion or wi thdrawal  to add m onitoring for l eukopenia and 
lymphopenia and to clarify other criteria.
20.Clarified the medical history  collect ion of smoking/nicotine usage status and collect ion of all 
medicat ions for Crohn’s disease.
21.Clarified vi tal signs collect ion.
22.Clarified that all fistula draining assessments are preferably be done by the same qualified 
designee.
23.Clarified that confirmat ion from a central  reader is required for magnetic resonance imaging 
eligibilit y.
24.Added the superficial category  for the Parks classificat ion.
25.Clarified the neutralizing anti- vedo lizumab antibodies (AVA) analysis.
26.Replaced the exis ting Contraception and Pregnancy Avo idance language with 4 new 
subsect ions containing updated language for contraception and pregnancy  avoi dance, and 
clarified in Appendix Cthat highly effect ive contraception must be used.
27.Clarified the pregnancy  form requi rement f or female partners of male subjects.
28.Added a requirement to document missed doses of antibiot ic co mpanio n medicat ion.
29.Changed wording in the safet y section from severity tointensity .
30.Added frequency  to list of pretreatm ent event and adverse event reporting.
31.Clarified that AVA titers are analyzed. 
32.Clarified that the subject diary for Crohn’s Disease Act ivity Index is el ectroni c.
33.Clarified when serum  versus urine pregnancy testing done.
34.Clarified that pregnancy  testing i sperformed before study  drug dosing at dosing visits.
35.Added an invest igator responsibilit y per updated Internat ional Conference on Harmonisat ion
guideline .
Vedolizumab IV
Vedolizumab -4003 Page 6of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALINVESTIGATOR AGREEMENT 
I confirm that I have read and that I understand this protocol, the Invest igator’s Brochure, the 
vedo lizumab IV (Entyvio) package insert and any other product information provided by the 
sponsor. I agree to conduct this study in accordance with the requirements of this protocol and also 
to protect the rights, safety , privacy, and well-being of study  subjects in accordance wit h the 
following:
The ethical principles that have their origin in the Declaration of Helsinki.
International Conference on Harmonisation, E6 Good Clinical Pract ice: Conso lidated 
Guideline.
All applicable laws a nd regulat ions, including, without limitat ion, data privacy laws and 
regul ations.
Regulatory  requi rements for reporting serious adverse events defined in Sect ion10.2 of this 
protocol .
Terms outlined in the stud y site agreement.
Responsibilit ies o f the invest igator ( Appendix B).
I further authorize that my  personal informat ion may be processed and transferred in accordance 
with the uses contem plated in
 Appendix Dof this protocol .
Signature of Investigator Date
Invest igator Name (print or ty pe)
Invest igator’s Tit le
Locati on of  Facilit y (Ci ty, State/Provi nce)
Locati on of  Facilit y (Country )
Vedolizumab IV
Vedolizumab -4003 Page 7of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALTABLE OF CONTENTS
1.0 ADMINISTRATIVE INFOR MATION ........................................................................... 2
1.1 Contacts ..................................................................................................................... 2
1.2 Approval .................................................................................................................... 3
1.3 Protocol  Amendment 05 Summary  of Changes .......................................................... 4
2.0 STUDY SUMMARY .................................................................................................... 13
3.0 STUDY REFERENC E INFORMATION ...................................................................... 16
3.1 Study -Related Responsibilit ies................................................................................. 16
3.2 Principal Invest igator/Coordinating Invest igator ...................................................... 16
3.3 List of Abbreviat ions............................................................................................... 17
3.4 Corporate Identificat ion........................................................................................... 19
4.0 INTRODUCTION ......................................................................................................... 20
4.1 Background ............................................................................................................. 20
4.1.1 Disease and Current Treatments ......................................................................... 20
4.1.2 Vedolizumab ...................................................................................................... 20
4.1.2.1 Nonclinical ................................................................................................... 21
4.1.2.2 Hum an Experience ....................................................................................... 21
4.2 Rationale for the Proposed Study ............................................................................. 23
4.3 Benefit:Risk Assessment .......................................................................................... 23
5.0 STUDY OBJECTIVES AND ENDPOINTS .................................................................. 25
5.1 Object ives................................................................................................................ 25
5.1.1 Primary Object ive.............................................................................................. 25
5.1.2 Secondary  Object ive.......................................................................................... 25
5.1.3 Addit ional Objectives ......................................................................................... 25
5.1.4 Safety Objective .................................................................................................25
5.2 Endpoints ................................................................................................................. 25
5.2.1 Primary Endpo ints............................................................................................. 25
5.2.2 Secondary  Endpo ints.......................................................................................... 26
5.2.3 Addit ional Endpo ints......................................................................................... 26
5.2.4 Safety Endpo ints................................................................................................ 27
6.0 STUDY DESIGN AND DES CRIPTION ....................................................................... 28
6.1 Study  Design ........................................................................................................... 28
6.2 Justification for Study Design, Dose, and Endpoints ................................................ 29
6.3 Prem ature Terminat ion or Suspension o f Study  or Study  Site................................... 29
Vedolizumab IV
Vedolizumab -4003 Page 8of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL6.3.1 Criteria for Premature Terminat ion or Suspension of the Study .......................... 29
6.3.2 Criteria fo r Premature Terminat ion or Suspension of Study  Sites....................... 30
6.3.3 Procedures for Premature Termination or Suspension of the Study  or the 
Parti cipation of  Study  Site(s).............................................................................. 30
7.0 SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS .............. 31
7.1 Inclusio n Cri teria..................................................................................................... 31
7.2 Exclusio n Cri teria.................................................................................................... 32
7.3 Excluded Medicat ions.............................................................................................. 35
7.3.1 Permi tted Medicat ions and Treatments ............................................................... 35
7.3.1.1 Oral Corti costeroi d Dosing and Tapering ..................................................... 36
7.4 Criteria for Di scontinuati on or Wi thdrawal  of a Subject ........................................... 37
7.5 Procedures for Discont inuat ion or Withdrawal o f a Subject ...................................... 38
8.0 CLINICAL TRIAL MATER IAL MANAGEMENT ...................................................... 39
8.1 Study  Drug and Materials ........................................................................................ 39
8.1.1 Dosage Form, Manufacturing, Packaging, and Labeling ..................................... 39
8.1.1.1 Vedolizumab IV and Placebo ....................................................................... 39
8.1.1.2 Com panion Medicati on................................................................................ 39
8.1.2 Storage ............................................................................................................... 39
8.1.3 Dose and Regimen ............................................................................................. 39
8.1.4 Overdose ............................................................................................................ 40
8.2 Study  Drug Assignment and Dispensing Procedures ................................................ 40
8.3 Randomization Code Creation and Storage .............................................................. 41
8.4 Study  Drug Blind Maintenance ................................................................................ 41
8.5 Unblinding Procedure .............................................................................................. 41
8.6 Accountabilit y and Destruction of Sponsor -Supplied Drugs ..................................... 41
9.0 STUDY PLAN .............................................................................................................. 43
9.1 Study  Procedures ..................................................................................................... 43
9.1.1 Inform ed Consent Procedure .............................................................................. 43
9.1.2 Dem ographics, Medi cal History , and Medic ation History  Procedure .................. 43
9.1.3 Crohn’s Disease History ..................................................................................... 43
9.1.4 Physical Examinat ion Procedure ........................................................................ 43
9.1.5 Weight, Height ................................................................................................... 44
9.1.6 Vital Sign Procedure .......................................................................................... 44
9.1.7 PML Checklist ................................................................................................... 44
9.1.8 Docum entati on of  Concurrent Medi cal Condit ions............................................. 44
Vedolizumab IV
Vedolizumab -4003 Page 9of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL9.1.9 ECG Procedure .................................................................................................. 44
9.1.10 MRI Procedure ................................................................................................... 44
9.1.10.1 Parks Cl assificat ion................................................................................ 45
9.1.10.2 Van Assche MRI -Based Score ................................................................ 46
9.1.11 Fistul a Draining Assessment .............................................................................. 46
9.1.12 Primary Endpo int Measurement ......................................................................... 46
9.1.13 PDAI ................................................................................................................. 46
9.1.14 CDAI ................................................................................................................. 46
9.1.15 CDAI Di ary Com pletion.................................................................................... 47
9.1.16 Patient Report ed Outcome Measures .................................................................. 47
9.1.16.1 IBDQ ..................................................................................................... 47
9.1.16.2 EQ-5D Questionnaire ............................................................................. 47
9.1.16.3 Likert Peri anal Pain Scale ....................................................................... 47
9.1.17 Pad Collect ion.................................................................................................... 48
9.1.18 Docum entati on of  Conco mitant Medi cations...................................................... 48
9.1.19 Docum entati on of  Concurrent Medi cal Condit ions............................................. 48
9.1.20 Procedures for Clinical Laboratory  Samples ....................................................... 48
9.1.21 Fecal Calprotectin Sample Co llection.................................................................50
9.1.22 Pharmacokinet ic Sample Co llection................................................................... 50
9.1.23 Anti-Vedo lizumab Ant ibodies Sampling ............................................................ 50
9.1.24 Tuberculosis Screening ...................................................................................... 50
9.1.25 Contraception and Pregnancy Avo idance Procedure ........................................... 51
9.1.25.1 Male Subjects and Their Female Partners ............................................... 51
9.1.25.2 Female Subjects and Their Male Partners ............................................... 51
9.1.25.3 Definit ions and Procedures for Contraception and Pregnancy 
Avoidance .................................................................................................... 51
9.1.25.4 General Guidance Wit h Respect to the Avo idance o f Pregnancy ............. 53
9.1.26 Pregnancy .......................................................................................................... 53
9.1.27 Docum entati on of  Screen Failure ....................................................................... 54
9.1.28 Docum entati on of  Rando mization ...................................................................... 54
9.2 Moni toring Subject Treatment Compliance .............................................................. 55
9.3 Schedule of Observat ions and Procedures ................................................................ 55
9.3.1 Screening Visit 1 ................................................................................................ 55
9.3.2 Randomization (Day 1) (Visit 2) ........................................................................ 55
9.3.3 Week 30 or Early Terminat ion (Vi sit 8)............................................................. 55
Vedolizumab IV
Vedolizumab -4003 Page 10of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL9.3.4 Week 40 Follow -up (or 18 Weeks Post -Treatment) ............................................ 55
9.3.5 Post Study  Long- Term  Follow -Up (or 26 Weeks Post -Treatment) ...................... 56
9.3.6 Unscheduled Visits Due to Exacerbat ion of CD ................................................. 56
9.3.7 Post Study  Care .................................................................................................. 56
9.4 Biological Sample Retent ion and Destruction .......................................................... 56
10.0 PRETREATMENT EVENTS (PTE) AND ADVERSE EV ENTS (AE) ......................... 57
10.1 Definit ions............................................................................................................... 57
10.1.1 PTEs .................................................................................................................. 57
10.1.2 AEs.................................................................................................................... 57
10.1.3 Addit ional Po ints to Consider for PTEs and AEs ................................................ 57
10.1.4 SAEs .................................................................................................................. 59
10.1.5 AEs of S pecial Interest ....................................................................................... 60
10.1.6 Intensit y of PTEs and AEs ................................................................................. 61
10.1.7 Causalit y of AEs................................................................................................ 62
10.1.8 Relationship to Study  Procedures ....................................................................... 62
10.1.9 Start Date ........................................................................................................... 62
10.1.10 Stop Date ..................................................................................................... 62
10.1.11 Frequency .................................................................................................... 62
10.1.12 Action Concerning Study  Drug .................................................................... 62
10.1.13 Outcom e....................................................................................................... 63
10.2 Procedures ............................................................................................................... 63
10.2.1 Collect ion and Reporti ng of AEs........................................................................ 63
10.2.1.1 PTE and AE Collection Period ............................................................... 63
10.2.1.2 PTE and AE Reporting ........................................................................... 64
10.2.1.3 Speci al Interest AE Reporting .................................................................64
10.2.2 Collect ion and Reporti ng of SAEs ...................................................................... 65
10.2.3 Reporting of Abnormal LFTs ............................................................................. 65
10.3 Follow-up of  SAEs .................................................................................................. 65
10.3.1 Safety Reporting to Invest igators, IRBs or IECs, and Regulatory  Authori ties.....66
11.0 STUDY -SPEC IFIC COMMITTEES ............................................................................. 67
11.1 Adjudicat ion Co mmittee .......................................................................................... 67
11.1.1 Risk Assessment and Minimizat ion for PML (RAMP) Program ......................... 67
12.0 DAT A HANDLING AND RE CORDKEEPING ............................................................ 68
12.1 Electronic CRFs ....................................................................................................... 68
12.2 Record Retention ..................................................................................................... 68
Vedolizumab IV
Vedolizumab -4003 Page 11of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL13.0 STATISTICAL METHODS .......................................................................................... 70
13.1 Statistical and Analyt ical Plans ................................................................................ 70
13.1.1 Analysis Sets ...................................................................................................... 70
13.1.2 Analysis of Demographics and Other Baseline Characterist ics........................... 70
13.1.3 Analysis of Fistula Healing ................................................................................ 70
13.1.4 PK Analysis ....................................................................................................... 71
13.1.5 Anti-vedo lizumab Ant ibodies Analysis .............................................................. 71
13.1.6 Safety Analysis .................................................................................................. 71
13.1.7 Other Analyses ................................................................................................... 72
13.2 Futility Analysis and Criteria for Early Term ination................................................ 72
13.3 Determinat ion of Sample Size .................................................................................. 72
14.0 QUALITY CONTROL AND QUALITY ASSURANCE ............................................... 73
14.1 Study  Site Moni toring Visits .................................................................................... 73
14.2 Protocol  Deviat ions.................................................................................................. 73
14.3 Qualit y Assurance Audits and Regulatory  Agency  Inspect ions................................ 73
15.0 ETHICAL ASPECTS OF T HE STUDY ........................................................................ 74
15.1 IRB and/or IEC Approval ........................................................................................ 74
15.2 Subject Informat ion, Inform ed Consent, and Subject Authorizat ion......................... 75
15.3 Subject Confidentialit y............................................................................................ 76
15.4 Publicat ion, Di sclosure, and Clinical Trial Registration Policy .................................76
15.4.1 Publicat ion and Disclosure ................................................................................. 76
15.4.2Clinical Trial Registration .................................................................................. 77
15.4.3 Clinical Trial Result s Disclosure ........................................................................ 77
15.5 Insurance and Co mpensation for Injury .................................................................... 77
16.0 REFERENCES .............................................................................................................. 78
LIST OF IN -TEXT TABLES
Table 8.a Dose and Regimen ............................................................................................. 40
Table 9.a Clinical Laboratory  Tests ................................................................................... 49
Table 10.a Takeda Medically Significant AE List ................................................................ 60
LIST OF IN -TEXT FIGURES
Figure 6.a Schemat ic of Study  Design ................................................................................ 29
Vedolizumab IV
Vedolizumab -4003 Page 12of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALLIST OF APPENDICES
Appendix A Schedule of Study  Procedures ............................................................................ 82
Appendix B Responsibilit ies o f the Invest igator ..................................................................... 86
Appendix C Elements of the Subject Informed Consent ......................................................... 88
Appendix D Invest igator Consent to Use of Personal Informat ion.......................................... 91
Appendix E PDAI ................................................................................................................. 92
Appendix F CDAI ................................................................................................................. 94
Appendix G Table for Determining Standard Body  Weight (CDAI Variable) ........................ 95
Appendix H IBDQ ................................................................................................................. 96
Appendix I EQ-5D............................................................................................................. 106
Appendix J Likert Scal e for Peri anal Pain ........................................................................... 108
Appendix K Detailed Desc ription of Amendments to Text ................................................... 109
Vedolizumab IV
Vedolizumab -4003 Page 13of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL2.0 STUDY SUMMARY
Name of Sponsor(s):
Takeda Development Center Americas, Inc.
Takeda Development Centre Europe, Ltd.Compound:
Vedolizumab IV
Title of Protocol: A Randomized Double -Blind Phas e 4 
Study to Evaluate the Safety and Proportion of Subjects 
With Fistula Healing in 2 Dose Regimens of Entyvio 
(Vedolizumab IV) in the Treatment of Fistulizing Crohn’s 
Disease (ENTERPRISE)IND No.: 
009125EudraCT No.:
2015 -000852 -12
Study Number: Vedoliz umab -4003 Phase: 4
Study Design:
This is a phase 4, randomized, double -blind, multicenter study to evaluate the safety and the proportion of subjects 
with fistula healing in 2 dose regimens of Entyvio (vedolizumab IV) over a 30 -week treatment period (with the last 
dose at Week 22). Approximately 100 subjects with moderately to severely active Crohn’s disease (CD) with 1 to 3 
draining perianal fistula(e) will be enrolled. Subjects must have historically had an inadequate response with, lost 
response to, or been intolerant to either conventional therapy or a tumor necrosis factor -alpha (TNF -α) antagonist for 
their underlying CD to be eligible. Subjects will be followed for approximately 52 weeks, including screening and 
post-study  telepho ne follow -up.
Primar y Objectives:
To evaluate the proportion of subjects with perianal fistula healing at Week 30 with 2 different dose regimens of 
vedolizumab IV 300 mg in subjects with fistulizing CD.
Secondary Objective:
To evaluate fistula healing over a 30 -week evaluati on period.
Additional Objectives:
To evaluate magnetic resonance imaging (MRI) assessment of fistula healing at Week 30 compared to Screening.
To evaluate clinical disease activity assessed by Perianal Disease Activity Index (PDAI) and Crohn’s Disease 
Activity Index (CDAI) from Day 1 to Weeks 2, 6, 10, 14, 22, and 30.
To evaluate perianal pain at Week 30 compared to Day 1.
To explore biomarkers (fecal calprotectin and C -reactive protein [CRP]) at Week 30 compared to Day 1.
To evaluate quality of life measur es (Inflammatory Bowl Disease Questionnaire [IBDQ] and EuroQol -5 
dimensions [EQ -5D]) at Weeks 14 and 30 compared to Day 1.
To assess perianal fistula draining by number of pads used at Week 30 compared to Baseline (at selected study 
sites).
To evaluate pha rmacokinetics of vedolizumab in CD subjects with fistula(e) over 30 -week treatment period.
To assess immunogenicity of vedolizumab over 40 weeks of follow -up.
Safety Objective:
The safety objective is to assess safety of vedolizumab IV in CD subjects with fistula(e) over 40 weeks of follow -up.
Subject Population: Adult subjects, aged 18 to 80 years, inclusive, with moderately to severely active CD and 1 to 3 
draining perianal fistula(e) of at least 2 weeks duration.
Number of Subjects:
Approximately 100 S ubjectsNumber of Sites: 
Approximately 40 sites in North America and Europe 
Vedolizumab IV
Vedolizumab -4003 Page 14of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALDose Level(s):
Group 1 : Vedolizumab IV 300 mg dose at Weeks 0, 2, 6, 
14 and 22, and a placebo infusion at Week 10.
Group 2 : Vedolizumab IV 300 mg dose at Weeks 0, 2, 6, 
10, 14 a nd 22.Route of Administration:
Intravenous (IV)
Duration of Treatment:
30-week Treatment Period (with last dose at Week 22) Period of Evaluation:
The study  includes a 4 -week Screening Period, a 
30-week Treatment Period (with last dose at Week 22), 
and a n 18-week Follow -up Period following last dose. 
The duration of the study from Screening to 18 weeks 
post last dose at Week 22 will be approximately 44 
weeks .All subjects will participate in a long -term, 
follow -up (LTFU) safety survey by telephone 6 
month s after their last dose.
Main Criteria for Inclusion:
Adult subjects, aged 18 to 80 years, inclusive, with moderately to severely active CDand 1 to 3 draining perianal 
fistula(e) of at least 2 weeks duration. 
Subjects who have historically had an inadeq uate response with, lost response to, or were intolerant to either 
conventional therapy or a TNF -α antagonist for their underlying CD (does not require treatment failure for currently 
active draining fistula); for subjects from France only: subjects who ha ve historically failed (ie, had an inadequate 
response with, lost response to, or was intolerant to) infliximab for treatment of their underlying CD or fistulizing CD.
Main Criteria for Exclusion:
Subjects who have perianal abscesses greater than 2 cm oran abscess that the investigator feels requires drainage 
based on either clinical assessment or MRI .
Subjects who have a CDAI score greater than 400.
Subjects who have ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine.
Subjects wh o have significant anal or rectal stenosis.
Subjects who have any evidence of an active infection (eg, sepsis, cytomegalovirus, or listeriosis) during Screening
other than related to the fistula(e).
Subjects who have a positive progressive multifocal leuko encephalopathy (PML) subjective checklist.
Subjects who have received any investigational or approved biologic or biosimilar agent within 60 days of 
randomization.
Subjects who have had prior exposure to vedolizumab, natalizumab, efalizumab, rituximab, etrolizumab, or anti -
mucosal addressin cell adhesion molecule -1 (MAdCAM -1)therapy .
Subjects who have active or latent tuberculosis.
Subjects who have a known history of hepatitis B virus (HBV), hepatitis C virus (HCV), acquired human 
immunodeficiency virus (HIV), or are found to be seropositive at Screening.
Main Criteria for Evaluation and Analyses:
The primary endpoint for this study is the proportion of subjects with a reduction of at least 50% from Day 1 in number 
of draining perianal fistulae at Week 3 0 (where closed fistulae are no longer draining despite gentle finger 
compression).
Secondary endpoints for this study are:
The proportion of subjects with a reduction of at least 50% from Day 1 in the number of draining perianal fistulae 
at both Week 22 a nd Week 30 (where closed fistulae are no longer draining despite gentle finger compression).
Vedolizumab IV
Vedolizumab -4003 Page 15of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALThe proportion of subjects with 100% perianal fistulae closure at Week 30 (where all fistulae are no longer 
draining despite gentle finger compression).
Time to fi rst perianal fistula closure.
Time to last (100%) perianal fistulae closure.
Duration of perianal fistula response (eg, number of days with drainage).
Additional endpoints for this study are:
Proportio n of subjects with reduction of fluid collections/absc ess (reduction in relative mean T2 intensity on 
MRI) at Week 30 compared to Screening.
Percentage reduction in relative mean T2 intensity on MRI at Week 30 compared to Screening.
Change in Van Assche total MRI score at Week 30 compared to Screening.
Change in individual MRI descriptors from post -contrast enhanced T1 -weighted images at Week 30 compared to 
Screening.
Changes in PDAI scores from Day 1 to Weeks 2, 6, 10, 14, 22 and 30.
Changes in CDAI scores from Day 1 to Weeks 2, 6, 10, 14, 22 and 30, for subs et with CDAI >220 at Day 1. 
Proportio n of subjects with ≥30% decrease in mean perianal pain as assessed by Likert scale for the 7 days prior to 
Week 30 compared to the 7 days prior to Day 1.
Change in biomarkers (fecal calprotectin and CRP) at Week 30 compared to Day 1.
Change in IBD Q total and subscale scores from Day 1 to Weeks 14 and 30.
Change in the EQ -5D utility score and visual analog scale from Day 1 to Weeks 14 and 30.
Change in number of pads used for perianal fistula drainage from Baseline to Week 30 (selected study sites o nly).
Trough concentrations of vedolizumab.
Proportio n of subjects with positive anti -vedolizumab antibodies (AVAs) and neutralizing AVAs.
Safety will be assessed by adverse events (AEs), adverse events of special interest (AESIs), serious adverse events 
(SAEs), vital signs, and results of standard laboratory tests (clinical chemistry, hematology, coagulation, and 
urinaly sis).
Statistical Considerations: For all dichotomous endpoints, corresponding rates and a 95% confidence intervals (CIs) 
will be reporte d by treatment group. The rate differences between treatment groups and their 95% CIs will also be 
reported.
Time to first fistula closure and time to last fistula closure will be analyzed by survival analysis procedures. Fistula 
closure rates from the tim e of randomization to the end of the study period will be estimated by Kaplan -Meier product 
limit methods and presented with appropriate 95% CIs.
Other endpoints will be summarized descriptively by treatment group.
Sample Size Justification: 
A sample siz e of 100 subjects (50 per group) will generate 95% CIs for fistulae closure rates for each treatment group 
with half widths no wider than 13.9%; in addition, the 95% CIs for the difference in fistulae closure rates between the 
2 groups will be no wider tha n 19.6%. The sample size calculation was not based on statistical power considerations 
but on estimates of precision.
Vedolizumab IV
Vedolizumab -4003 Page 16of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL3.0 STUDY REFERENCE INFO RMATION
3.1 Study -Related Responsibilities 
The sponsor will perform all study -related activit ies wi th the except ion of t hose i dentified in the 
Study -Related Responsibilit ies document. The ident ified vendors in the template for specific 
study -related activit ies will perform  these act ivities in full or in partnership with the sponsor.
3.2 Principal Investigator/Coordinating Inves tigator 
Takeda will select a Signatory Coordinating Investigator fro m the invest igators who participate in 
the study . Selection criteria for thi s investi gator will include significant knowledge of the study  
protocol , the study  drug, their expert ise in the therapeuti c area and the conduct of clinical research 
as well as study  parti cipati on. The Si gnatory  Coordinat ing Investigator will be required to review 
and sign the clinical study  report and by doing so agrees that it accurately describes the results of 
the study .
Vedolizumab IV
Vedolizumab -4003 Page 17of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL3.3 List of Abbreviations
5-ASA 5-aminosalicylate
6-MP 6-mercaptopurine
ACCENT II A Crohn’s Disease Clinical Trial Evaluating Infliximab in a New Long -term Treatment 
Regimen in Patients With Fistulizing Crohn’s Disease
AE adverse event
AESI adverse event of special interest
ALT alanine aminotransferase
AST aspartate aminotransferase
AVA anti-vedolizumab antibody
BID twice daily
CD Crohn’s disease
CDAI Crohn’s Disease Activity Index
CI confidence interval
CRA clinical research assistant 
CRO contract research organization
CRP C-reactive protein
CSR clinical study report
Ctrough trough serum concentration
ECG electrocardiogram
eCRF electronic case report form 
ELISA enzyme-linked immunosorbent assay
EMA European Medicines Agency
ENTYVIO vedolizumab IV
EQ-5D Euro Quality of Life -5D
FAS full analy sis set
FDA Food and Drug Administration
FSH follicle -stimulating hormone
GCP Good Clinical Practice
GGT γ-glutamyl transferase
GI gastrointestinal
HBsAg hepatitis B virus surface antigen
HBV hepatitis B virus
HCV hepatitis C virus
HIV human immunodeficiency virus
hCG human chorionic gonadotropin
HRQOL health -related quality of life
IAC Independent Ad judication Committee
IAG Image Acquisition Guidelines
IB Investigator’s Brochure
Vedolizumab IV
Vedolizumab -4003 Page 18of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALIBD inflammatory bowel disease
IBDQ Inflammato ry Bowel Disease Questionnaire
ICH International Conference on Harmonisation
IEC independent ethics committee
Ig immunoglo bulin
INR internatio nal no rmalized ratio
IRB institutional review board
IUD intrauterine device
IWRS interactive web response system
IV intravenous(ly)
JCV John Cunningham virus
LFT liver function tests
LTFU long-term follow -up
mAb monoclonal anti body
MAdCAM -1 mucosal addressin cell adhesion molecule -1
MedDRA Medical Dictionary for Regulatory Activities
Med ID medication identification number
MRI magnetic resonance image
nAVA neutralizing anti -vedolizumab antibodies
NSAID nonsteroidal anti -inflammatory drug
PDAI Perianal Disease Activity Index
PD pharmacodynamics
PK pharmacokinetics
PML progressive multifocal leukoencephalopathy
PO orally
PP per protocol
PTE pretreatment event
Q4W once ever y 4 weeks
Q8W once ever y 8 weeks
QD once dai ly
QuantiFERON test for mycobacterium tuberculosis
RAMP Risk Assessment and Minimization for PML
RF radiofrequency
SAE serious adverse event
SAP statistical analysis plan
SmPC Summary of Product Information 
SUSAR suspected unexpected serious advers e reaction
T1 T1 weighted MRI image
T2 T2 weighted MRI image
TB tuberculosis
Vedolizumab IV
Vedolizumab -4003 Page 19of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALTID 3 times daily
TNF -α tumor necrosis factor -alpha
TYSABRI natalizumab
UC ulcerative colitis
ULN upper limit of normal
US United States
VAS visual analog scale
VCAM -1 vascular cell adhesion molecule -1
WBC white blood cell
WHODRUG World Health Organization Drug Dict ionary
3.4 Corporate Identification 
TDC Europe Takeda Development Centre Europe Ltd.
TDC Americas Takeda Development Center Americas , Inc.
TDC TDC Europe and/or TDC Americas, as applicable
Takeda TDC Europe and/or TDC Americas, as applicable
Vedolizumab IV
Vedolizumab -4003 Page 20of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL4.0 INTRODUCTIO N
4.1 Background
4.1.1 Disease and Current Treatments
Inflammatory  bowel  disease (IBD) i s a chronic, relapsing, inflammatory  disorder of the 
gastrointestinal (GI) tract that includes 2 ent ities, namely ulcerat ive colit is (UC) and Crohn’s 
disease (CD). In contrast to the diffuse, superficial, continuous inflammat ion limited to the colon 
in UC, the inflammat ion of CD is focal, may be transmural, and can invo lve any segment of the GI 
tract from mouth to anus. The prevalence of CD is approximately 150/100,000 of the Unit ed States 
(US) popul ation and approximately 125/100,000 of populat ion in Western Europe [1-3] . The
characterist ic patho logy involves a chronic inflammatory  infiltr ate consisting of neutrophils and 
macrophages. Hallmarks of CD include granulo matous inflammat ion and aphthous ulceration.
CD i s neither medically or surgi cally  curable at the current time. Fistulizing disease complicates 
CD in up to 40% of pat ients [4,5].Patients with fistulizing CD experience symptoms of anal pain, 
purul ent di scharge, and incont inence, whic h result in high morbidit y and impaired qualit y of life 
[6,7].
Fistul ae rarely heal spontaneously  and usu ally requi re medical  therapy  or surgery . Although a 
range of medical and surgical options is available for CD, effect ive treatment options for 
fistulizing disease are limited. There is no demonstrated role for amino salicylates or 
corticosteroi ds in periana l CD [8].While ant ibiotics may contribute to healing, they are 
recommended as adjunct ive therapy for fistulae [8].Thiopurines may have a moderate effect in 
treating fistulizing CD, however the data are limited or mixed [8-10 ].Infliximab, a tumor necrosis 
factor -alpha (TNF- a) antagonist m onocl onal ant ibody , has been shown to be effect ive in fistula 
healing in 2 prospective rando mized controlled trials [11,12] .A Crohn’s Disease Clinical Trial 
Evaluat ing Infliximab in a New Long- term Treatment Regimen in Pat ients with Fistulizing 
Crohn’s Disease (Accent II) study  reported that 36% of patie nts who responded to induct ion 
therapy  and received maintenance infliximab therapy  maintained complete fistula closure 
compared wi th 19% receiving placebo (p=0.009) [13]. Infliximab has approved indicat ions in 
fistulizing CD by both the US and European regulatory  agencies. Other TNF -a antagoni st 
therapi es (eg adalimumab, certolizumab) have post hoc subgroup analyses and limited prospective 
data dedi cated to fistuli zing CD [14-16].
The m anagement of peri anal CD is challenging and often requires a comprehensive approach 
including medical and surgical intervent ions. The rec ent global consensus guidelines on fistulizing 
CD contain algorithms including medical therapy +/ -surgical seton [8,17] , and a recent 
meta -analysis suggests an advantage of combinat ion of medical and surgical therapy co mpared to 
either therapy  alone [18]. 
4.1.2 Vedolizumab
Vedolizumab (also called MLN0002) is a humanized immunoglobulin (Ig) G1 monoclonal 
antibody  (mAb) di rected against the human lymphocy te integrin α 4β7. The α 4β7integrin mediates 
Vedolizumab IV
Vedolizumab -4003 Page 21of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALlymphocy te trafficking to the GI mucosa and gut -associated lymphoid t issue through adhesive 
interact ion with mucosal  addressin cell adhesion molecule -1 (MAdCAM -1), whi ch is expressed 
on the endothelium o fmesenteric lymph nodes and GI mucosa [19-22 ].Vedolizumab binds the 
α4β7integrin, antagonizing its adherence to MAdCAM -1 and as such, impairs the migrat ion of gut 
homing lymphocytes into gastrointest inal mucosa. As a result, vedo lizumab acts as a gut -selective 
immuno modulator [23].
Vedolizumab IV (also known as ENTYVIO; KYNTELES; or MLN0002 IV) has been granted 
market ing approval in several regio ns, including the United States and European Unio n. 
Vedolizumab IV is approved for the treatment of adult patients with moderately to severely act ive 
UC and CD, who have failed convent ional treatment, such as immuno modulators, corticosteroids, 
or TNF -α antagonists. The approved dosing and administration regimen is 300 mg vedo lizumab 
IV infused intravenously at Weeks 0, 2 and 6, then once every  8 weeks (Q8W) there after.
Previously  conducted clinical  studi es have characterized the efficacy, safety , tolerabili ty, 
pharmacokinet ic (PK), pharmacodynamic (PD), and immunogenicit y of vedo lizumab in healt hy 
subjects and subjects with UC or CD.
4.1.2.1 Nonclinical
No nonclinical st udies have been conducted to evaluate vedo lizumab specifically for fistulizing 
CD.
Nonclinical in vitro and in vivo studies have been conducted with vedo lizumab and its murine 
homolo gue, Act -1. Act -1 has demonstrated clinical and histomorpho logic evi dence of efficacy  in 
an animal model of IBD (cotton -top tamarins). Extensive nonclinical evaluat ions of the 
cardi ovascular, acute, local, subchronic, chronic, immunologic, and reproductive toxicit y of 
vedo lizumab in pharmaco logically responsive species (New Zeal and white rabbit s and 
cyno molgus monkeys) have been conducted and support its clinical development. Nonclinical 
studi es also show that vedolizumab does not antagonize α 4β1integrin [23].
4.1.2.2 Human Experience
In the clinical development program, more than 4200 subjects have recei ved at l east 1 dose of 
vedo lizumab (see Invest igator’s Brochure [IB], Edit ion 19). Phase 3 placebo -controlled studies 
enrolled 2427 subjects with UC or CD, of who m 1434 subjects were administered 300 mg of 
vedo lizumab for induct ion followed by  once every 4 weeks (Q4W) or Q8W for up to a total of 52 
weeks and 488 subjects were administered 300 mg vedo lizumab for induct ion only [24,25] [26] . 
In subjects wi th moderately  to severely act ive CD (Study  C13007), including subjects who had 
failed treatment with 1 or more therapies including TNF -α antagonists, vedolizumab 300 mg 
infusio n at Weeks 0 and 2 (induct ion) fo llowed by  administrati on Q4W or Q8W f rom Weeks 6 
through 52 (maintenance) demonstrated statist ically significant differences in efficacy  com pared 
to placebo for both the induct ion and m aintenance phases. The study  met its primary  endpoint for 
the induct ion phase, clinical remissio n at Week 6, but did not meet the second primary endpo int of 
enhanced clinical response (Crohn’s Disease Act ivity Index [CDAI] -100) at Week 6 in the overall 
Vedolizumab IV
Vedolizumab -4003 Page 22of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALpopul ation, although the treatm ent difference favored vedolizumab. The study  did m eet its 
primary  endpoint for the maintenance phase, clinical remissio n at Week 52, as well as important 
secondary  endpoints, including enhanced clinical response at Week 52 and corticosteroid- free 
clinical remissio n at Week 52 [25].
In Study  C13007, 37% of subjects had a history of fistulizing disease and 15% had active draining 
fistul ae at Baseline (Week 0) [25]. The majorit y of fistul ae were located perianally (72% placebo; 
82% vedolizumab group). At Week 52, 41.2% of subjects administered vedo lizumab Q8W and 
22.7% of subjects administered vedo lizumab Q4W compared to 11.1% of placebo subjects 
achieved complete closure of baseline draining fist ulae [27]. In a post hoc, exploratory analysis o f 
the subpopulat ion with baseline draining fistula, 28% of subjects who received vedo lizumab 
(combined Q4W and Q8W) had closure at Week 14 comp ared with 11% of subjects who received 
placebo. Kaplan -Meier probabilit y estimates of fistul a closure wi th vedolizumab were 29% and 
33% at 6 and 12 months, respectively; notably, the number of subjects at risk was small. The 
hazard ratio for fistula closur e for the vedolizumab treatment group was 2.54 (95% confidence 
interval  [CI], 0.54 -11.96) [28].
Vedoli zumab has shown an acceptable and consist ent safet y profile in clinical trials (see current 
versio n of IB). In the pivotal phase 3 studies (C13006 in UC and C13007 in CD), the most 
commo n (≥5% and at a higher incidence than placebo) adverse reactions in su bjects administered 
vedo lizumab were nausea, nasopharyngit is, upper respiratory  tract infect ion, arthralgia, py rexia, 
fatigue, headache, and cough. Most serious adverse events (SAEs) have been related to 
exacerbations or complications of the underlying UC or CD. F or those infect ions that were 
reported more frequent ly in vedo lizumab -treated subjects, the sites of these infect ions correlated 
with the known tissue distribut ion of MAdCAM -1 binding sites. Anal abscess, abdo minal abscess, 
and gastroenteritis were the most frequent ly reported serious infections. Extraintestinal infect ions 
(bronchit is, pneumonia, urinary tract infect ion, sepsis) occurred at low frequency (<1%). A total of 
4% of vedo lizumab -treated subj ects and 3% of placebo -treated subjects experienced an 
infusio n-related reacti on. In C13006 and C13007, 10% of subjects were posit ive for 
anti-vedo lizumab antibodies (AVAs) 16 weeks fo llowing the last dose of vedo lizumab. Result s 
from the clinical program to date do not suggest an increased risk for mal ignancy wit h 
vedo lizumab treatment. Overall, the safet y profile fo llowing lo ng-term treatm ent wi th 
vedo lizumab in C13008, a long -term safet y study , is consistent with safet y in the co mpleted 
studi es.
Concomitant use of corticosteroids and/or convent ional i mmuno modulators di d not appear to be 
associ ated wi th any increased rate of infect ions based on the comparative rates of infections in the 
phase 3 trials amo ng subjects who had and had not received these medicat ions.
Overall, vedo lizumab was well tolerated in clinical studies. For addit ional safet y related 
inform ation from the clinical trial experience, see the current edit ion of the IB. 
Vedolizumab IV
Vedolizumab -4003 Page 23of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL4.2 Rationale for the Proposed Study
The treatment of fistulizing CD is challenging and there are limit ations in the availabl e CD 
literature, which further complicates an evidence -based approach to treatment. Well -designed 
prospective clinical trials specific to the fistulizing CD pati ent populati on are needed. 
The current study  will generate meaningful data with vedolizumab IV in the treatment of perianal 
fistul a(e) and is expected to provide guidance on an optimal dose regimen for this co mplex patient  
popul ation.
The study  will evaluate peri anal fistula(e) healing rates in 2 vedo lizumab treatment arms: the 
standard dosage regi men and the standard dosage regimen plus an addit ional Week 10 dose. It is 
postul ated that addit ion of a Week 10 dose may be beneficial based on data fro m no nresponders at 
Week 6 that continued Q4W dosing in the C13007 study, where it was suggested that subjects who  
do not respond by  Week 6 shoul d be given an additi onal dose at Week 10. Week 10 dosing is an 
approved dose regimen for the treatment of CD in the European Unio n.The study  hypothesis i s 
that both treatment arms will be efficacious and safe for t he treatment of perianal fistula(e) in 
subjects wi th CD wi th or wi thout setons, and the intent ion is to estimate perianal fistula healing 
rates at Week 30 in both treatment arms, although no formal co mpar ison between the groups will 
be perform ed.
4.3 Benefit:R isk Assessment
Perianal fistulae are a debilitating complication o f CD. The treatment approach is challenging and 
therapeuti c outcom e is often insufficient or has limitat ions.Results fro m Study  C13007 showed 
that treatment with vedo lizumab IV 300 mg Q8W o r Q4W maintained remissio n in the broad CD 
popul ation and achieved fistula closure in a subpopulat ion of subjects who had draining fistulae at 
Baseline. 
Study  Vedolizumab -4003 is designed to investigate vedo lizumab IV in the treatment of perianal 
fistul aeand is expected to provide guidance on an optimal dosing regimen for this co mplex pat ient 
popul ation. The study will evaluate perianal fistula healing rates in 2 vedo lizumab treatment arms: 
the standard dosage regimen and the standard dosage regimen plus an addi tional Week 10 dose. 
Week 10 dosing is an approved dose regimen for the treatment of CD in the European Unio n (EU). 
The study  hypothesis is that both treatment arms will be efficacious and safe for the treatment of 
perianal fistul a in subjects with CD, and the intent ion is to estimate perianal fistula healing rates at 
Week 30 in both treatment arms, although no formal co mpar ison between the groups will be 
perform ed. Di agnost ic procedures to be used in this study (eg, MRI) are commo nly used in 
medical pract ice and in this patient populat ion. 
The dosing and administration regimen are consistent with the approved vedo lizumab IV label in 
the EU [29]. The proposed protocol will include safet y measures similar to those conducted in the 
vedo lizumab IV UC and CD clinical program s, including sufficient safet y measures, evaluat ions, 
and discont inuat ion criteria to assure safet y in the individual subjects in the planned study.
Vedolizumab IV
Vedolizumab -4003 Page 24of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALOverall, vedo lizumab IV has been well tolerated in clinical studies and the benefit -risk profile is 
positive.
Vedolizumab IV
Vedolizumab -4003 Page 25of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL5.0 STUDY OBJECTIVES AND ENDPOINTS
5.1 Objectives
5.1.1 Primary Obj ective
The primary  object ive is to evaluate the proportion of subjects with perianal fistula healing at 
Week 30 in 2 different dose regimens o f vedo lizumab IV 300 mg in subjects with fistulizing CD.
5.1.2 Secondary Objective
The secondary  objective i s to evaluat e fistula healing over a 30-week evaluation period .
5.1.3 Additional Objectives 
Addit ional objectives include:
To evaluate magnet ic resonance imaging (MRI) assessment of fistula healing at Week 30 
compared to Screening.
To evaluate clinical disease act ivity assessed by  Peri anal Disease Activit y Index (PDAI) and 
CDAI from Day 1 to Weeks 2, 6, 10, 14, 22 and 30.
To evaluate perianal pain using a Likert scale at Week 30 compared to Day  1.
To expl ore bi omarkers of disease act ivity (fecal calprotectin and C -react iveprotein [CRP]) at 
Week 30 com pared to Day  1.
To evaluate qualit y of life measures (inflammatory bowel disease questionnaire [IBDQ] and 
Euro Qualit y of Life -5D [EQ -5D]) at Week 14 and Week 30 compared to Day  1.
To assess perianal  fistul a draining bynumber of pads used at Week 30 compared to Baseline 
(selected study  sites only ).
To evaluate the PK of vedo lizumab in CD subjects with fistula (e) over the treatm ent peri od.
To assess immunogenicit y of vedo lizumab over 40 weeks of fo llow-up .
5.1.4 Safety Objective
To assess safet y of vedolizumab IV in CD subjects with fistula(e) over 40 weeks of fo llow-up.
5.2 Endpoints
5.2.1 Primary Endpoints 
The primary  endpoint for thi s study  is the proportion of subjects with a reduction of at least 50% 
from Day 1 in the number of draining p erianal fist ulae at Week 30 (where closed fistulae are no 
longer draining despite gentle finger compressio n).
Vedolizumab IV
Vedolizumab -4003 Page 26of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL5.2.2 Secondary Endpoints 
Secondary  endpoints are as follows:
The proporti on of  subjects with a reduction of at least 50% from Day 1 in the number of 
draining perianal fistulae at both Week 22 and Week 30 (where closed fistulae are no longer 
draining despite gent le finger compression).
The proporti on of  subjects with 100% perianal fistulae closure at Week 30 (where all fistulae 
are no l onger draining des pite gentle finger com pressi on).
Time to first perianal fistula closure .
Time to last (100%) perianal fistulae closure .
Durati on of  perianal fistula response (number of days with drainage ).
5.2.3 Additional Endpoints 
Addit ional endpoints include the fo llowing:
Proporti on of  subjects wi th reducti on of  fluid co llections/abscess (reduction in relat ive mean 
T2 intensit y on MRI) at Week 30 compared to Screening.
Percentage reduction in relat ive mean T2 intensit y on MRI at Week 30 compared to Screening.
Change in Van Assche total MRI score at Week 30 compared to Screening.
Change in individual MRI descriptors from post- contrast enhanced T1 -weighted images at 
Week 30 com pared to Screening.
Changes in PDAI scores fro m Day 1 to Weeks 2, 6, 10, 14, 22 and 30.
Changes in CD AI scores from Day 1 to Weeks 2, 6, 10, 14, 22 and 30, for subset with CDAI 
>220 at Day  1. 
Proporti on of  subjects wi th ≥30% decrease in mean perianal pain as assessed by  Likert scale 
for the 7 day s prior to Week 30 com pared to the 7 days prior to Day  1.
Change in bio markers (fecal calprotectin and CRP) at Week 30 compared to Day  1.
Change in IBD Q total and subscale scores from Day  1 to Weeks 14 and 30.
Change in the EQ -5D utilit y score and visual analo g scal e from Day  1 to Weeks 14 and 30.
Change in number of pads used for perianal fistula drainage from Baseline to Week 30 
(selected study  sites o nly).
Trough serum concentrations (C trough) of vedolizumab.
Proporti on of  subjects wi th posi tive (AVAs), and neutralizing ant i-vedo lizumab ant ibodies 
(nAVAs).
Vedolizumab IV
Vedolizumab -4003 Page 27of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL5.2.4 Safety Endpoints
Safety will be assessed by adverse events (AEs), adverse events of special inter est (AESIs), SAEs, 
vital signs, and results of standard laboratory  tests (clinical chemistry , hematol ogy, coagul ation, 
and urinalysis).
Vedolizumab IV
Vedolizumab -4003 Page 28of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL6.0 STUDY DESIGN AND DES CRIPTION
6.1 Study Design
This is a phase 4, randomized, double -blind, m ulticenter study  to eval uate the safet y and the 
proporti on of  subjects wi th fistula healing in 2 dose regimens of vedo lizumab IV 300 mg, 
administered as a 30 -minute infusion, over a 30 -week treatment period (with the last dose at 
Week 22) in the healing of draining perianal fistulae in s ubjects wi th active CD. Subjects in both 
treatm ent groups entering the study  may have had surgi cal seton pl acement as standard of care 
prior to enrollment in the study .
Approximately  100 CD subjects wi th moderately to severely act ive CD and 1 to 3 draining
perianal fistul a(e) of at least 2 weeks duration will be included. To be eligible, subjects must have 
histori cally  had an inadequate response with, lost response to, or been intolerant to either 
convent ional therapy  or a TNF -α antagonist for their underlying CD; for subjects from France 
only: subjects must have historically failed (ie, had an inadequate response with, lost response to, 
or was intolerant to) infliximab for treatment of their underlying CD or fistulizing CD. Subjects 
will be rando mized in a 1:1 ratio into 1 of 2 treatment groups:
Group 1: vedolizumab IV 300 m gdose at Week 0, 2, 6, 14, 22 and a placebo IV dose at 
Week 10. 
Group 2: vedolizumab IV 300 m gdose at Week 0, 2, 6, 10, 14, and 22.
The study  consists of a 4-week Screening Period, a 30 -week Treatment Period (with last dose at 
Week 22), and an 18 -week Follow- up Peri od following the last dose. The duration of the study  
from Screening to 18 weeks post last dose at Week 22 will be approximately  44 weeks for a ll 
subjects. All subjects in the study will also be required to complete a long -term follow-up (LTFU) 
safet y survey by telephone 6 months fo llowing the last dose. The end o f trial will be the date of the 
last vi sit of the l ast subject at the Week 40 Follow -up Visit.
In both groups, for subjects with a seton at study entry, setons may be removed at or after Week 6 
at the discretion of the invest igator, provided that significant reduction in fistula drainage has 
occurred . All setons must be removed by  Week 14 .
A schemat ic of the study  design is included as Figure 6.a. A schedule o f assessments is listed in 
Appendix A.
Vedolizumab IV
Vedolizumab -4003 Page 29of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALFigure 6.a Schematic of Study Design
6.2 Justification for Study Design, Dose, and Endpoints
Perianal fistulae are a debilitating complication o f CD. The treatment approach is challenging and 
therapeuti c outcom e is often insufficient or has limitat ions [30].Results fro m the maintenance 
study  C13007 showed that treatm ent wi th vedo lizumab IV 300 mg Q8W or Q4W maintained 
remission in the broad CD populat ion and achieved fis tula(e) cl osure in a subpopul ation of 
subjects who had draining fistula(e) at Baseline.
The obj ective o f this study  is to prospectively evaluate vedolizumab IV in the treatment of 
fistulizing CD using 2 dose regimens. All subjects who meet the eligibilit ycriteria will  randomly  
be assigned to 1 of the 2 treatment groups . The choice of different active treatment groups, rather 
than a placebo comparator group was made due to ethical considerat ions. MRI, read by a central 
reader, will be used to ensure consist ent classificat ion of perianal fistulae as per Parks’ criteria for 
classificat ion as simple or complex fistulae [31], for scoring using the Van Assche MRI score [32], 
and to object ively measure perianal fistulae healing by reduct ion in T2 hyperintensit yfrom 
Baseline and assess change in inflammatory  process fro m Baseline on post -contrast enhanced 
T1-weighted images.
6.3 Premature Termination or Suspension of Study or Study Site
6.3.1 Criteria for Premature Termination or Suspension of the Study
The study  will be completed as pl anned unless one or more of the fo llowing cri teria are satisfied 
that require temporary  suspensi on or early  terminati on of  the study :
Vedolizumab IV
Vedolizumab -4003 Page 30of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALNew informat ion or other evaluat ion regarding the safet y or efficacy  of the study  drug that 
indicates a cha nge in the known risk/benefit profile for vedo lizumab, such that the risk /benefit  
is no longer acceptable for subjects participat ing in the study.
Significant vio lation of Good Clinical Practice (GCP) that compromises the ability to achieve 
the primary  study objectives or compromises subject safet y.
At the futilit y analysis, if the probabilit y of success does not meet the predetermined fut ility 
thresho ld and the study is stopped for fut ility at this point.
6.3.2 Criteria for Premature Termination or Suspension of Study Sites
A study  site may  be terminated prematurely  or suspended if the site (including the invest igator) is 
found in significant vio lation of GCP, protocol, or contractual agreement, is unable to ensure 
adequate performance of the study , or as otherwi se permitted by  the contractual  agreem ent.
6.3.3 Procedures for Premature Termination or Suspension of the Study or the 
Participation of Study Site(s)
In the event that the sponsor, an inst itutional review board (IRB)/independent ethics committee 
(IEC) or regula tory authori ty elects to terminate or suspend the study  or the parti cipat ion of an 
study  site, a study -specific procedure for early  terminat ion or suspensio n will be provided by the 
sponsor; the procedure will be fo llowed by  applicable study  sites during t he course of terminatio n 
or study  suspensi on.
Vedolizumab IV
Vedolizumab -4003 Page 31of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL7.0 SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS
All entry criteria, including test results, need to be confirmed prior to randomizat ion. In the case of 
subject screen failure, the subject may be considered for rescreening on a case -by-case basis but 
only with the consul tation of  the m edical m onitor.
7.1 Inclusion Criteria
Subject eligibilit y is determined according to the following criteria prior to entry  into the study : 
1.In the opinion o f the invest igator, the subject is capable of understanding and complying wit h 
protocol  requi rements.
2.The subject or, when applicable, the subject’s legally acceptable representative has signed and 
dated a written, informed consent form and any  requi red privacy authorization pri or to the 
initiation of any study  procedures. 
3.The subject is male or female and aged 18 to 80 years, inclusive.
4.The subject has a diagnosis of CD established at least 3 months prior to randomizat ion by 
clinical and endoscopic evidence and corroborated by  a histopathol ogy report. 
5.The subject has a diagnosis of a minimum o f 1 perianal draining fistula of at least 2 weeks 
durati on as a com plicat ion of moderately to severely act ive CD, as ident ified on MRI at 
Screening. Other ty pes of  fistulae (enterocutaneou s, abdo minal) except rectovaginal fistulae 
are permitted, but the number of draining perianal fistulae is limited to 3.
6.All countries except France: The subject, hi storically , had an inadequate response with, lost 
response to, or was i ntolerant to either c onvent ional therapy or a TNF -α antagonist for their 
underlying CD (does not require treatment failure for currently act ive draining fistula) . 
France only: The subject, hi storically , failed (i e, had an inadequate response with, lost 
response to, or was i ntolerant to) infliximab for treatment of their underlying CD or fistulizing 
CD.
7.If the subject had noncutting perianal seton pl acement as part of standard care, seton must be 
removed by Week 14 of the study .
8.The subject is willing and able to undergo MRI pe r protocol requirements.
9.The subject is willing and able to take antibiot ic treatment (metronidazo le, cipro floxacin, 
amoxicillin clavulanate, or tinidazole, as per local label) from Day  1 through study  Week 6.
10.A male subject who is nonsterilized* and sexua lly active wit h a female partner of childbearing 
potenti al* agrees to use a barrier method of contraception (eg, condom with spermicide)* fro m 
signing of informed consent throughout the duration of the study  and for 18 weeks after last 
dose. The female par tner of a male subject should also be advised to use a highly effect ive 
method of contraception*.
Vedolizumab IV
Vedolizumab -4003 Page 32of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL11.A female subject of childbearing potential* who is sexually act ive with a nonsterilized* male 
partner agrees to use a highly effective method of contraception * from signing o f informed 
consent throughout the duration of the study  and for 18 weeks after last dose. 
*Definit ions and highly  effect ive methods of contraception are defined in 
Secti on9.1.25Contraception and Pregnancy Avo idance Procedure and 
reporting responsibilit ies are defined in Sect ion 9.1.26 Pregnancy.
12.Subjects with a family history  of colorectal  cancer, personal history  of increased col orectal  
cancer risk, age >50 years, or other known risk factors must be up -to-date on colorectal cancer
surveillance (may  be perform ed during Screening as standard of care).
7.2 Exclusion Criteria
Any subject who meets any  of the fo llowing cri teria will not qualify  for entry  into the study : 
1.The subject has a diagnosis of ulcerat ive colit is or indeterminate colit is.
2.The subject has a perianal abscess greater than 2 cm or an abscess that the invest igator feels 
requi res drainage based on either clinical assessment or MRI. (Note: if subject has an abscess 
larger than 2 cm, and abscess is drained and seton placed, then subject may be rescreened wit h 
consultation fro m the medical m onitor).
3. The subject has a CDAI score >400.
4.The subject has an ileostomy, colostomy , or known fixed symptom atic stenosis o f the 
intestine.
5.The subject has significant anal or rectal stenosis.
6.The subject has act ive or latent tuberculosis (TB), regardless of treatment history, as 
evidenced by any of the f ollowing:
a.A diagnostic TB test performed during Screening that is posit ive, as defined by:
i.A posi tive test for tuberculosis (Quant iFERON) or 2 successive 
indeterminate QuantiFERON tests OR
ii.A tuberculin skin test reaction ≥10 mm (≥5 mm in subjects receiving the 
equivalent of >15 mg/day predniso ne)
b.Chest X -ray within 3 m onths pri or to Day  1, that is suspi cious f or pulm onary TB, 
and a posi tive or 2 successive indeterminate QuantiFERON tests within 30 days 
prior to Screening or during the Screening Period.
Note: if the subject has a documented negat ive diagnostic TB test in the prev ious 3 
months, screening testing does not need to be repeated provided subject has no risk 
factors for exposure .
7.The subject has chronic hepat itis B virus (HBV) infect ion* or chronic hepat itis C virus 
(HCV) infect ion** or a known history  of human immunodef iciency virus (HIV) infect ion 
Vedolizumab IV
Vedolizumab -4003 Page 33of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL(or is found to be seroposit ive at Screening) or subject is immunodeficient (eg, due to organ 
transpl antati on, history  of comm on variable immunodeficiency). 
* Subj ects who are posit ive for hepatit is B virus surface ant igen (H BsAg) will be excluded. 
For subjects who are negative for HBsAg but are posit ive for either surface ant ibodies 
and/or core antibodies, HBV DNA polymerase chain reaction will be performed and if any 
test result meets or exceeds detection sensit ivity, the su bject will be excluded.
** If the subject is HCV ant ibody  posi tive, then a viral load test will be performed. If the 
viral load test is posit ive, then the subject will be excluded.
8.The subject has evidence of act ive C. difficile infection or is having trea tment for C. difficile
infect ion or other intest inal pathogens during Screening.
9.The subject has evidence of an act iveinfect ion (eg, sepsis, cytomegalo virus, or listeriosis) 
during Screening, other than related to the fistula(e).
10.The subject currently  requires orhasaplanned surgi cal intervent ionfor CD during thestudy .
11.The subject has a contraindicat ion for MRI. See MRI Image Acquisit ion Guidelines (IAG) for 
additional information.
12.The subject has allergies to and/or contraindicat ions for m etroni dazole and ciproflo xacin and 
amoxicillin clavulanate and tinidazole (including interacting drugs such as tizanidine).
13.In the opinion o f the invest igator, the subject is likely to require greater than 6 weeks of 
treatm ent after Day 1 with metronidazo le, ciproflo xacin, amoxicillin clavulanate, or tinidazole 
for the treatm ent of  abscess.
14.The subject is taking, has taken, or is required to take any  excluded m edicati ons (as listed in 
Secti on 7.3).
15.The subject has received non -biologic inve stigational therapy wit hin 30 days prior to 
rando mizat ion.
16.The subject has received an approved non -biologic therapy  (including 5 -amino salicylate
[5-ASA], corticosteroid, azathioprine, 6 -mercaptopurine [6-MP], etc.) in an invest igational 
protocol  within 30 days pri or to randomizat ion.
17.The subject has received any invest igational or approved bio logic or biosimilar agent within 60 
days of rando mizat ion.
18.The subject has a history  of hypersensi tivity or allergi es to vedolizumab or its components.
19.The subject ha s any  prior exposure to vedolizumab, natalizumab, efalizumab, rituximab ,
etrolizumab, or anti -MAdCAM -1 therapy .
20.The subject has received any live vaccinat ions wit hin 30 days prior to randomizat ion.
21.The subject has current rectovaginal fistula.
22.The subject currently has more than 3 draining perianal fistulae.
Vedolizumab IV
Vedolizumab -4003 Page 34of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL23.The subject has a posit ive progressive mult ifocal leukoencephalopathy (PML) subjective 
symptom  checklist at Screening or Day  1 visit.
24.The subject has a history  of malignancy , except for the following: a dequately -treated 
nonmetastati c basal cell skin cancer; squamous cell skin cancer that has been adequately 
treated and that has not recurred for at least 1 y ear pri or to Screening; or history  of cervical 
carcino ma in situ that has been adequately treated a nd that has not recurred for at least 3 years 
prior to Screening. Subjects with a remote history  of malignancy (eg, >10 years since 
completion of curative therapy  without recurrence) will be considered based on the nature of 
the malignancy  and the therapy  received, and must be discussed with the sponsor on a 
case-by-case basis prior to randomizat ion.
25.The subject has a history  of any major neurol ogical disorders, including stroke, mult iple 
sclerosi s, brain tum or, demyelinat ing or neurodegenerat ive disease.
26. T he subject has condit ions which, in the opinio n of the investigator, may interfere with the
subject’s abilit y tocomply wit h the study  procedures.
27.The subject has any  unstable or uncontrolled cardiovascular, pulmo nary, hepatic, renal, GI,
genitourinary ,hematol ogical,coagul ation, immunological, endocrine/metabo lic, neuro logic 
or other medical disorder that, in the opinio n of the invest igator, would confound the study  
resul tsorcompromise subject safet y.
28.The subject has any  ofthefollowing laboratory  abno rmalities during the Screening Period:
i. Hemoglobinlevel <8 g/dL.
ii. White blood cell (WBC) count <3 × 109/L.
iii. Lymphocy tecount <0.5 × 109/L.
iv. Plateletcount<100 × 109/L or >1200 × 109/L.
v. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) 
>3× the upper limit of normal (ULN).
vi. Alkaline phosphatase >3 × ULN.
vii. Serum  creatinine >1.5 × ULN.
Note: Retesti ng laboratory  values during the screening interval may  be considered wi th 
consultation fro m the medical m onitor.
29.Iffemale, the subject is pregnant or lactating or intending tobeco mepregnant before, during,
or within 18 weeks after participat ing in this study; or intending to donate ova during such time
period.
30.Ifmale, the subject intends to donate sperm during the course of this study  orfor 18 weeks
thereafter.
Vedolizumab IV
Vedolizumab -4003 Page 35of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL31.The subject is an immediate family member, study site emplo yee, or i s in a dependent 
relationship with a study  site em ployee who i s involved in conduct of this study  (eg, spouse, 
parent, child, sibling) or may consent under duress. 
32.The subjec t has a history  of drug abuse (defined as any  illici t drug use) or a hi story  of alcohol  
abuse within 1 y ear pri or to Vi sit 1.
7.3 Excluded Medications 
The fo llowing medicat ions are excluded fromuse during the study  from the time of screening 
unless specified otherwise:
Any treatment for CD other than those listed belo w in Sect ion 7.3.1 (either approved or
investigat ional).
Within 30 days prior to randomizat ion and throughout the study, any o f the following for the 
treatm ent of CD:
–Nonbio logic therapies (eg, cycl osporine, thali domide) other than those specifically  listed 
in Section
 7.3.1 .
–A nonbio logic invest igational therapy .
–An approved nonbio logic therapy  in an invest igational protocol .
Any invest igational or approved bio logic or bi osimilar agent wi thin 60 days or of 
rando mizat ion and throughout the study . 
All live vaccines wit hin 30 days prior to rando mization, throughout the study treatment period 
and for at least 6 months after the last dose ofstudy  drug.
Either approved or invest igationalbiologic agents for the treatment of non -IBD condi tions,
other than localized inject ions (eg, intraocular injections forwetmacular degenerat ion).
Metroni dazo le, ci profl oxacin, am oxicillin clavul anate, or tinidazole after Week 6. Addit ional 
courses of antibiotics may be allowed, as needed, and in consultation with the medical mo nitor.
Oral corti costeroi ds for CD, except as described in Section 7.3.1.1 .
Chronic nonstero idal ant i-inflammatory  drug (NSAID) use. (Note: occasional use of NSAIDs 
for headache, arthrit is, myalgias, menstrual cramps, etc, and daily use of baby or low -dose 
[81162.5 m g] aspi rin for cardi ovascular prophylaxis are permitted.)
Subjects must be instr ucted not to take any  medicati ons, including over
-the-counter products,
withoutfirstconsult ingwith theinvest igator.
7.3.1 Permitted Medications and Treatments
The fo llowing medicat ions for CD are permitted during the study :
Vedolizumab IV
Vedolizumab -4003 Page 36of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALOral 5-ASA co mpounds, probiotics ( eg, Culturelle, Saccharomyces boulardii) , with a stable 
dose for at l east 2 weeks prior to randomizat ion.
5-ASA or corticosteroid enemas/suppositories, with a stable dose for at least 2 weeks prior to 
rando mizat ion.
Oral corti costeroi d therapy  for CD, with mandatory  tapering started by Week 4 as described in 
Secti on7.3.1.1 .
Antidiarrheals for control of chronic diarrhea.
Immunomodulators (methotrexate, azathioprine, 6 -mercaptopurine), stable for at least 8 weeks
prior to random ization.
 Antibiotics to be provided to all subjects fro m Day 1 through Week 6 (cipro floxacin, 
metronidazo le, amoxicillin clavulanate, or tinidazole, as per local label) to decrease incidence 
of abscess . Subjects may  have been on ant ibiot ics prior to random ization. Addit ional 
courses of a ntibiotics may be allowed, as needed, and in consultation wit h the m edical 
monitor. 
7.3.1.1 Oral Corticosteroid Dosing and Tapering
Themaximum dose oforalcorticosteroi dsforthetreatm entofCDthatmay becoadministered
with vedolizumab IV is 20 mg/day prednisone or 9mg/day budesonide (or equivalent) as long 
as the corti costeroi d dose has been stable for at least 4weeks prior to randomizat ion.
Itisrequi red that subjects receiving oral corticosteroids begin a tapering regimen by Week 4. 
An example tapering schedule is as fo llows:
Forprednisone at doses >10 mg/day (or equivalent), the dose should be reduced at a rate of 5
mg/week untila 10 m g/day is reached.
For prednisone at doses ≤10 mg/day (or equivalent) or once a 10 mg/day dose (or equivalent) is
achieved by tapering, the dose should be reduced at a rate of 2.5 mg/week unt il
discontinuat ion.
Budesonide should be reduced at a rate of 3 mg every  3 weeks unt il discont inuat ion.
For pati ents who coul d not tol erate the corti costeroid taper without recurrence of clinical 
symptoms, corticosteroids may have been increased up to the original dose at the start of the study 
(shoul d not exceed baseline dose). In such c ases, the tapering regimen must be reinit iated wi thin 
2weeks.
Vedolizumab IV
Vedolizumab -4003 Page 37of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL7.4 Criteria for Discontinuation or Withdrawal of a Subject
The primary  reason for di scont inuat ion or wi thdrawal  of the subject from  the study  or study drug 
shoul d be recorded in the electronic cas e report form (eCRF) using the following categories. For 
screen failure subjects, refer to Section 9.1.27 .
1.Pretreatment event (PTE) or AE. The subject has experienced a PTE or AE that requires early 
termination b ecause cont inued participat ion imposes an unacceptable risk to the subject’s 
healt h or the subject is unwilling to continue because of the PTE or AE.
Liver Funct ion Test (LFT) Abnormalit ies.
Study  drug shoul d be discont inued immediately with appropriate cl inical fo llow-up 
(including repeat laboratory  tests, until a subject’s laboratory  profile has returned to 
norm al/baseline status, see Section 9.1.20 ), if the following circumstances occur at any 
time during stud y drug treatment:
–ALT or AST >8 × ULN, or
–ALT or AST >5 × ULN and persists for more than 2 weeks, or
–ALT or AST >3 × ULN in conjunct ion with elevated total  bilirubin >2 × ULN or 
internat ional norm alized rati o (INR) >1.5, or
–ALT or AST >3 × ULN with appeara nce of fat igue, nausea, vo miting, right upper 
quadrant pain or tenderness, fever, rash and/or eosinophilia (>5%).
Leukopenia or lymphopenia: WBC and lymphocy te counts will be mo nitored for all 
subjects. Azathioprine, 6
-MP, or methotrexate, if applicable, s hould be discont inued and 
the dose of vedo lizumab held for an abso lute lymphocyte count <0.5×109/L at any point in 
the study . The absol ute lymphocy te count m ust be repeated at appropriate intervals as 
determined by the invest igator. The next dose of vedoli zumab can be administered only  if 
the abso lute lymphocy te count i s ≥0.5×109/L. If the abso lute lymphocy te count rem ains 
<0.5×109/L, study  drug shoul d be discont inued and the subject withdrawn fro m the study .
2.Significant protocol  deviat ion. The discovery  post-rando mizat ion that the subject failed to 
meet protocol entry  criteria or di d not adhere to protocol requirements, and continued 
participat ion poses an unacceptable risk to the subject’s healt h.
3.Lost to follow -up. The subject did not return to the clinic and attem pts to contact the subject 
were unsuccessful. Attempts to contact the subject must be documented in the subject’s source 
docum ents.
4.Voluntary  withdrawal. The subject (or subject’s legally  acceptable representative) wishes to 
withdraw from  the stu dy. The reason for withdrawal, if provided, should be recorded in the 
eCRF.
Note: All attempts should be made to determine the underlying reason for the withdrawal and, 
where possible, the primary  underlying reason should be recorded (ie, withdrawal due to an 
Vedolizumab IV
Vedolizumab -4003 Page 38of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALAE should not be recorded in the voluntary withdraw alcategory . Similarly , lack of efficacy  
shoul d not be recorded in the voluntary withdrawal category).
5.Study  terminat ion. The sponsor, IRB, IEC, or regulatory  agency  terminates the study .
6.Pregnancy. Th e subject is found to be pregnant. 
Note: If the subject is found to be pregnant, the subject must be withdrawn immediately. The 
procedure is described in Sect ion 9.1.26 .
7.Lack of efficacy. The invest igator has d etermined that the subject is not benefit ing fro m 
investigat ional treatm ent; and, continued participatio n would pose an unacceptable risk to the 
subject. 
8.Other.
Note: The specific reasons should be recorded in the “specify” field of the eCRF.
7.5 Procedures f or Discontinuation or Withdrawal of a Subject
The invest igator may discont inue a subject’s study participat ion at any t ime during the study when 
the subject meets the study termination criteria described in Section 7.4. In addition, a subject may 
discontinue his or her participat ion without giving a reason at any  time during the study . Shoul d a 
subject’s participat ion be di scontinued, the primary  criterion for terminat ion must be recorded by  
the invest igator. In addition, efforts should be made to perform all procedures scheduled for the 
Early Terminat ion Visit as well as safet y follow
-up visi ts 18 and 26 weeks post -treatment. 
Discontinued or withdrawn subjects will not be replaced .
Vedolizumab IV
Vedolizumab -4003 Page 39of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL8.0 CLINICAL TRIAL MATER IAL MANAGEMENT
This sect ion contains informat ion regarding all medicat ion and m aterials provi ded di rectly by the 
sponsor, and/or sourced by  other m eans, that are requi red by the study  protocol , including 
important sections describing the management of clinical trial material.
8.1 Study Drug and Materials
8.1.1 Dosage Form, Manufacturing, Packaging, and Labeling
8.1.1.1 Vedolizumab IV and Placebo
The study  sites will be supplied by the sponsor with the following medicat ion for infusio n in an 
open -label manner: vedolizumab IV 300 mg/vial, for single use, in 20 mL vials. The study  drug 
will be provided in a glass vial as a lyophilized so lid for reconstitution using 4.8 ml o f sterile water 
for inject ion and dilut ion in 250 mL o f sterile 0.9% sodium chloride. Each vial will be packaged in 
an appropriately labeled single vial carton. 
The pl acebo infusio n will be 250 mL o f commercially  available 0.9% sodium chloride. For both 
active vedo lizumab and placebo infusio ns, the unblinded invest igational pharmacist or designee 
will mask the IV bags after preparation in order to maintain the study  blind.
Addit ional reference informat ion and administration instructions can be found in the pharmacy 
manual.
8.1.1.2 Companion Medication 
Treatment with ant ibiotics is requi red per pr otocol  from Day  1 until  Week 6 in order to ensure 
adequate care of subjects with perianal abscesses/fistulae. Antibiot ics (metroni dazol e 250 m g 
orally  [PO] 3 times daily [TID], or ciprofloxacin 500 mg twice daily  [BID], or amoxicillin 
clavulanate 875 m g BID, or tinidazo le 500 mg once daily [QD] ) must be prescribed by  the 
investigator as per the local label to decrease incidence of abscess. 
8.1.2 Storage
Study  drug must be kept in an appropriate, limited -access, secure place unt il it is used or returned 
to the sponsor or desi gnee for destructi on. Study must be stored under the condit ions specified on 
the label, and remain in the original container unt il dispensed. 
Vedolizumab IV must be stored at 2ºC to 8ºC (36ºF to 46ºF). A daily temperature log of the drug 
storage area must be maintained.
8.1.3 Dose and Regimen
The vedo lizumab IV dose and regimen for both rando mized groups is provided in Table 8.a. The 
infusio n will be administered intravenously over 30 minutes. Instructi ons fo r reconstitution and 
blinded administration will be provided in the pharmacy manual. Subjects shoul d be observed for 
2hours fo llowing the first 2 infusio ns, at a minimum, and 1 hour after each subsequent infusio n.
Vedolizumab IV
Vedolizumab -4003 Page 40of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALAll subjects m ust al so be prescribed comp anion antibi otic m edicat ion (metroni dazo le 250 mg PO 
TID, cipro floxacin 500 mg PO BID, amoxicillin clavulanate 875 mg BID, or tinidazo le 500 mg 
QD) f rom Day  1 unt il Week 6.
Table 8.a Dose and Regimen
Treat ment Group Dose Treatment Description
1 300 mg IV IV infusion with vedolizumab at Weeks 0, 2, 6, 14, 22
IV infusion with placebo at Week 10
2 300 mg IV IV infusion with vedolizumab at Weeks 0, 2, 6, 10, 14, 22
8.1.4 Overdose
An overdose is defined as a known deliberate or accidental administration of study drug, to or by a 
study  subject, at a dose above that which is assigned to that individual subject according to the 
study  protocol .
All cases of overdose (with or without associated AEs) will be documented on an Overdose page 
of the eCRF, in order to capture this important safety  information consistent ly in the database. 
Cases of overdose without manifested signs or symptoms are not considered AEs. AEs associated 
with an overdose will be documented on AE eCRF( s) according to Section 10.0, Pretreatm ent 
Events and Adverse Events.
SAEs associated with overdose should be reported according to the procedure outlined in 
Secti on10.2.2 , Collect ion and Reporting of SAEs.
In the event of drug overdose, the subject should be treated symptomat ically.
8.2 Study Drug Assignment and Dispensing Procedures
The invest igator or the invest igator’s designee will access the interactive web response system  
(IWRS) at Screening to obtain the study -specific subject identificat ion number (subject number). 
The invest igator or the invest igator’s designee will utilize the IWRS to randomize the subject into 
the study . During thi s contact, the invest igator or designee will provide the necessary 
subject -ident ifying informat ion, including the subject number assigned at Screening. At 
drug-dispensing visits, the invest igator or designee will again contact the IWRS to register the 
visits.
At Weeks 0, 2, 6, 14, and 22, for all subjects in both treatment groups, a medicat ion ident ificat ion 
number (Med ID) will be assigned by IWRS and provided to the site by  email  notificat ion. At 
Week 10, if the subject was randomized to the active treatment arm the Med ID number of t he 
study  drug to be di spensed will then be provided by  the IWRS by  email notificat ion to the 
unblinded site pharmacist/nurse. At Week 10, if the subject was rando mized to receive placebo at 
Week 10, the IWRS will provide email notificat ion to the unblinded site/pharmacist/nurse, but no 
Med ID will be assigned. 
Vedolizumab IV
Vedolizumab -4003 Page 41of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALTo maintain the blind the IWRS will ensure the investigator or designee is unaware if a Med ID has 
been assigned. If sponsor -supplied drug (active vials) is lost or damaged, the site can request a 
replacement fro m IWRS by  the unblinded si te pharmacist/nurse. Refer to IWRS manual provided 
separately .
8.3 Randomization Code Creation and Storage 
Randomization personnel o f the sponsor or designee will generate the randomization schedule. All 
rando mizat ion information will  be stored in a secured area, accessible only  by authori zed 
personnel. Subjects will be rando mized to the 2 dose regimens of vedo lizumab in a 1:1 ratio using 
an IWRS. Rando mizat ion will be stratified by TNF naïve versus TNF non -naïve (TNF fai led) and 
by seton or no seton at Baseline.
8.4 Study Drug Blind Maintenance 
The invest igational drug blind will be maintained using the IWRS. All subjects and study 
personnel except for those directly invo lved with study  drug preparation will be blinded to st udy 
drug assignment for the ent ire study . In order to maintain the blind, unblinded individuals 
preparing study  drug will  cover the product i n a blinding bag prior to dispensing. All unblinded 
dosing information must be maintained in a secured area, access ible only by unblinded personnel, 
and separate from blinded informat ion.
8.5 Unblinding Procedure 
The study  drug blind shall not be broken by  the investi gator unl ess inform ation concerning the 
study  drug i s necessary for the medical treatment of the subject. In the event of a medical 
emergency, if possible, the medical mo nitor should be contacted before the study  drug blind is 
broken to di scuss the need for unblinding.
The invest igator can perform emergency unblindings using the IWRS, if medically necessary. In 
all scenarios, the sponsor must be notified as soon as possible if the study drug blind is broken. The 
date, time, and reason the blind is broken must be recorded in the source documents and the same 
inform ation (except the time) must be recorded on the eCRF.
If any site personnel (with the except ion of the dispensing pharmacist or pharmacy personnel) are 
unblinded, study  drug m ust be stopped immediately  and the subject m ust be wi thdrawn from  the 
study . 
8.6 Accountability and Destruction of Sponsor-Supplied Drugs
The invest igator and invest igator’s designated site pharmacy must ensure that the 
sponsor -supplied drug is used in accordance wit h the protocol and is dispensed only to subjects 
enrolled in the study . To docum ent appropri ate use of sponsor -supplied d rug (vedolizumab IV ),
the invest igator pharmacy must maintain records of all sponsor -supplied drug delivery to the site, 
site inventory , dispensation and use by  each subject, and return to the sponsor or designee.
Vedolizumab IV
Vedolizumab -4003 Page 42of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALUpon recei pt of sponsor -supplied drug, the designated site pharm acy must verify the contents of 
the shipments against the packing list. The verifier should ensure that the quant ity is correct, and 
the medicat ion is in good condit ion. If quantit y and condi tions are acceptable, designated site 
pharm acy shoul d acknowl edge the receipt of the shipment by  signing bottom  half of the packing 
list and by recording in IWRS. If there are any discrepancies between the packing list versus the 
actual product received, Takeda must be contacted to resolve the issu e. The packing list should be 
filed in the investigator’s essent ial document file.
The invest igator’s designated site pharmacy must maintain 100% accountabilit y for all 
sponsor -supplied drugs received and dispensed during his or her ent ire parti cipat ion inthe study . 
Proper drug accountabilit y includes, but is not limited to:
Moni toring expirat ion dates (monitored via IWRS).
Frequent ly verifying that actual inventory  matches docum ented inventory .
Verifying that the drug accoun tabilit y log is completed for t he Med ID used to prepare each 
dose.
Verifying that all containers used are documented accurately on the log.
Verifying that required fields are co mpleted accurately and legibly.
If any dispensing errors or discrepancies are discovered, the sponsor must be notified immediately.
The IWRS will include all required informat ion as a separate entry  for each subject to whom 
sponsor -supplied drug is dispensed.
The invest igator’s designated site pharmacy must record the current inventory of all 
sponsor -supplied drugs (vedolizumab IV) on a sponsor -approved drug accountabilit y log. The 
following informat ion will be recorded at a minimum: protocol number and tit le, name of 
investigator, site ident ifier and number, descript ion of sponsor -supplied drugs, expiry date and 
amount dispensed, and amount returned to the pharmacy  (if applicable) including init ials, seal, or 
signature of the person dispensing the drug. The log shoul d include all required informat ion as a 
separate entry for each subject (by subject identifier) to whom sponsor -supplied drug is dispensed. 
The invest igator’s designated site staff administering the study drug infusio n must com plete an 
individual subject accountabilit y log to docum ent if infusio n was co mplete or if inco mplete and 
study  drug was returne d to the pharmacy, including the date and amount returned to the pharmacy, 
including the init ials, seal, or signature of the person administering the infusio n. Only unblinded 
site personnel and unblinded clinical research assistants (CRAs) can perform drug accountabilit y 
and drug returns in order to preserve blinding.
Prior to si te closure or at appropriate intervals, a representative from the sponsor or its designee 
will perform sponsor -supplied drug accountabilit y and reconciliat ion before sponsor -supplied 
drugs are returned to the sponsor or its designee for destruction. The invest igator or designee will 
retain a copy  of the docum entati on regarding sponsor -supplied drug accountabilit y, return, and/or 
destruction, and originals will be sent to the sponsor or desi gnee.
Vedolizumab IV
Vedolizumab -4003 Page 43of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL9.0 STUDY PLAN
9.1 Study Procedures
The fo llowing sect ions describe the study procedures and data to be collected. For each procedure, 
subjects are to be assessed by the same invest igator or site personnel whenever possible. The 
Schedule of Study  Proc edures is located in Appendix A.
9.1.1 Informed Consent Procedure
The requi rements of the informed consent process are described in Sect ion 15.2 and Appendix C .
Inform ed consent m ust be obtained prior to the subject entering into the study , and before any 
protocol -directed procedures are performed.
A unique subject ident ificat ion number (subject number) will be assigned to each subject a t the 
time that informed consent is obtained through the IWRS system; this subject number will be used 
throughout the study .
9.1.2 Demographics, Medical History, and Medication History Procedure
Dem ographic informat ion to be obtained will include date of birth o r age, sex, Hispanic 
ethnicit y(as applicable), race as described by the subject, andsmoking/nicotine usage status of
the subject at Screening.
Medical history  to be obtained will include determining whether the subject has any  
significant condi tionsordiseases relevant tothedisease under study  that resolved at or prior 
to signing of informed consent. Ongoing condit ions are considered concurrent medical 
condi tions (see Section 9.1.8 .)
Medicat ion history  informat ion to be obt ained includes any medicat ionrelevant to eligibilit y
criteria stopped at or within 30days priortosigning of informed consent.
In addit ion,all pri orbiologic and/or any  medicat ion history  forthetreatment of CD, including 
date of di agnosis, wi th the reason for discontinuation is to be collected for subjects where 
possible.
9.1.3 Crohn’s Disease History
CD history  will include details of CD diagnosis, disease severit y, surgery , hospi talizati ons, and 
extraintestinal manifestations.
9.1.4 Physical Examination Procedu re
A Visit 1 (Screening) physical examinat ion will consist of the following body  systems: (1) ey es; 
(2) ears, nose, throat; (3) cardiovascular system; (4) respiratory  system; (5) gastrointest inal 
system; (6) dermatologic system; (7) extremit ies; (8) muscul oskeletal  system; (9) nervous system; 
(10) lymph nodes ; and (11) other. All subsequent physical examinat ions should assess clinically  
Vedolizumab IV
Vedolizumab -4003 Page 44of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALsignificant changes from the assessment prior to first dose examinat ion. Addit ionally , abdominal  
mass assessment will be p erformed at all visits where CDAI is calculated.
9.1.5 Weight, Height
A subject should have weight and height measured while wearing indoor clothing and with shoes 
off. The Takeda standard for collect ing height is cent imeters without decimal places and for 
weight it is kilograms (kg) with 1 decimal place.
9.1.6 Vital Sign Procedure
Vital signs will  include body  temperature, respi ratory  rate, supine blood pressure (sy stolic and 
diastolic, resting more than 5 minutes), and pulse (resting more than 5 minutes).
When vita l signs are scheduled at the same t ime as blood draws, vital signs take priorit y and vital 
signs will be taken wi thin 5 minutes before the scheduled blood draw.
9.1.7 PML Checklist
Site staff will administer the subjective PML checklist during screening to exclu de subjects wi th 
positive responses fro m enrolling into the study . The subject ive PML checklist will be 
administered prior to dosing at each visit, as shown in Appendix A, to evaluate symptoms 
suggest ive of PML. An y subjects reporting signs or symptoms of PML will undergo object ive 
testing and may  be referred to a neurol ogist f or a full evaluat ion. The symptom s from a posi tive 
PML checklist obtained after randomizat ion will be recorded as an AE. Addit ional informat ion 
and tools will be found in the Invest igator Site File.
9.1.8 Documentation of Concurrent Medical Conditions
Concurrent medical condit ions are those significant ongoing condit ions or diseases that are present 
at signing of informed consent. This includes clini cally significant laboratory , electrocardi ogram  
(ECG), or physical examinat ion abnormalit ies noted at the screening or baseline examinat ion. The 
condi tion (ie, diagnosis) should be described.
9.1.9 ECG Procedure 
A standard 12- lead ECG will be recorded. The inve stigator (or a qualified observer at the study  
site) will interpret the ECG using 1 of the fo llowing categories: wit hin normal limits, abnormal but 
not clinically significant, or abnormal and clinically significant. A copy of the ECG trace should be 
kept w ith the subject’s notes.
9.1.10 MRI Procedure
Subjects m ust have safet y laboratory  resul ts reviewed pri or to MRI scan being performed. If a 
subject’s serum creat inine is > 1.5 times the ULN (>1.5x ULN), the subject should not undergo the 
MRI procedure (see Exclus ion Cri teria 28).
Vedolizumab IV
Vedolizumab -4003 Page 45of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALA co mprehensive descript ion of MRI procedures is provided in the IAG and the Site Operations 
Manual.
MRI i s the imaging modalit y of choice for eval uation of perianal fistulizing CD as it allows 
accurate localizat ion and assessment of disease. In addit ion, MRI has been found to be sensit ive to 
the degree of perianal disease act ivity and thereby  offers an assessment of response to therapy  in 
clinical trials.
A pelvic MRI will be performed at Screening (Visit 1) and Week 30 (Visit 8). Sites w ill use a 
1.5T/3T Who le Body MRI scanner retrofitted with body radio frequency (RF) co il for pelvic MRI. 
MRIs will be assessed by central radio logists for eligibilit y and scoring.
At Screening (Visit 1), the site radio logist will measure any  perianal absces s for assessment of 
eligibilit y criteria (an abscess greater than 2 cm on MRI is exclusio nary). Confi rmation must be 
obtained fro m the central  reader to confirm MRI eligibilit y.
An assigned central radio logist will classify fistulae using the simple and co mplex schema, the 
Parks’ classificat ion, and Van Assche score components.
Van Assche et al have developed an MRI -based scoring method for assessment of disease severit y 
in patients with perianal fistulizing CD [32]. This object ive scoring method will be used in this 
study  for assessing response to therapy . Briefly, central  radiologist will classify fistula(e) after 
reviewing T1 -and T2 -weighted images o f the perianal regio n (pelvic MRI) which demo nstrate the 
full extent of the perianal disease. Local inflammatory  activit y, an important parameter, will be 
assessed on T2- weighted images. Act ive fistulae and abscesses with act ive inflammatory  process 
are visible o n T2 images as hyperintense lesions due to their fluid contents, while scar tissue 
appears hypo intense. 
Relative mean T2 signal intensit y changes will be assessed by  com paring norm alized T2 si gnal 
intensity values o f inflamed perianal regions including fi stula tracts to T2 signal intensit y of 
healt hy tissue (eg, muscle or fat) at follow -up time point wi th baseline values. In addit ion, post 
Gadolinium contrast enhanced T1- weighted imaging will be performed as part of the study  MRI 
protocol  in all subjects. Follow -up contrast -enhanced T1- weighted images will be co mpared to 
baseline images by the central reader in order to assess response to therapy . 
9.1.10.1 Parks Classification
Parks described a classificat ion system for perianal fistula [31], that will be used at Screening for 
classificat ion of active fistula(e) as superficial, intersphincteric, transsphincte ric, suprasphincteric, 
or extrasphincteric. 
Vedolizumab IV
Vedolizumab -4003 Page 46of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL9.1.10.2 Van Assche MRI -Based Score
The Van Assche MRI-based score for severity of perianal CD [32]will be calculated at Screening 
(Visit 1) and Week 30 (Visit 8). The 6 co mponents of the score, summarized below are summed to 
a total  score of 0 to 24.
Number of fistula tracks None = 0
Single, unbranched = 1
Single, branched = 2
Multiple = 3
Location None/Not applicable = 0
Extra -or intersphincteric = 1
Transsphincteric = 2
Suprasphincteric = 3
Extension None/Not applicable = 0
Infralevatoric = 1
Supralevatoric = 2
Hyperintensity on T2 -weighted images Absent = 0
Mild = 4
Pronounced = 8
Collections (cavities 3 mm diamete r) Absent = 0
Present = 4
Rectal wall involvement Normal = 0
Thickened = 2
9.1.11 Fistula Draining Assessment 
Fistul a(e) (perianal, enterocutaneous) will be assessed for draining or closed status at each visit, as 
shown in Appendix A.Fistul a draining assessment will preferably be performed by the same 
qualified designee for all assessments.
9.1.12 Primary Endpoint Measurement
The primary  endpoint m easure is ≥50% reducti on from  Day  1 in number of draining perianal 
fistul ae at Week 30 (where closed fistulae are assessed by the investigator to be no longer draining 
despite gent le finger co mpressio n).
9.1.13 PDAI
The PDAI [33]includes 5 elements: the presence or absence of discharge, pain or restrict ion of 
activit ies o f daily living, restrict ion of sexual act ivity, the ty pe of  perianal disease, and the de gree 
of indurat ion. Scores range from 0 to 20, with higher scores indicat ing more severe disease. See 
Appendix E.
9.1.14 CDAI
A CDAI [34]score will be evaluated during Screening, using subject diary entries wi thin 14 days 
prior to enrollment, and hematocrit results collected during Screening. A CDAI score will also be 
Vedolizumab IV
Vedolizumab -4003 Page 47of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALderived at the time po ints specified in the Schedule of Events and at any  unscheduled visit(s) due 
to disease exacerbat ion. See Appendix F. A Standard Weight Table is provided in  Appendix G.
9.1.15 CDAI Diary Completion
Diary entries will  be made daily by subjects and will be used for CDAI score calculat ion. During 
screening, subjects will be instructed on how to appropriately co mplete the daily diary . The 
symptoms of CD must be recorded throughout the study, including the Screening Period. Di ary 
entries will be made daily by the subject through an electronic system. Entries should be reviewed 
and mo nitored by  the study  staff.
9.1.16 Patient Reported Outcome Measures
Subjects will co mplete the IBDQ and EQ -5D health -related qualit y of life (HRQOL) 
questionnai res at the time points specified in the schedule of events ( Appendix A). Subjects will 
also complete a Likert scale daily to assess perianal pain.
9.1.16.1 IBDQ
The IBDQ is a valid and reliable [
35-37]instrument used to assess qualit y of life in adult subjects 
with IBD. It i ncludes 32 quest ions on 4 domains of HRQOL: Bowel Sy stems (10 i tems), 
Emotional Funct ion (12 items), Social Functi on (5 i tems), and Systemic Funct ion (5 i tems). 
Subjects are asked to recall symptoms and qualit y of life from the last 2 weeks and rate each item 
on a 7 -point Likert scale (higher scores equate to higher qualit y of life). A total IBDQ score is
calculated by  summing the scores fro m each do main; the total IBDQ score ranges fro m 32 to 224. 
See Appendix H.
9.1.16.2 EQ-5D Questionnaire
The EQ -5D questionnaire, developed by EuroQol, is a simple, valid and reliable [38] instrument 
used to m easure general HRQOL in pat ients and incl udes 5 dom ain items -mobility, self-care, 
usual act ivities, pain/disco mfort, and a nxiet y/depressi on. Pati ents choose the level o f health 
probl ems they current ly have on each item as “None”, “Moderate”, or “Extreme” and are scored a 
1, 2, or 3, respectively . A com posite EQ -5D score can be calculated fro m the individual scores to 
assess o verall HRQOL. The EQ -5D visual analog scale (VAS) score is a self -assigned rating of 
overall health using a 20 cm visual, vert ical scale, wi th a score of 0 as the worst and 100 as best 
possible health. The EQ -5D total score and EQ -5D VAS score have been sh own in many studies to 
be valid and reliable instruments for measuring HRQOL in pat ients with GI diseases [39,40] . See 
Appendix I.
9.1.16.3 Likert Perianal Pain Scale
Subjects will complete an 11 -point Likert scale as part of the subject diary to assess perianal pain, 
where 0 represents no perianal pain and 10 represents the worst possible perianal pain. Subjects 
will co mplete thi s scale every  day. A mean score will be calculated for the 7 days prior to every  
visit. See Appendix J.
Vedolizumab IV
Vedolizumab -4003 Page 48of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL9.1.17 Pad Collection
The number of pads used daily will be collect ed to measure fistula drainage at selected study sites 
only.
9.1.18 Documentation of Concomitant Medications
Concomitant medicat ion is any drug given in addit ion to the study  drug. These m ay be prescribed 
by a phys ician or obtained by the subject over the counter . Concomitant medicat ion is no t provided 
by the sponsor. At each study visit, subjects will be asked whether they have taken any medicat ion 
other than the study  drug (used from signing of informed consent through the end of the study ), 
and all medicat ion including vitamin supplements, over- the-counter m edicat ions, and oral herbal 
preparati ons, m ust be recorded in the eCRF.
9.1.19 Documentation of Concurrent Medical Conditions
Concurrent medical condit ions are those significant ongoing condit ions or diseases that a re present 
at signing of informed consent. This includes clinically significant laboratory , ECG, or phy sical 
examinat ion abnormalit ies noted at screening/baseline examinat ion. The condit ion (ie, diagnosis) 
shoul d be described as current on the Medical Hist ory eCRF.
9.1.20 Procedures for Clinical Laboratory Samples
All samples will be co llected in accordance with acceptable laboratory procedures. The maximu m 
volume of blood at any  single visit is approximately  30 mL, and the approximate total volume of 
blood for th e study is 166 mL. Details of these proc edures, specimen handling and required safet y 
monitoring will be given in the laboratory  manual.
The clinical laboratory  tests to be conducted during the study  are summarized in Table 9.a. 
Vedolizumab IV
Vedolizumab -4003 Page 49of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALTable 9.a Clinical Laboratory Tests
Hematology Serum Chemistry Urinalysis
RBC
WBC with differential (a)
Hemoglobin
Hematocrit (b)
Platelets
PT/INRALT
Albumin
Alkaline phosphatase
AST
Total bilirubin
Total protein
Creatinine
Blood urea nitrogen
Creatine kinase
GGT
Potassium
Sodium
Calcium
Chloride
Magnesium
Phospho rus
Uric Acid
GlucoseBilirubin
Blood
Glucose
Ketones
Leukocyte esterase
Nitrite
pH
Protein
Specific Gravity
Other: 
HIV
Hepatitis panel, in cluding HBsAg and anti -HCV
Serum Urine Stool
CRP
Pharmacokinetic samples
AVA/nAVA
QuantiFERON for TBhCG (for pregnancy in female 
subjects of childbearing potential only) Fecal calprotectin
beta hCG (for pregnancy in female subjects of 
childbearing p otential only)
FSH, if menopause is suspected (Screening Visit only)
(a) WBC differential to include lymphocytes, monocytes, basophils, eosinophils, and neutrophils.
(b) Hematocrit only collected at Visits 3, 4, and 6
AVA= Anti-vedolizumab antibodies, nA VA=neutralizing anti -vedolizumab antibodies, FSH=follicle -stimulating 
hormone, GGT=γ -glutamyl transferase, HBsAg = hepatitis B surface antigen, hCG=human chorionic gonadotropin, 
PT=prothrombin time, RBC=red blood cells.
The central laboratory  will perform laboratory  tests for hematology , serum  chemistri es, stool , and 
urinalysis. The results of safet y laboratory  tests will  be returned to the investigator, who is 
responsible for reviewing and filing these results.
If subjects experience ALT or AST >3 ×ULN, fo llow-up laboratory tests (at a minimum, serum 
alkaline phosphatase, ALT, AST, total bilirubin, GGT, and INR) should be performed wit hin a 
maximum o f 7 day s and preferably within 48 to 72 hours after the abnormalit y was noted.
Vedolizumab IV
Vedolizumab -4003 Page 50of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL(Please refer to Section 7.4for discont inuat ion criteria, and Sect ion 10.2.3 for the appropriate 
guidance on Reporting of Abnormal LFTs in relat ion to ALT or AST >3 ×ULN in conjunct ion 
with total bilirubin >2 ×ULN.)
If the ALT or AST remains elevated >3 ×ULN on 2 consecutive occasio ns the invest igator must 
contact the medical mo nitor for consi derat ion of addi tional testing, cl ose m onitoring, possible 
discontinuat ion of study  drug, discussio n of th e relevant subject details and possible alternat ive 
etiologies. The abnormalit y shoul d be recorded as an AE (please refer to Section 10.2.3 Reporting 
of Abnorm al LFTs f or reporting requirements).
9.1.21 Fecal Calprotec tin Sample Collection
A stool  sample will be collected at Day 1 and at Weeks 14 and 30 for the analysis o f fecal 
calprotectin, a bi omarker of intestinal inflammatory  activi ty.
9.1.22 Pharmacokinetic Sample Collection 
Blood sam ples will be drawn for serum PK analy sis in all subjects within 30 minutes prior to the 
start of infusio n on Day 1, Weeks 6, 10, 14, 22, and at Week 30. One addit ional PK sample will be 
collected at Week 10 post end of infusio n (as clo se to the end o f the infusio n as feasible and wit hin 
30 mi nutes of the end of the infusio n). Serum concentrations of vedo lizumab will be measured by 
a sandwich enzyme -linked immunosorbent assay (ELISA) assay with a validated range of 0.20 to 
8.0 µg/m L.
9.1.23 Anti
-Vedolizumab Antibodies Sampling
Blood sam ples f or AVA as sessment will be obtained wi thin 30 minutes prior to dosing on Day  1, 
Weeks 6, 10, 14, 22, 30, and 40. All subjects will have a sample for AVA collected at Week 10 
regardl ess of treatment group. A Week 40 fo llow-up AVA sample will be collected 18 weeks aft er 
the last dose of vedo lizumab for subjects who do not con tinue on to commercial supply  
vedo lizumab post -study  (eg, l ast dose of vedo lizumab at Week 22). A sample will be assessed for 
neutralizing AVA if a posit ive AVA is detected. 
Serum  titers of AVA wi ll be determined using a validated assay. Neutralizing AVA (nAVA) will 
be determined on AVA positive samples using a validated assay.
Please refer to the laboratory  manual for information on sample collect ion and preparation.
9.1.24 Tuberculosis Screening
Allsubjects will co mplete TB screening to determine eligibilit y, unless a negative test result is 
available fro m within 3 m onths pri or to Screening and the subject has no risk factors for 
exposure. If required during screening, either aQuant iFERON test or atuberculin skin test will 
be perform ed. Subjects will be excluded fromthestudy iftheyhave active or latent TB, 
regardl ess of treatm ent history .
Vedolizumab IV
Vedolizumab -4003 Page 51of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL9.1.25 Contraception and Pregnancy Avoidance Procedure
9.1.25.1 Male Subjects and Their Female Partners
From  signing of informed consent, throughout the durati on of the study, and for 18 weeks after last 
dose of study drug, nonsterilized** male subjects who are sexually act ive with a female partner of 
childbearing potential* must use barrier contraceptio n (eg, condom wit h spermici dal cream  or 
jelly). In addition, they  must be advised not to donate sperm during this period. Women of 
childbearing potential who are partners of male subjects are also advised to use addit ional 
contraception as shown in the list of highly effective contr aception below.
9.1.25.2 Female Subjects and Their Male Partners
From  signing of informed consent, throughout the durati on of the study, and for 18 weeks after last 
dose of study  drug, female subjects of childbearing potential* who are sexually  active wi th a 
nonste rilized male partner** must use a highly  effective method of contraception (from the list 
below). 
In addit ion, they  must be advised not to donate ova during this period.
9.1.25.3 Definitions and Procedures for Contraception and Pregnancy Avoidance
The follow ing de finitions apply for contraception and pregnancy avoidance procedures.
* A wom an is considered a woman of childbearing potential (ie, fert ile) fo llowing m enarche and 
until becoming post -menopausal unless permanently  sterile. Perm anent sterilizat ion methods 
include hysterectomy, and bilateral oophorectomy . A post -menopausal state is defined as no 
menses for 12 months wit hout an alternative medical cause. A high fo llicle -stimulat ing hormone 
(FSH) level in the post -menopausal range (FSH >40 IU/L) may  be used to confirm a 
post-menopausal state in y ounger wom en (ie, younger than age 45) or women who are not using 
horm onal contracepti on or horm onal replacement therapy. However, in the absence of 12 months 
of amenorrhea, a single FSH measurement is insufficient.
** Sterilized males should be at least 1 year post -bilateral vasectomy and have confirmed that they 
have obtained documentation of the absence of sperm in the ejaculate or have had bilateral 
orchi dectomy .
The follow ing procedures apply for contraception and p regnancy avoidance.
1.Highly effect ive methods of contraception are defined as “those that, alone or in combinat ion, 
resul t in a l ow failure rate (i e, less than 1% failure rate per y ear when used consistent ly and 
correctly ). In this study, where medicat ions and devices containing hormones are included, the 
only acceptable methods of contraception are: 
Non-horm onal methods: 
Intrauterine device (IUD). 
Bilateral tubal occlusio n. 
Vedolizumab IV
Vedolizumab -4003 Page 52of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALVasectomised partner (provided that partner is the sole sexual partner of the tr ial 
participant and that the vasectomised partner has received medical assessment of 
the surgi cal success. 
Horm onal methods: 
Combined (estrogen and progestogen) hormonal contraception associated with 
inhibit ion of ovulation initiated at least 3 months pr ior to the first dose of study  
drug OR combined wit h a barrier method (male condo m, female condom or 
diaphragm ) if for shorter duration unt il she has been on contraceptive for 3 months;
Oral. 
Intravaginal (eg, ring).
Transdermal. 
Progestogen -only hormonal contracepti on associ ated wi th inhibit ion of ovulation1 
initiated at least 3 months prior to the first dose of study drug OR combined with a 
barrier m ethod (m ale condom , female condo m or diaphragm) if shorter till she has 
been on contraceptive for 3 month s;
Oral. 
Injectable.
Implantable.
2.Unacceptable methods of contraception are:
Periodic abst inence (eg, calendar, ovulat ion, symptothermal, post -ovulation methods).
Spermicides only .
Withdrawal.
No m ethod at all.
Use of female and male condoms together.
Cap/diaphragm/sponge wi thout spermicide and w ithout condom .
Sexual abst inence is NOT an acceptable method of contraception.
3.Subjects will be provided with information on highly effect ive methods of contraception as 
part of the subject informed consent process and will be asked to sign a consent form stating 
that they  understand the requirements for avo idance of pregnancy, donat ion of ova, and sper m 
donati on during the course of the study .
4.During the course of the study, regular urine human chorionic gonadotrop in (hCG) pregnancy 
tests will be performed only for women of childbearing potential and all subjects (male and 
female) will receive continued guidance with respect to the avo idance of pregnancy and sperm 
Vedolizumab IV
Vedolizumab -4003 Page 53of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALdonati on as part of the study  procedures. Such guida nce should include a reminder of the 
following:
a.Contraceptive requirements of the study
b.Reasons for use of barrier methods (ie, condom) in males with pregnant partners
c.Assessment of subject compliance through questions such as
i.Have you used the contracepti on consistent ly and correctly since the last 
visit?
ii.Have y ou forgotten to use contraception since the last visit ?
iii.Are your menses late (even in women with irregular or infrequent menstrual 
cycles a pregnancy test must be performed if the answer is “yes”)?
iv.Is there a chance you could be pregnant ?
5.In addit ion to a negative serum hCG pregnancy test at Screening, female subjects of 
childbearing potential must also have confirmed menses in the mo nth before first dosing (no 
delayed menses), a negat ive urine hCG pregnancy  test prior to receiving each IV dosing.
9.1.25.4 General Guidance With Respect to the Avoidance of Pregnancy
Such guidance should include a reminder of the fo llowing:
Contraceptive requirements of the study .
Reasons for use of barrier methods (ie, condom) in males with pregnant partners.
Assessment of subject compliance through questions such as:
–Have you used the contraception consistent ly and correctly since the last visit ?
– H ave y ou forgotten to use contraception since the last visit ? 
–Are y our menses l ate (even in wom en wi th irregular or infrequent menstrual cy cles a 
pregnancy test must be performed if the answer is “yes”)?
–Is there a chance you could be pregnant ?
9.1.26 Pregnancy
If any subject is found to be pregnant during the study  she shoul d be wi thdrawn a nd vedo lizumab 
shoul d be immediately discont inued. In addit ion, any  pregnancies in the partner of a male subject 
during the study  or for 18 weeks after the last dose, should also be recorded following 
authori zation from the subject’s partner.
If the pregna ncy occurs during administration of active study  drug, eg, after Visit 1 or within 18 
weeks of the last dose of active study drug, the pregnancy should be reported immediately, using a 
pregnancy notificat ion form, to the contact listed in Section 1.0.
Vedolizumab IV
Vedolizumab -4003 Page 54of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALShoul d the pregnancy  occur during or after administration of blinded drug, the invest igator must 
inform  the subject of their right to receive treatment information. If the subject chooses to receive 
unblinded treatm ent inform ation, the individual blind should be broken by the invest igator. 
If the female subject and/or female partner of a male subject agrees to the primary care physician 
being informed, the invest igator should notify the primary care physician that t he subject/female 
partner of the subject was participat ing in a clinical study  at the time she became pregnant and 
provi de details o f treatm ent the subject received (blinded or unblinded, as applicable).
All pregnancies in subjects, including female partne rs of m ale subjects, on active study  drug 
including comparator will be fo llowed up to final outcome, using the pregnancy form. Pregnancies 
will remain blinded to the study team. The outcome, including any premature terminat ion, must be 
reported to the spon sor. An evaluation after the birth of the child will also be conducted.
9.1.27 Documentation of Screen Failure
Invest igators must account for all subjects who sign informed consent.
If the subject is found to be not eligible at the Screening visit, the invest igator should co mplete the 
eCRF. The IWRS should be contacted as a notification of screen failure.
The primary  reason for screen failure is recorded in the eCRF using the following categories:
PTE/AE.
Did not m eet incl usion criteria or di d meet exclusion crite ria (specify  reason).
Significant protocol  deviat ion.
Lost to follow -up.
Voluntary  withdrawal (specify  reason).
Study  terminat ion.
Other, specify.
Subject numbers assigned to subjects who fail screening should not be reused.
9.1.28 Documentation of Randomization
Randomization will be performed through the IWRS system. Only subjects who meet all o f the 
inclusio n criteria and none of the exclusion criteria are eligible for randomizat ion into the 
treatm ent phase.
If the subject is found to be not eligible for randomi zation, the invest igator should record the 
primary  reason for failure on the applicable eCRF.
Vedolizumab IV
Vedolizumab -4003 Page 55of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL9.2 Monitoring Subject Treatment Compliance
A vedo lizumab dispensing log, including records of drug received fro m the sponsor and vo lume o f 
vedo lizumab dispensed to e ach subject intravenously, will be maintained by the site. 
The site will also document missed doses of ant ibiotic co mpanio n medication.
If a subject is persistently nonco mpliant with the study drug, it may be appropriate to withdraw the 
subject from the s tudy. 
9.3 Schedule of Observations and Procedures
The schedule for all study -related procedures for all evaluat ions is shown in Appendix A. 
Assessments should be co mpleted at the designated visit/time po int(s).
9.3.1 Screen ing Visit 1
Subjects will be screened within 28 days prior to randomizat ion. Subjects will be screened in 
accordance with predefined inclusio n and exclusio n criteria as described in Sect ion7.0.
 See 
Secti on 9.1.27 for procedures for documenting screening failures.
Procedures to be completed at Screening Visit 1 can be found in the Schedule of Study Procedures 
(Appendix A). 
9.3.2 Randomization (Day 1) (Visit 2)
Randomization will take place on Day  1. The Day  1 procedures are documented in
 Appendix A.
If the subject has sat isfied all o f the inclusio n criteria and none of the exclusio n criteria for 
rando mizat ion,the subject should be rando mized using the IWRS as described in Section
 8.2. 
Subjects will be given infusio n instructions for the first dose of study drug as described in Sect ion 
8.1.3 .
 The procedure for documenting screening failures is provided in Sect ion 9.1.27 .
9.3.3 Week 30 or Early Termination (Visit 8)
The final treatment period visit will be performed at Week 30 (Visit 8) or at the Early Terminat ion 
Visit, if applicable (see Appendix A).
For all subjects rando mized, the invest igator must complete the End of Study Drug and End of 
Study  Visi ts eCRF pages.
9.3.4 Week 40 Follow -up (or 18 Weeks Post -Treatment)
Follow
-up will begin the first day  after the last dose of vedolizumab and will continue for 
18weeks. This fo llow-up visi t will  be scheduled for safet y for all subjects and for AVA 
assessments for all subjects who stopped vedolizumab during study (ie, not for those who continue 
on commercial supply vedo lizumab therapy post -study) as per Appendix A.
Vedolizumab IV
Vedolizumab -4003 Page 56of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL9.3.5 Post Study Long -Term Follow- Up (or 26 Weeks Post -Treatment)
Upon complet ion of or early termination fro m the study, all subjects will complete a LTFU safet y 
survey by  telephone. Thi s questi onnai re will  be administered at 6 m onths from the last dose of 
study  drug.
9.3.6 Unscheduled Visits Due to Exacerbation of CD
Subjects who are seen by the invest igator or site staff at a time point not requ ired by the protocol 
(ie, unscheduled visit) due to disease exacerbat ion will undergo the fo llowing:
Physical examinat ion.
Urine pregnancy  test (f or females of childbearing potential).
Clinical chemistry  and hematol ogy, if indicated.
AVA sample.
Concomitan t mediat ions.
AE/SAE assessment.
9.3.7 Post Study Care
Vedolizumab IV treatment will not be supplied upon completion o f the subject’s participation in 
the study . The subject shoul d be returned to the care of a physician and standard therapies as 
requi red. The su bject may be continued on co mmercial supply o f vedo lizumab, at the discret ion of 
their physician.
9.4 Biological Sample Retention and Destruction
In thi s study , samples for AVA analysis will be collected as described in Section 9.1.23 .
The AVA samples will be stored for up to but not longer than 15 years fro m when the study result s 
are reported or as required under applicable law or unt il consent is withdrawn. After that time, the 
sample swill be destroy ed. 
The samp leswill be sent to a sponsor ident ified laboratory  that will serve as a secure storage 
facilit y. The sponsor, i ts agents and affiliated companies will have access to the samples. All 
samples collected during the study will be stored securely wit h limited access and the sponsor will 
requi re any one who works wi th the samples to agree to hold the research informat ion and any  
individual results in confidence.
The sample swill be labeled wi th a unique sample ident ifier. The samples and data are linked to 
person al healt h informat ion with code numbers. This link means that the subject may be ident ified 
but only indirectly. The code numbers will be kept secure by or on behalf o f the sponsor.
Vedolizumab IV
Vedolizumab -4003 Page 57of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL10.0 PRETREATMENT EVENTS (PTE) AND ADVERSE EV ENTS (AE)
10.1 Definitions
10.1.1 PTEs
A PTE i s defined as any  untoward m edical  occurrence in a clinical invest igation subject who has 
signed inform ed consent to participate in a study  but pri or to administration of any study  drug; i t 
does not necessarily  have to have a causal relat ionship wit h study  participat ion.
10.1.2 AEs
An AE is defined as any untoward medical occurrence in a clinical invest igation subject 
administered a drug; it does not necessarily have to have a causal relat ionship with this treatment.
An AE can therefore be any unfavorable and unint ended sign (eg, a clinically significant abnormal 
laboratory  value), symptom, or disease temporally associated with the use o f a drug whether or not 
it is considered related to the drug.
10.1.3 Additional Points to Consider for PTEs and AEs
An untoward finding ge nerally  may:
Indicate a new diagnosis or unexpected worsening of a pre- exist ing condit ion. (Intermittent 
events for pre -exist ing condit ions or underlying disease should not be considered PTEs or 
AEs.)
Necessitate therapeutic intervent ion.
Requi re an invasi ve diagnosti c procedure.
Requi re discont inuat ion or a change in dose of study  drug or a concomitant medicat ion.
Be considered unfavorable by the invest igator for any reason.
PTEs/AEs caused by a study procedure (eg, a bruise after blood draw) should be rec orded as a 
PTE/AE.
Diagnoses versus signs and symptoms:
Each event should be recorded to represent a single  diagnosis. Acco mpanying signs (including 
abnorm al laboratory  values or ECG findings) or symptoms should NOT be recorded as 
additional AEs. If  a diagnosis is unknown, sign(s) or symptom(s) should be recorded 
appropriately  as a PTE(s) or as an AE(s).
Laboratory  values and ECG findings:
Changes in laboratory  values or ECG findings are only  considered to be PTEs or AEs if they 
are judged to be clinically significant (i e, if so me action or intervent ion is required or if the 
investigator judges the change to be bey ond the range of normal physio logic fluctuati on). A 
Vedolizumab IV
Vedolizumab -4003 Page 58of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALlaboratory  or ECG re -test and/or continued mo nitoring of an abnormal finding are not 
considere d an intervention. In addit ion, repeated or additional noninvasive testing for 
verification, evaluat ion or monitoring o f an abnormalit y is not consi dered an intervent ion.
If abnormal laboratory values or ECG findings are the result of pathology for which t here is an 
overall diagnosis (eg, increased creat inine in renal failure), the diagnosis only should be 
reported appropriately  as a PTE or as an AE.
Pre-exist ing condit ions:
Pre-exist ing condit ions (present at the time o f signing of informed consent) are co nsidered 
concurrent medical condit ions and should NOT be recorded as PTEs or AEs. Baseline 
evaluat ions (eg, l aboratory  tests, ECG, X -rays etc.) should NOT be recorded as PTEs unless 
related to study  procedures. However, if the subject experiences a worseni ng or com plicati on 
of such a concurrent medical condit ion, the worsening or complicat ion should be recorded 
appropriately  as a PTE (worsening or complicat ion occurs before start of study drug) or an AE 
(worsening or complicat ion occurs after start of study drug). Invest igators should ensure that 
the event term recorded captures the change in the condit ion (eg, “worsening of…”).
If a subject has a pre -exist ing episodic concurrent medical condit ion (eg, asthma, epilepsy) any 
occurrence of an episode should on ly be captured as a PTE/AE if the condit ion beco mes more 
frequent, serious or severe in nature. Investigators should ensure that the AE term recorded 
captures the change in the condit ion from Baseline (eg “worsening of…”).
If a subject has a degenerat ive c oncurrent medical condit ion (eg, cataracts, rheumatoid 
arthri tis), worsening of the condition should only  be recorded as a PTE/AE if occurring to a 
greater extent to that which would be expected. Investigators should ensure that the AE term 
recorded captur es the change in the condit ion (eg, “worsening o f…”).
Worsening of PTEs or AEs:
If the subject experiences a worsening or complicatio n of a PTE after starting administration of 
the study  drug, the worsening or complicat ion should be recorded appropriately as an AE. 
Invest igators should ensure that the AE term recorded captures the change in the condit ion (eg, 
“worsening o f…”).
If the subject experiences a worsening or complication of an AE after any  change in study  
drug, the worsening or complicat ion shoul dbe recorded as a new AE. Invest igators should 
ensure that the AE term recorded captures the change in the condit ion (eg, “worsening of…”).
Changes in intensit y of AEs /Serious PTEs:
If the subject experiences changes in intensit y of an AE/seri ous PTE, the event should be 
captured once with the maximum intensit y is recorded.
Prepl anned procedures (surgeries or intervent ions):
Prepl anned procedures (surgeries or therapies) that were scheduled prior to signing of 
inform ed consent are not considered PTEs or AE s. However, if a preplanned procedure is 
Vedolizumab IV
Vedolizumab -4003 Page 59of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALperform ed early  (eg, as an emergency) due to a worsening of the pre -exist ing condit ion, the 
worsening of the condit ion shoul d be recorded as a PTE or an AE. Complications result ing 
from any planned surgery  shoul d be reported as AEs.
Elect ive surgeries or procedures:
Elect ive procedures performed where there is no change in the subject’s medical condit ion 
shoul d not be recorded as PTEs or AEs, but should be documented in the subject’s source 
docum ents. Com plicat ions resulting from an elect ive surgery should be reported as AEs.
Insufficient clinical response (lack of efficacy):
Insufficient clinical response, efficacy, or pharmacologic act ion, should NOT be recorded as 
an AE. The invest igator must make the dist inction between exacerbation o f pre-exist ing illness 
and lack of therapeutic efficacy.
Overdose:
Cases of overdose with any  medicati on wi thout m anifested si de effects are NOT considered 
PTEs or AEs, but instead will be documented on an Overdose page of the eCRF. An y 
manifested side effects will be considered PTEs or AEs and will be recorded on the AE page of 
the eCRF.
10.1.4 SAEs
An SAE is defined as any untoward medical occurrence that at any  dose:
1.Results in DEATH.
2.Is LIFE THREATENING.
The term “life threatening” refers to an event in which the subject was at risk of death at the 
time of the event; it does not refer to an event that hypothetically might have caused death 
if it were m ore severe.
3.Requi res inpat ient HOSPITALIZATION or prolongation of exist ing hospitalizat ion.
4. Results in persistent or significant DISABILITY/INCAPACITY.
5.Is a CONGENITAL ANOMALY/BIRTH DEFECT.
6.Is an IMPORTANT MEDICAL EVENT that satisfies any of the fo llowing:
May require intervent ion to prevent items 1 through 5 above.
May expose the subject to da nger, even though the event is not immediately life 
threatening or fatal or does not result in hospitalization.
Includes any event or synonym described in the Takeda Medically  Significant AE List 
(Table 10.a ).
Vedolizumab IV
Vedolizumab -4003 Page 60of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALTabl e 10.a Takeda Medically Significant AE List
Term
Acute respiratory failure/acute respiratory distress 
syndromeHepatic necrosis
Torsade de pointes / ventricular fibrillation / ventricular 
tachycardiaAcute liver failure
Anaphy lactic shock
Malignant hypertension Acute renal failure
Convulsive seizure Pulmonary hypertension
Agranulocytosis Pulmonary fibrosis 
Aplastic anemia Confirmed or suspected endotoxin shock
Toxic epidermal necrolysis/Stevens -Johnson sy ndrome Confirmed or suspected transmission of infectious agent by a 
medicinal product
Neuroleptic malignant syndrome / malignant hyperthermia
Spontaneous abortion / stillbirth and fetal death
PTEs that fulfill 1 or more of the serious criteri a above are also to be considered SAEs and should 
be reported and fo llowed up in the same manner (see Sections 10.2.2 and 10.3) .
10.1.5 AEs of S pecial Interest
An AESI (seri ous or non -serious) is an AE of scient ific and medical concern specific to the 
compound or program , for whi ch ongoing mo nitoring and rapid communicat ion by the 
investigator to Takeda may be appropriate. Such events may require further invest igation in orde r 
to characterize and understand them and would be described in protocols and instructions provided 
for invest igators as to how and when they should be reported to Takeda.
AESIs for this co mpound are serious infections including opportunist ic infect ion suc h as PML, 
liver injury , malignancies, infusio n-related or systemic reacti ons and hypersensit ivity, as 
described in further detail below.
Hypersensitivity Reactions (Including Infusion- Related Reactions)
Current ly, there is no evidence to support the routin e prophylactic administration of premedicat ion 
(eg, antihistamines, corticosteroids) to subjects receiving vedo lizumab; hence such 
prem edicat ions are unlikely to be necessary or beneficial. At the discret ion of the invest igator, 
however, subjects may  be administered premedicatio n prior to any  study  drug administrati on. 
Corti costeroi ds, if given as a premedicat ion, should be limited to the day  of administrati on. 
Vedolizumab IV should be administered by a healt h care practit ioner prepared to manage 
hypersens itivity react ions including anaphylaxis, if they occur. Appropriate monitoring and medical 
support measure should be available for immediate use. Subjects should be observed for 2 hours 
following the first 2 infusio ns, at a minimum, and 1 hour after each s ubsequent infusio n.
Subjects and caregivers will be instructed to report the development of rash, hives, pruritus, flushing, 
urticaria, injection site pain, redness and/or swelling, etc. that may  represent an 
Vedolizumab IV
Vedolizumab -4003 Page 61of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALadministration -related reaction (ie, infusio n-related reaction) to study drug. Subjects will be asked to 
report administration -related AEs to the si tes immedi ately as they  are experienced. Appropri ate 
treatm ent and follow -up will be determined by  the investi gator. If si gns or symptoms of an 
administrat ion-related reacti on are observed during the administration of study  drug, it shoul d be 
immediately discontinued and the subject treated as medically appropriate. In the case of a mild 
reacti on, study  drug administrati on m ay be reinit iated (with appropriat e premedicat ion and 
investigator supervisio n) at the discretion o f the investigator. Subjects with a severe or serious 
administration -related reacti on (eg, shortness of breath, wheezing, stridor, angioedema, 
life-threatening change in vital signs, severe i njection site reactions) must be withdrawn fro m the 
study . 
In all cases of administration -related reacti on, the medical mo nitor must be informed as soon as 
practi cal. The disposit ion of subjects with less severe administration -related reacti ons shoul d be 
discussed wi th the m edical m onitor.
Serious Infections 
Subjects will be mo nitored for si gns and symptoms of infect ion and for lymphopenia during the 
study . Subjects with signs and symptoms suggestive of infect ions, including GI infect ions, will be 
treated as clinically indicated. Interventions may include ant ibiotic treatment, if appropriate and/or 
discontinuat ion of conco mitant immuno modulators. Bl ood, sputum , urine, and/or stool cultures 
shoul d be obtained as appropriate for the detection and diagnosis o f infection. Withho lding or 
terminating study  drug administrati on m ay be considered as described in Sect ion 7.4.
Malignancy 
All cases of malignancies that are detected during the study will be reported as AEs. Local medica l 
practices for the management of malignances will apply. Subjects with history  of malignancy 
(except for specific cancers) or at high risk for malignancy will be excluded from the study per the 
exclusio n criteria. 
Other 
Other special interest AEs include li ver injury and PML, which are discussed in Sections 10.2.3
and
 11.1.1 , respectively.
10.1.6 Intensity of PTEs and AEs
The different categories o f intensit y (severit y) are characteri zed as follows:
Mild: The event is transient and easily tolerated by the subject.
Moderate: The event causes the subject discomfort and interrupts the subject’s usual activities.
Severe: The event causes considerable interference with the subject’s usual activities.
Vedolizumab IV
Vedolizumab -4003 Page 62of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL10.1.7 Causality of AEs
The rel ationship of each AE to study  drug(s) will be assessed using the fo llowing categori es:
Related: An AE that follows a reasonable temporal sequence from administration of a drug (including the 
course after withdrawal of the drug), or for which possible involvement of the drug cannot be 
ruled out , although factors other than the drug, such as underlying diseases, complications, 
concomitant drugs and concurrent treatments, may also be responsible.
Not Related: An AE that does not follow a reasona ble temporal sequence from administration of a drug and/o r 
that can reasonably be explained by other factors, such as underlying diseases, complications, 
concomitant drugs and concurrent treatments.
10.1.8 Relationship to Study Procedures
Relationship (causalit y) to study  procedures should be determined for all PTEs and AEs.
The relationship should be assessed as Related if the investigator considers that there is reasonable 
possibilit y that an event is due to a study procedure. Otherwise, the relationship should be assessed 
as Not Related. 
10.1.9 Start Date
The start date of the AE/PTE is the date that the first signs/symptoms were noted by  the subject 
and/or physician, and the time, if available.
10.1.10 Stop Date 
The stop date of the AE/PTE is the date at which the subject recovered, the event resolved but with 
sequelae or the subject died, and the time, if available.
10.1.11 Frequency 
Episodi c AEs/PTE (eg, vomit ing) or those which occur repeatedly over a period of consecutive 
days are intermittent. All other events are continuous.
10.1.12 Action Concerning Study Drug 
Drug withdrawn –a study  drug i s stopped due to the particular AE.
Dose not changed –the particular AE did not require stopping a study  drug.
Unknown –only to be used if it has not been possible to determine what action has been taken.
Not Applicable –a study  drug was stopped for a reason other than the particular AE (eg, the 
study  has been terminated, the subject died, dosing with study drug was already stopped before 
the onset of the AE).
Dose Interrupted –the dose was i nterrupted due to the particular AE.
Vedolizumab IV
Vedolizumab -4003 Page 63of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL10.1.13 Outcome
Recovered/Resolved – Subject returned to first assessment status with respect to the AE/PTE.
Recovering/Reso lving –the intensit y is lowered by  1 or m ore stages: the diagnosis or 
signs/symptom s has almost di sappeared; the abnormal laboratory  value improved, but has not 
returned to the normal range or to Baseline; the subject died from a cause other than the 
particular AE/PTE with the condit ion rem aining “recovering/reso lving”.
Not recovered/not resolved –there is no change in the diagnosis, signs or symptoms; the 
intensity of the di agnosis, si gns/ symptom s or laboratory  value on the last day  of the observed 
study  period has got worse than when it started; is an irreversible congenital anomaly; the 
subject died fr om another cause with the particular AE/PTE state remaining “Not 
recovered/not resolved”.
Reso lved with sequelae –the subject recovered from an acute AE/PTE but was left with 
perm anent/si gnificant impairment (eg, recovered from a cardiovascular accident b ut wi th 
some persisting paresis).
Fatal  –the AEs/PTEs which are considered as the cause of death. 
Unknown –the course of the AE/PTE cannot be followed up due to hospital change or 
residence change at the end of the subject’s participation in the study .
10.2 Procedures
10.2.1 Collection and Reporting of AEs
10.2.1.1 PTE and AE Collection Period
Start of PTE collect ion:
Collect ion of PTEs will co mmence from the time the subject signs the informed consent to 
participate in the study and cont inue unt il the subject is first admin istered study drug (Day 1; Visit  
2) or until screen failure. For subjects who discont inue prior to study drug administration, PTEs are 
collected unt il the subject discont inues study  parti cipat ion.
Start of AE collection: 
AEs must be collected fro m the tim e that the subject is first administered study drug (Day 1; Visit  
2). Any  drugs provi ded by the sponsor are considered study  drugs, including placebo.
End of AE collection: 
Routine co llection of AEs will continue unt il the end of study fo llow-up (Week 40; Visit 9).
Vedolizumab IV
Vedolizumab -4003 Page 64of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL10.2.1.2 PTE and AE Reporting
At each study  visit, the investi gator will assess whether any  subjective AEs have occurred. A 
neutral  quest ion, such as “How have you been feeling since your last visit ?” may be asked. 
Subjects m ay report AEs occurri ng at an y other time during the study . Subjects experi encing a 
serious PTE m ust be monitored until the symptoms subside and any clinically relevant changes in 
laboratory  values have returned to Baseline or there is a sat isfactory  explanati on for the change. 
Non-serious PTEs, rel ated or unrel ated to the study  procedure, need not to be followed up for the 
purposes of the protocol.
All subjects experiencing AEs, whether considered associated with the use of the study  drug or 
not, m ust be m onitored until  the symptoms s ubside and any clinically  relevant changes in 
laboratory  values have returned to Baseline or until there is a sat isfactory  explanati on for the 
changes observed. All PTEs and AEs will be documented in the PTE/AE page of the eCRF, 
whether or not the invest igator concl udes that the event is related to the drug treatment. The 
following informat ion will be documented for each event:
1.Event term .
2.Start and stop date, and time (if available).
3.Frequency.
4.Intensit y.
5.Invest igator’s opinio n of the causal relat ionship b etween the event and administration of study 
drug (s) (related or not related) (not completed for PTEs).
6.Invest igator’s opinio n of the causal relat ionship to study  procedure(s), including the details of 
the suspected procedure.
7.Action concerning study  drug (not applicable for PTEs).
8.Outcom e of event.
9.Seriousness.
CDAI, PDAI and qualit y of life instruments will not be used as a primary  means to collect AEs. 
However, should the invest igator become aware of a potential AE through the information 
collected with this instrum ent, proper follow -up with the patient for medical  evaluat ion shoul d be 
undertaken. Through this fo llow-up if it is determined that an AE not previously reported has been 
ident ified, normal reporting requirements should be applied.
10.2.1.3 Special Interest AE Reporting
If an AESI , whi ch occurs during the treatment period or the fo llow-up peri od, is considered to be 
clinically significant based on the criteria in Sect ion 10.1.5 , it should be recor ded in a spe cial 
interest AE eCRF or SAE Form. The applicable form shoul d be com pleted and reported to the 
SAE reporting contact in Sect ion
 1.1within 24 hours.
Vedolizumab IV
Vedolizumab -4003 Page 65of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALThe special interest AEs have to be recorded as AEs in the eCRF. An evaluat ionform along wi th 
all other required documentation must be submitted to the sponsor.
10.2.2 Collection and Reporting of SAEs
When an SAE occurs through the AE collection period it should be reported according to the 
following procedure:
A Takeda SAE eCRF or form m ust be com pleted in English and signed by the invest igator 
immediately  or wi thin 24 hours of first onset or notification o f the event. The informat ion shoul d 
be co mpleted as fully as possible but con tain, at a minimum:
A short descript ion of the event and the reason why  the event i s categori zed as serious.
Subject identificat ion number.
Invest igator’s name.
Nam e of the study  drug(s).
Causalit y assessment.
The SAE eCRF should be co mpleted wi thin 24 hours of first onset or notification o f the event. 
However, as a back -up, if required, the SAE form should be co mpleted and reported to Takeda 
Pharmacovigilance or designee within 24 hours to the attention of the contact listed in Section 1.1.
Any SAE spontaneously repo rted to the invest igator fo llowing the AE collect ion period should be 
reported to the sponsor if considered related to study  parti cipat ion.
Reporting of Serious PTEs will fo llow the procedure described for SAEs.
10.2.3 Reporting of Abnormal LFTs
If a subject is n oted to have ALT or AST elevated >3 ×ULN on 2 consecut ive occasions, the 
abnorm ality shoul d be recorded as an AE. In addition, an LFT Increases eCRF must be co mpleted 
provi ding addit ional information on relevant recent history , risk factors, clinical signs and 
symptoms and results of any addit ional diagnosti c tests performed.
If a subject is noted to have ALT or AST >3 ×ULN and total bilirubin >2 ×ULN for which an 
alternat ive etio logy has not been i dentified, the event should be recorded as an SAE and repor ted 
as per Secti on 10.2.2 . The investigator must con tact the m edical m onitor for discussi on of the 
relevant subject details and possible alternative etiologies, such as acute viral hepat itis A or B or 
other acut e liver disease ormedical history /concurrent m edical  condi tions. Foll ow-up laboratory  
tests as described in Sect ion
 9.1.20 must also be performed. In addit ion, an LFT Increases eCRF 
must be completed and transm itted wi th the Takeda SAE form (as per Section 10.2.2 ).
10.3 Follow -up of SAEs
If informat ion not available at the time of the first report becomes available at a later date, the 
investigator should complete a fo llow
-up SAE form  or provi de other wri tten docum entati on and 
Vedolizumab IV
Vedolizumab -4003 Page 66of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALfax it immediately wit hin 24 hours of receipt . Copies of any relevant data from the hospital notes 
(eg, ECGs, laboratory  tests, di scharge summary, postmortem results) should be sent to the 
addressee, if requested.
All SAEs should be fo llowed up unt il reso lution or perm anent outcome of the event. The timelines 
and procedure for follow -up reports are the same as those for the init ial report.
10.3.1 Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities
The sponsor will be responsible for reporting all suspected unexpected serious adverse react ions 
(SUSARs) and any other applicable SAEs to regulatory  authori ties, including the European 
Medicines Agency (EMA), investigators and IRBs or IECs, a s applicable, in accordance wit h 
national regulat ions in the countries where the study is conducted. Relat ive to the first awareness 
of the event by /or further provi sion to the sponsor or sponsor’s designee, SUSARs will be 
submitted to the regulatory  autho rities as expedi ted report within 7 days for fatal and 
life-threatening events and 15 day s for other serious events, unless otherwise required by national 
regul ations. The sponsor will also prepare an expedited report for other safet y issues where these 
might m aterially alter the current benefit -risk assessment of an invest igational medicinal product 
or that woul d be sufficient to consider changes in the invest igational medicinal products 
administration or in the overall conduct of the trial. The study  sitealso will forward a copy  of all 
expedited reports to his or her IRB or IEC in accordance with national regulat ions.
Vedolizumab IV
Vedolizumab -4003 Page 67of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL11.0 STUDY- SPECIFIC COMMITTEES
No data safet y monitoring co mmittee will be used in this study.
11.1 Adjudication Committee
A PML Independent Adjudica tion Commi ttee (IAC) will be inst ituted for this study . The PML 
IAC will consist of a panel of leading PML experts, including a neuro logist, neuroradio logist, and 
a viro logist.
11.1.1 Risk Assessment and Minimization for PML (RAMP) Program
Natalizumab (TYSABRI), another integrin receptor antagonist, has been associated with PML, a 
rare and often fatal opportunist ic infection o f the central  nervous system . PML is caused by  the 
John Cunningham virus (JCV) and typically only occurs in pat ients who are immunocompro mised 
[41,42]. Natalizumab is a pan -α4 integrin antagonist that binds to both the α 4β1and α 4β7integrins 
and i nhibit s cellular adhesio n to vascular cell adhesion mo lecule -1 (VCAM -1) and MAdCAM -1 
[43,44]. In contrast, vedolizumab binds to the α 4β7integrin only  [23]and inhibit s adhesio n to 
MAdCAM -1, but not VCAM -1. Al though no cases of PML have been reported in c linical trials 
with vedolizumab to date, a risk of PML cannot be ruled out.
To address the theoretical risk o f the development of PML in subjects treated with vedo lizumab, 
the sponsor, with input fro m renowned PML experts, has developed a RAMP program. The
complete descri ption of the RAMP program, including materials and instructions for its 
implementation and mo nitoring, i s included in the Invest igator Site File.
The RAMP is focused on early  clinical detecti on and management of that specific safet y risk, 
including the di scont inuat ion of study  drug, if applicable. Subjects are assessed for signs and 
symptoms of PML prior to the administration of each dose of study  drug using a PML subject ive 
symptom  checklist. Subj ects wi th a posi tive PML subjective symptom checklist at any  time after 
enrollment in a vedolizumab clinical study will be evaluated according to a prespecified algorithm 
(the PML Case Evaluat ion Algori thm). The next dose of study  drug will be held unt il the 
evaluat ion is co mplete and results are av ailable. Subsequent doses of study  drug will  be 
administered only  if the possibilit y of PML is definit ively  excl uded, as described in the RAMP 
algorithm. An IAC has been established as part of the RAMP program to review new neuro logical 
signs and symptoms potenti ally consistent wi th PML, and will provide input regarding subject 
evaluat ion and m anagement as defined in the IAC charter. 
To ensure success of the RAMP program, site personnel will be trained to recognize the features of 
PML, and subjects will be trained to report specific neurological signs and symptoms without 
delay. Educati onal materi als for teaching site personnel and subjects about PML and the RAMP 
procedures will be distributed to all sites and are included in the Invest igator Site File. For mal 
teaching and training will be performed for site personnel prior to the start of the study . Subjects 
will receive training and educat ional materi als pri or to receiving treatm ent. The informed consent 
form will contain specific informat ion on the hypoth etical risk of PML. Any documented case of 
PML will be reported as an SAE, regardless of whether hospitalizat ion occurs.
Vedolizumab IV
Vedolizumab -4003 Page 68of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL12.0 DATA HANDLING AND RE CORDKEEPING
The full details of procedures for data handling will be documented in the Data Management Plan. 
AEs, P TEs, medical history, and concurrent condit ions will be coded using the Medical Dict ionary 
for Regul atory  Activit ies (MedDRA). Drugs will be coded using the World Health Organizat ion 
Drug Dict ionary (WHODRUG) .
12.1 Electronic CRFs 
Com pleted eCRFs are required for each subject who signs an informed consent.
The sponsor or its designee will supply invest igative sites with access to eCRFs. The sponsor or 
delegated contract research organization (CRO) will make arrangements to train appropriate site 
staff in the us e of the eCRF. These forms are used to transmit the information co llected in the 
perform ance of thi s study  to the sponsor and regulatory  authori ties. eCRFs must be completed in 
English.
After complet ion of the entry process, computer logic checks will be r un to identify items, such as 
inconsistent dates, missing data, and questionable values. Queries may be issued by Takeda 
personnel (or designees) and will be answered by the site. 
Correcti ons to eCRFs are recorded in an audit trail that captures the old i nformation, the new 
inform ation, identificat ion of the person making the correction, the date the correction was made, 
and the reason for change.
The principal invest igator must review the eCRFs for completeness and accuracy and must sign 
and date the app ropriate eCRFs as indicated. Furthermore, the investigator must retain full 
responsibilit y for the accuracy  and authent icity of all data entered on the eCRFs.
The principal invest igator must review the data change for completeness and accuracy , and m ust 
sign, or si gn and seal, and date.
eCRFs will be reviewed for completeness and acceptabilit y at the study  site during peri odic visi ts 
by study  monitors. The sponsor or i ts designee will be permitted to review the subject’s medical 
and hospital records pertine nt to the study to ensure accuracy of the eCRFs. The completed eCRFs 
are the sole property  of the sponsor and should not be made available in any form to third parties, 
except for authorized representatives of appropriate governmental healt h or regulatory authori ties, 
without wri tten permissio n of the sponsor.
12.2 Record Retention
The invest igator agrees to keep the records stipulated in Section 12.1 and those documents that 
include (but are not limited to) the study -specific documents, the ident ificat ion log of all 
participat ing subjects, medical records, temporary media such as thermal sensit ive paper, source 
worksheets, all original signed and dated informed consent forms, subject authorizat ion forms 
regarding the use of personal healt h information (if separate from the informed consent forms), 
electroni c copy  of eCRFs, incl uding the audi t trail, and detailed records of drug disposit ion to 
enable evaluat ions or audits from regulatory  authori ties, the sponsor or its d
esignees. Any  source 
Vedolizumab IV
Vedolizumab -4003 Page 69of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALdocum entati on printed on degradable thermal sensitive paper should be photocopied by the site 
and filed wit h the original in the subject’s chart to ensure long -term legibilit y. Furthermore, 
International Conference on Harmonisation (IC H) E6 Secti on 4.9.5 requi res the investigator to 
retain essential documents specified in ICH E6 (Section 8) until at least 2 y ears after the last 
approval  of a market ing applicat ion for a specified drug indicat ion being invest igated or, if an 
applicat ion is not approved, until at least 2 years after the invest igation is discont inued and 
regul atory  authori ties are notified. In addit ion, ICH E6 Secti on4.9.5 states that the study  records 
shoul d be retained unt il an amount of time specified by applicable regul atory  requirements or for a 
time specified in the study  site agreem ent between the invest igator and sponsor.
Refer to the study  site agreement for the sponsor’s requirements on record retention. The 
investigator should contact and receive written approval from the sponsor before disposing of any 
such documents.
Vedolizumab IV
Vedolizumab -4003 Page 70of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL13.0 STATISTICAL METHODS
13.1 Statistical and Analytical Plans
A statistical analysis plan (SAP) will be prepared and finalized prior to unblinding of any subject’s 
treatm ent assi gnment. Thi s docum ent will pro vide further details regarding the definit ion of 
analysis variables and analysis methodology  to address all study  object ives.
A blinded data review will be conducted prior to unblinding of subjects’ treatment assignments. 
This review will assess the accura cy and completeness of the study  database, subject evaluabilit y, 
and appropriateness o f the planned statist ical methods.
13.1.1 Analysis Sets
All subjects who received at least 1 dose of study drug and have a post -randomizat ion assessment 
of fistula healing will be included in the full analysis set (FAS). The FAS populat ion will be used 
for the analysis o f the proporti on of  subjects wi th fistula healing and const itutes the primary 
analysis population for the endpoints associated with fistula healing. 
All FAS subj ects who do not have any  major protocol  violations will be included in the per 
protocol  (PP) population. Major protocol vio lations will be specified in the SAP. All decisio ns to 
exclude subjects from the PP populat ion dataset will be made prior to the unbl inding of the study. 
Analyses using the PP populat ion may be provided as a sensit ivity analysis.
Safety analyses will be based on the safety analysis set. All subjects who received at least 1 dose of 
study  drug will  be included in the safet y analysis set.
The PK evaluable population is defined as all subjects who receive at least 1 dose of study drug 
and have sufficient blood sampling to allow for PK evaluat ion.
13.1.2 Analysis of Demographics and Other Baseline Characteristics
Baseline and demographic informat ionwill be listed and summarized. For continuous variables, 
the summary  will consist of descri ptive statist ics (number of subjects, mean, SD, minimum, 
median, and maximum). For categorical variables, the summary will consist of number and 
percentage of subje cts in each category .
Medical history and concurrent medical condit ions will be summarized by system organ class and 
preferred term. Medicat ion history  and conco mitant medicat ions will be summarized by preferred 
term.
13.1.3 Analysis of Fistula Healing
No inferen tial stati stical testing will be performed in this study . Instead, an estimat ion approach 
will be taken.
The primary  endpoint for thi s study  is the proportion of subjects with a reduction of at least 50% 
from Day 1 in the number of draining fistulae at Wee k 30 (where cl osed fistulae are no longer 
draining despite gent le finger compression). 
Vedolizumab IV
Vedolizumab -4003 Page 71of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALThe first secondary  endpoint i s the proporti on of  subjects with a reduction of at least 50% fro m 
Day 1 in the number of draining perianal fistulae at both Week 22 and W eek 30 (where cl osed 
fistul ae are no l onger draining despite gent le finger compressio n).
Other secondary  endpoints include the proportion of subjects with 100% fistulae closure at Week 
30 (where all fistulae are no longer draining despite gent le finger co mpressio n), time to first fistula 
closure, time to l ast (100%) fistula closure, and duration of fistula response (eg, number of days 
with drainage). 
For all dichotomous endpo ints (proporti on of  subjects a reduction of at least 50% from Screening 
in the number of draining fistulae at Week 30 and proportion of subjects with 100% fistulae 
closure at Week 30 ), corresponding rates and 95% CIs will be reported by  treatm ent group. The 
rate differences between treatment groups and their 95% CIs will also be reporte d.
Time to first fistula closure and time to last fistula closure will be analyzed by  survival  analysis 
procedures. Fistula closure rates from the time of rando mizat ion to the end of the study period will 
be est imated by Kaplan -Meier product limit methods and presented with appropriate 95% CIs.
Other endpoints will be summarized descript ively by treatment group.
13.1.4 PK Analysis 
Serum  concentrati ons of  vedo lizumab will be summarized by co llection time po ints, and by 
treatm ent group using descriptive statist ics.Individual  serum  concentrati on data versus t ime will 
be presented in a data list ing.
Data might be pooled with data fro m other studi es. The resul ts from these analyses will not be 
reported in the clinical study  report (CSR) and will be part of a stand- alone report.
13.1.5 Anti- vedolizumab Antibodies Analysis
The proporti on of  subjects with posit ive and titers of AVA (transient and persistent), and 
proporti on of  subjects wi th posi tive neutralizing AVA during the study  will be summarized. The 
impact of AVA on serum concentrati on, safet y, and efficacy will be explored.
13.1.6 Safety Analysis
Safety analyses will be based on the safet y analysis set.
No formal stati stical tests or inference will be performed for safet y analyses. Safet y data will be 
presented by treatment grou p.
The number and percentage of subjects with AEs (regardless of relat ionship to study drug), AEs of 
special interest (ie, serious infections including opportunist ic infect ion such as PML, liver injury, 
malignancies, infusio n-related or systemic reactions, and hypersensit ivity), AEs leading to 
discontinuat ion, and SAEs that occur on or after the first dose date and up to 18 weeks after the last 
dose date of the study  drug will be summarized by MedDRA System Organ Class, High Level 
Term , and Preferred Term  overall, by intensit y, and by  relati onship to study  drug. If a subject 
Vedolizumab IV
Vedolizumab -4003 Page 72of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALexperienced more than 1 AE for a given PT, intensity is defined as the intensit y of the most severe 
event and relat ionship to study  drug is the relationship of the most related event. 
Change from Baseline in clinical laboratory  tests, vital signs and weight will be summarized by  
treatm ent group. Subj ects wi th markedly  abnorm al values for laboratory  tests and vi tal signs will  
be tabulated.
Physical examinat ion findings and PML checklist d ata will be presented in data list ings.
Data from the LTFU survey will be summarized descript ively.
13.1.7 Other Analyses
Changes fro m Baseline to Weeks 14 and 30 in EQ -5D and IBDQ will be summarized.
13.2 Futility Analysis and Criteria for Early Termination
A futility analysis will  be perform ed after 25 patients per treatment arm co mplete to Week 30. 
There i s no intent ion to stop for efficacy  at this point. 
13.3 Determination of Sample Size
A sample size o f 100 subjects (50 per group) will generate 95% CIs for fistula clo sure rate with a 
half width no wider than 13.9%; in addit ion, the 95% CIs for the difference in fistula closure rates 
between the 2 groups will be no wider than 19.6%. The sample size was not based on statist ical 
power considerat ions but on an est imate of precision.
Vedolizumab IV
Vedolizumab -4003 Page 73of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL14.0 QUALITY CONTROL AND QUALITY ASSURANCE
14.1 Study Site Monitoring Visits
Moni toring visit s to the study  site will  be made peri odically  during the study  to ensure that all 
aspects of the protocol are fo llowed. Source documents will be reviewed for veri fication of data 
recorded on the eCRFs. Source documents are defined as original documents, data, and records. 
The invest igator and inst itution guarantee access to source documents by  the sponsor or i ts 
designee (CRO) and by  the IRB or IEC.
All aspects of the study and its documentation will be subject to review by the sponsor or designee 
(as long as blinding is not jeopardized), including but not limited to the Invest igator’s Binder, 
study  drug, subject medical records, informed consent documentation, docu mentation of  subject 
authori zation to use personal healt h information (if separate from the informed consent forms), 
and review of eCRFs and associated source documents. It is important that the invest igator and 
other study  personnel are available during t he mo nitoring visit s and that sufficient time is devoted 
to the process.
14.2 Protocol Deviations
The invest igator should not deviate fro m the protocol , except where necessary  to eliminate an 
immediate hazard to study subjects. Should other unexpected circumsta nces arise that will require 
deviat ion from protocol -specified procedures, the investigator should consult with the sponsor or 
designee (and IRB or IEC, as required) to determine the appropriate course of action. There will be 
no exempt ions (a prospectivel y approved deviat ion) from the inclusio n or exclusio n criteria.
The site should document all protocol deviat ions in the subject’s source documents. In the event of 
a significant devi ation, the si te shoul d notify  the sponsor or i ts desi gnee (and IRB or EC, as 
requi red). Si gnificant devi ations include, but are not limited to, those that invo lve fraud or 
misconduct, increase the health risk to the subject, or confound interpretation of primary study 
assessment. A Protocol Deviation Form should be completed by the site and signed by the sponsor 
or desi gnee for any  significant deviat ion from the protocol.
14.3 Quality Assurance Audits and Regulatory Agency Inspections
The study  site also m ay be subject to qualit y assurance audi ts by  the sponsor or desi gnees. In this 
circumstance, the sponsor -designated audi tor will  contact the si te in advance to arrange an 
auditing visit. The auditor may ask to visit the facilit ies where laboratory  samples are collected, 
where the medication is stored and prepared, and any other facili ty used during the study . In 
addition, there is the possibilit y that this study may be inspected by regulatory agencies, including 
those of foreign governments (eg, the Food and Drug Administration (FDA), the United Kingdo m 
Medicines and Healt hcare product s Regulatory Agency, the Pharmaceut icals and Medical Devices 
Agency o f Japan). If the study site is contacted for an inspect ion by a regulatory body, the sponsor 
shoul d be notified immediately. The invest igator and inst itution guarantee access for qualit y 
assurance auditors to all study  docum ents as described in Sect ion 14.1.
Vedolizumab IV
Vedolizumab -4003 Page 74of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL15.0 ETHICAL ASPECTS OF T HE STUDY
This study  will be conducted wi th the highest respect for the individual participants (ie, subjects) 
according to the protocol, the ethical principles that have their origin in the Declaration o f 
Helsinki, and the ICH Harmonised Tripart ite Guideline for GCP. Each investigator will conduct 
the study  according to applicable local or regional regulatory  requi rements and align his or her 
conduct in accordance with the “Responsibilit ies of the Invest igator” that are listed in Appendix B. 
The Principles of Helsinki are addressed through the protocol and through appendices containing 
requi rements for informed consent and invest igator responsibilities.
15.1 IRB and/or IEC Approval
IRBs and IECs must be constituted according to the applicable {state and federal/local }
requi rements of each participating regio n. The sponso r or desi gnee will  require docum entati on 
noting all names and t itles of members who make up the respective IRB or IEC. If any member of 
the IRB or IEC has direct participat ion in this study, written notificat ion regarding his or her 
abstinence fro m voting must also be obtained. Those Americas sites unwilling to provide names 
and tit les of all members due to privacy  and conflict of interest concerns should instead provide a 
Federal Wide Assurance Number or comparable number assigned by the Depart ment of Heal th 
and Human Services.
The sponsor or designee will supply relevant documents for submissio n to the respective IRB or 
IEC for the protocol’s review and approval. This protocol, the IB, the vedo lizumab IV (Entyvio) 
package insert, a copy  of the informed con sent form, and, if applicable, subject recruit ment 
materi als and/or advertisements and other documents required by all applicable laws and 
regul ations, m ust be submitted to a central or local IRB or IEC for approval. The IRB’s or IEC’s 
written approval  of the protocol  and subject informed consent must be obtained and submitted to 
the sponsor or designee before commencement of the study  (ie, before shipment of the 
sponsor -supplied drug or study specific screening activit y). The IRB or IEC approval must refer to 
the study  by exact protocol  title, number, and version date; ident ify versio ns of other documents 
(eg,informed consent form) reviewed; and state the approval date. The sponsor will {ship 
drug/notify site once }the spo nsor has confirmed the adequacy o f site regul atory  docum entati on 
and, when applicable, the sponsor has received permissio n from co mpetent authorit y to begin the 
trial. Until the si te receives [drug/notificat ion] no protocol  activit ies, including screening may 
occur.
Sites m ust adhere to all requirements stipulated by  their respect ive IRB or IEC. This may include 
notification to the IRB or IEC regarding protocol amendments, updates to the informed consent 
form, recrui tment m aterials intended for viewing by  subjects, l ocal safety  reporti ng requirements, 
reports and updates regarding the ongoing review of the study  at intervals specified by  the 
respective IRB or IEC, and submissio n of the investigator’s final status report to IRB or IEC. All 
IRB and IEC approva ls and relevant documentation for these items must be provided to the 
sponsor or its designee.
Vedolizumab IV
Vedolizumab -4003 Page 75of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALSubject incentives should not exert undue influence for participat ion. Payments to subjects must 
be approved by the IRB or IEC and sponsor.
15.2 Subject Information, Informed Consent, and Subject Authorization
Written consent documents will embody  the elements of informed consent as described in the 
Declaration of Helsinki and the ICH Guidelines for GCP and will be in accordance with all 
applicable laws and regulations . The inform ed consent form , subject authori zation form (if 
applicable), and subject informat ion sheet (if applicable) describe the planned and permitted uses, 
transfers, and disclo sures of the subject’s personal and personal healt h informat ion for purposes of 
conducting the study. The informed consent form and the subject informat ion sheet (if applicable) 
further explain the nature of the study, its object ives, and potential risks and benefit s, as well as the 
date informed consent is given. The informed consent form will detail the requirements of the 
participant and the fact that he or she is free to withdraw at any  time wi thout giving a reason and 
without prej udice to hi s or her further m edical care.
The invest igator is responsible for the preparation, co ntent, and IRB or IEC approval of the 
inform ed consent form  and if applicable, the subject authorization form. The informed consent 
form, subject authorizat ion form (if applicable), and subject information sheet (if applicable) must 
be approved by both the IRB or IEC and the sponsor prior to use.
The informed consent form, subject authorizat ion form  (if applicable), and subject informat ion 
sheet (if applicable) must be written in a language fully co mprehensible to the prospective subject. 
It is the responsi bility of the invest igator to explain the detailed elements of the informed consent 
form, subject authorizat ion form (if applicable), and subject informat ion sheet (if applicable) to the 
subject. Information should be given in both oral and written form wh enever possible and in the 
manner deemed appropriate by the IRB or IEC. In the event the subject is not capable of rendering 
adequate written informed consent, then the subject’s legally  acceptable representative may 
provi de such consent for the subject in accordance wi th applicable l aws and regul ations.
The subject, or the subject’s legally acceptable representative, must be given ample opportunit y to: 
(1) inquire about details of the study and (2) decide whether or not to participate in the study. If the 
subject, or the subject’s legally acceptable representative, determines he or she will part icipate in 
the study , then the informed consent form and subject authorizat ion form (if applicable) m ust be 
signed and dated by  the subject, or the subject’s legally acceptable representative, at the time of 
consent and prior to the subject entering into the study . The subject or the subject’s legally 
acceptable representative should be instructed to sign using their legal names, not nicknames, 
using blue or black ballpo int ink. The invest igator must also sign and date the informed consent 
form and subject authorizat ion (if applicable) at th e time of consent and prior to subject entering 
into the study; however, the sponsor may  allow a designee of the invest igator to s ign to the extent 
permitted by  applicable law.
Once signed, the original informed consent form, subject authorization form (if applicable), and 
subject informat ion sheet (if applicable) will be stored in the invest igator’s site file. The 
investigator must document the date the subject signs the informed consent in the subject’s 
Vedolizumab IV
Vedolizumab -4003 Page 76of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALmedical record. Copies of the signed informed consent form, the signed subject authorization for m 
(if applicable), and subject informat ion sheet (if applicable) shall be given to the subject.
All revised informed consent forms must be reviewed and signed by relevant subjects or the 
relevant subject’s legally  acceptable representative in the same manner as the original informed 
consent. The date the revised consent was ob tained shoul d be recorded in the subject’s medical 
record, and the subject should receive a copy  of the revised informed consent form.
15.3 Subject Confidentiality
The sponsor and designees affirm and upho ld the principle of the subject’s right to protection 
against invasio nof privacy. Throughout this study , a subject’s source data will only be linked to 
the sponsor’s clinical trial database or documentation via a subject ident ification number. As 
permitted by all applicable laws and regulat ions, limited subject attributes, such as sex, age, or date 
of birth, and subject init ials may be used to verify the subject and accuracy o f the subject’s unique 
ident ificat ion number.
To com ply with ICH Guidelines for GCP and to verify co mpliance with this protocol, the sponsor 
requi res the invest igator to permit the monitor or the sponsor’s designee, representatives fro m any 
regul atory  authori ty (eg, FDA, Medi cines and Heal thcare products Regul atory  Agency, 
Pharmaceut icals and Medical Devices Agency), the sponsor’s designated auditors, an d the 
appropriate IRBs and IECs to review the subject’s original medical records (source data or 
docum ents), including, but not limited to, laboratory  test resul t reports, ECG reports, admissio n 
and discharge summaries for hospital admissio ns occurring dur ing a subject’s study participation, 
and autopsy  reports. Access to a subject’s original medical records requires the specific 
authori zation of the subject as part of the informed consent process (see Section 15.2).
Copi es of  any subject source documents that are provided to the sponsor must have certain 
personally ident ifiable informat ion rem oved (ie, subject name, address, and other ident ifier fields 
not collected on the subject’s eCRF).
15.4 Publication, Disclosure, and Clinical Trial Registration Policy
15.4.1 Publication and Disclosure
The investigator is obliged to provide the sponsor with complete test results and all data derived by 
the invest igator from the study . During and after the study , only  the sponsor m ay make study  
inform ation available to other study  invest igators or to regulatory  agencies, except as required by  
law or regulation. Except as otherwise allo wable in the study site agreement, any public disclosure 
(including publicly accessible websites) related t o the protocol or study  resul ts, other than study  
recrui tment m aterials and/or advertisements, is the sole responsibilit y of the sponsor.
The sponsor may publish any data and informat ion fro m the study (including data and informatio n 
generated by  the inves tigator) wi thout the consent of the invest igator. Manuscript authorship for 
any peer -reviewed publicat ion will appropriately reflect contribut ions to the production and 
review of the document. All publicat ions and presentations must be prepared in accordan ce wi th 
Vedolizumab IV
Vedolizumab -4003 Page 77of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALthis sect ion and the study site agreement. In the event of any discrepancy between the protocol and 
the study  site agreement, the study  site agreement will  prevail.
15.4.2 Clinical Trial Registration
In order to ensure that informat ion on clinical trials reaches the public in a timely manner and to 
comply with applicable laws, regulat ions and guidance, Takeda will, at a minimum register all 
intervent ional clinical tri als it sponsors anywhere in the worl d on ClinicalTrials.gov and/or other 
publicly  accessib le websites before start of study , as defined in Takeda Policy/Standard . Takeda 
contact informat ion, along with invest igator’s cit y, state (for American investigators), country, and 
recrui ting status will be registered and available for public viewing. 
For some registries, Takeda will assist callers in lo cating study  sites cl osest to thei r homes by 
provi ding the invest igator name, address, and phone number to the callers request ing trial 
inform ation. Once subjects receive invest igator contact informat ion, they may call  the si te 
requesting enrollment into the trial. The invest igative sites are encouraged to handle the trial 
inquiries according to their established subject screening process. If the caller asks addit ional 
questions bey ond the topic of trial en rollment, they should be referred to the sponsor. 
Any invest igator who objects to the sponsor providing this informat ion to callers must provide the 
sponsor with a written notice request ing that their informat ion not be listed on the registry  site. 
15.4.3 Clini cal Trial Results Disclosure
Takeda will post the results of clinical trial son ClinicalTrials.gov and/or other publicly accessible 
websites, as required by Takeda Policy/Standard, applicable laws and/or regulat ions.
15.5 Insurance and Compensation for Injury
Each subject in the study must be insured in accordance with the regulations applicable to the site 
where the subject is participat ing. If a local underwriter is required, then the sponsor or sponsor’s 
designee will obtain clinical study  insurance against t he risk o f injury to study  subjects. Refer to 
the study site agreement regarding the sponsor’s policy on subject compensat ion and treatment for 
injury . If the invest igator has questions regarding this policy, he or she should contact the sponsor 
or sponsor ’s designee.
Vedolizumab IV
Vedolizumab -4003 Page 78of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL16.0 REFERENCES
1. Loftus EV, Jr. Clinical epidemio logy of inflammat ory bowel  disease: Incidence, 
prevalence, and environmental influences. Gastroenterology  2004;126(6):1504-17.
2. Shivananda S, Lennard -Jones J, Logan R, Fear N, Price A, Carpenter L, et al. Incidence o f 
inflammatory  bowel  disease across Europe: is there a difference between north and south? 
Results of the European Collaborative Study  on Inflammatory  Bowel  Disease (EC -IBD). 
Gut 1996;39(5):690-7.
3. Trallori G, Pal li D, Saieva C, Bardazzi G, Bonanomi AG, d'Albasio G, et al. A 
popul ation-based study of inflammatory bowel disease in Florence over 15 years (1978 -92). 
Scand J Gastroenterol 1996;31(9):892 -9.
4. Schwartz DA, Pemberton JH, Sandborn WJ. Diagnosis and treatm ent of peri anal fistul as in 
Crohn disease. Ann Intern Med 2001;135(10):906 -18.
5. Schwartz DA, Loftus EV, Jr., Tremaine WJ, Panaccione R, Harmsen WS, Zinsmeister AR, 
et al. The natural  history  of fistulizing Crohn's disease in Olmsted County , Minnesota. 
Gastroenterology  2002;122(4):875-80.
6. Bouri kas LA, Koutroubakis IE. Anti -TNF and fist ulizing perianal Crohn's disease: use in 
clinical practice. Curr Drug Targets 2010;11(2):187 -97.
7. Vavricka SR, Rogler G. Fistula treatment: The unreso lved challenge. Dig Dis 
2010;28(3):556 -64.
8. Gecse KB, Bemelman W, Kamm MA, Stoker J, Khanna R, Ng SC, et al. A global consensus 
on the classificat ion, diagnosis and mult idisciplinary  treatm ent of peri anal fistulising 
Crohn's disease. Gut 2014;63(9):1381 -92.
9. Prefontaine E, Macdonal d JK, Sutherl and LR. Azathi oprine or 6 -mercaptopurine for 
induct ion of remissio n in Crohn's disease. Cochrane Database Syst Rev 2010(6):Cd000545.
10. Pearson DC, May  GR, Fick GH, Sutherland LR. Azathioprine and 6 -mercaptopurine in 
Crohn disease. A meta -analysis. Ann Intern Med 1995;123(2):132 -42.
11. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. 
Infliximab for the treatment of fistulas in pat ients with Crohn's disease. N Engl J Med 
1999;340(18):1398 -405.
12. Sand s BE, Anderson FH, Bernstein CN, Chey  WY, Feagan BG, Fedorak RN, et al. 
Infliximab maintenance therapy  for fistulizing Crohn's disease. N Engl J Med 
2004;350(9):876 -85.
13. Sands BE, Blank MA, Patel K, van Deventer SJ. Long- term treatm ent of rectovaginal 
fistulas in Crohn's disease: response to infliximab in the ACCENT II Study . Clin 
Gastroenterol Hepatol 2004;2(10):912 -20.
Vedolizumab IV
Vedolizumab -4003 Page 79of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL14. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. 
Adalimumab for maintenance of clinical response and remissio n in pat ients with Crohn's 
disease: the CHARM trial. Gastroenterology  2007;132(1):52 -65.
15. Schreiber S, Lawrance IC, Thomsen OO, Hanauer SB, Bloomfield R, Sandborn WJ. 
Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease -subgroup 
resul ts from a placebo -controlled study . Aliment Pharmaco l Ther 2011;33(2):185 -93.
16. Castano -Milla C, Chaparro M, Saro C, Barreiro -de Acosta M, Garcia -Albert AM, Bujanda 
L, et al. Effect iveness of adalimumab in perianal fistulas in crohn's di sease patients naive to 
anti-TNF therapy . J Clin Gastroenterol 2015;49(1):34-40.
17. Schwartz DA, Ghazi LJ, Regueiro M, Fichera A, Zoccali M, Ong EM, et al. Guidelines for 
the multidisciplinary management of Crohn's perianal fistulas: summary  statement. 
Inflamm Bowel Dis 2015;21(4):723-30.
18. Yassin NA, Askari A, Warusavitarne J, Faiz OD, Athanasiou T, Phillips RK, et al. 
System atic review: the combined surgical and medical treatment of fistulising perianal 
Crohn's disease. Aliment Pharmacol Ther 2014;40(7 ):741 -9.
19. Butcher EC, Williams M, Youngman K, Rott L, Briskin M. Lymphocy te trafficking and 
regional immuni ty. Adv Immunol  1999;72:209-53.
20. Salmi M, Jalkanen S. Lymphocy te homing to the gut: attraction, adhesio n, and 
commit ment. Immuno l Rev 2005;206: 100-13.
21. Briskin M, Winsor -Hines D, Shyjan A, Cochran N, Bloom S, Wilso n J, et al. Human 
mucosal addressin cell adhesio n molecule -1 is preferent ially expressed in intestinal tract 
and associated lympho id tissue. Am J Pathol 1997;151(1):97 -110.
22. Erle DJ, Briskin MJ, Butcher EC, Garcia- Pardo A, Lazarovits AI, Tidswell M. Expressio n 
and function of the MAdCAM -1 receptor, integrin alpha 4 beta 7, on human leukocy tes. 
Immuno 1994;153(2):517-28.
23. Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER. Th e binding specificit y and 
select ive antagonism o f vedo lizumab, an anti -alpha4beta7 integrin therapeut ic antibody in 
development for inflammatory  bowel  diseases. J Pharmaco l Exp Ther 2009;330(3):864- 75.
24. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colo mbel JF, Sandborn WJ, et al . 
Vedolizumab as induct ion and maintenance therapy for ulcerative co litis. N Engl J Med 
2013;369(8):699 -710.
25. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colo mbel JF, Sands BE, et al. 
Vedolizumab as induct ion and maintenanc e therapy  for Crohn's disease. N Engl  J Med 
2013;369(8):711 -21.
26. Sands B, Feagan B, Rutgeerts P, Colombel J -F, Sandborn W, Sy  R, et al . Vedolizumab 
induct ion therapy  for pati ents wi th Crohn's disease and prior anti -tumour necrosi s factor 
antagonist fail ure: a randomised, placebo -controlled, double -blind, mult icentre trial. 
Vedolizumab IV
Vedolizumab -4003 Page 80of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALJournal  of Crohn's and Co litis 2013;7(Suppl. 1):Pages S5 –S6. 8th Congress of the European 
Crohn's and Co litis Organisat ion.
27. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colo mbel JF, Sands BE, et al. 
Vedolizumab as induct ion and maintenance therapy for Crohn’s disease. N Engl J Med 
2013;369:Supplementary  Appendix.
28. Feagan B, Schwartz D, Danese S, Rubin D, Abhyankar B, Smyt h M, et al . P508. 
Vedolizumab for the Treatment of Fistu lising Crohn's Disease: An Exploratory Analysis o f 
Data From GEMINI 2. J Crohns Co litis 2015;9 Suppl 1:S333 -4.
29. Entyvio (vedo lizumab) 300 mg powder for concentrate for solution for infusio n. Summary  
of Product Characterist ics. Denmark: Takeda Pharma A/S , Issued 25 September 2015.
30. Rogl er G. Crohn's disease: Fistulising disease --a probl em shared i s a probl em halved? Nat 
Rev Gastroenterol Hepatol 2014;11(10):581 -3.
31. Parks AG, Gordon PH, Hardcastle JD. A classification of fistula -in-ano. Br J Surg 
1976;63(1):1 -12.
32. Van Assche G, Vanbeckevoort D, Bielen D, Coremans G, Aerden I, Noman M, et al. 
Magnet ic resonance imaging o f the effects of infliximab on perianal fistulizing Crohn's 
disease. Am J Gastroenterol 2003;98(2):332 -9.
33. Irvine EJ. Usual ther apy improves perianal Crohn's disease as measured by  a new disease 
activit y index. McMaster IBD Study  Group. J Clin Gastroenterol 1995;20(1):27 -32.
34. Best WR, Becktel JM, Singleton JW, Kern F, Jr. Development of a Crohn's disease act ivity 
index. National Cooperative Crohn's Disease Study . Gastroenterol ogy 1976;70(3):439 -44.
35. Irvine EJ. Development and subsequent refinement of the inflammatory  bowel  disease 
questionnaire: a qualit y-of-life instrument for adult patients with inflammatory bowel 
disease. J Pediatr Gastroenterol  Nutr 1999;28(4):S23 -7.
36. Guyatt G, Mitchell A, Irvine EJ, Singer J, Williams N, Goodacre R, et al. A new measure o f 
healt h status for clinical trials in inflammatory  bowel  disease. Gastroenterology  
1989;96(3):804 -10.
37. Guyatt GH, Deyo RA, Charlson M, Levine MN, Mitchell A. Responsiveness and validit y in 
healt h status m easurement: a cl arificat ion. J Clin Epidemio l 1989;42(5):403 -8.
38. Rabin R, de Charro F. EQ -5D: a m easure of healt h status from the EuroQol Group. Ann 
Med 2001;33(5):337 -43.
39. Stark RG, Reit meir P, Lei dl R, Konig HH. Validit y, reliabilit y, and responsiveness of the 
EQ-5D in inflammatory  bowel  disease in Germany. Inflamm Bowel Dis 2010;16(1):42 -51.
40. Konig HH, Ulsho fer A, Gregor M, von Tirpitz C, Reinshagen M, Adl er G, et al. Validat ion 
of the EuroQol  quest ionnaire in pat ients with inflammatory  bowel  disease. Eur J 
Gastroenterol Hepatol 2002;14(11):1205 -15.
Vedolizumab IV
Vedolizumab -4003 Page 81of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL41. Major EO. Progressive m ultifocal leukoencephalo pathy  in pat ients on immuno modulatory  
therapi es. Annu Rev Med 2010;61:35 -47.
42. Steiner I, Berger JR. Update on progressive mult ifocal  leukoencephalopathy . Curr Neurol  
Neurosci Rep 2012;12(6):680 -6.
43. Sandborn WJ, Colo mbel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, et al. 
Natalizumab induct ion and mainten ance therapy  for Crohn's di sease. N Engl  J Med 
2005;353(18):1912 -25.
44. TYSABRI (natalizumab) injection. Full Prescribing Information. Cambridge, MA: Biogen 
Idec Inc., Revised June 2013.
45. Hussein K, Hay ek T, Yassin K, Fischer D, Vlodavsky  E, Kra -Oz Z, et al. Acute 
cytomegalovirus infecti on associ ated wi th the onset of inflammatory  bowel  disease. Am J 
Med Sci  2006;331(1):40 -3.
Vedolizumab IV
Vedolizumab -4003 Page 82of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALAppendix ASchedule of Study Procedures
Screen TreatmentFinal 
Visit 
or ET Follow -up Post Study
Study Day/Week:Days
-28 to -1Wk0
/ Day 
1Wk 
2Wk 
6Wk 
10Wk 
14Wk 
22Wk 
30Wk 40
(or 18 wks 
post-tx if 
ET)LTFU by 
Telephone
Wk 48 
(or 26 wks 
post-tx if 
ET)
Visit Windows (Days): ±2 ±2 ±3 ±7 ±7 ±7 ±7 ±7
Visit Number: 1 2 3 4 5 6 7 8 9 10
Informed consent X
Assess 
inclusion/exclusion 
criteriaX X
Demographics /medical 
and medication history/ 
concurrent medical 
conditions X
Crohn’s disease history X
Tuberculosis 
QuantiFERON or skin 
testX
Physi cal examination (a) X X X X X X X X
Fistula draining 
assessment (b)X X X X X X X X
Vital signs X X X X X X X X
Height and weight (c) X X X X X
CDAI X (d) X (e) X (e) X (e) X (e) X (e) X (e) X (e)
PDAI X X X X X X X
ECG X
MRI X (f) X (f)
Hematology, serum 
chemistry X X X X X
Hematocrit (for CDAI 
scoring)X X X
HIV/Hepatitis Panel X
Urinalysis X X X X
AVA (g) X X X X X X X (h)
PK (i) X X X X X X
CRP (j) X X X X
Fecal calprotectin (k) X X X
Footnotes are on last table page.
Vedolizumab IV
Vedolizumab -4003 Page 83of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALAppendix A Schedule of Study Procedures (continued)
Screen TreatmentFinal 
Visit 
or ET Follow -up Post Study
Study Day/Week:Days
-28 to -1Wk0
/ Day 
1Wk 
2Wk 
6Wk 
10Wk 
14Wk 
22Wk 
30Wk 40
(or 18 wks 
post-tx if 
ET)Phone
Wk 48 
(or 26 wks 
post-tx if 
ET)
Visit Windows (Days): ±2 ±2 ±3 ±7 ±7 ±7 ±7 ±7
Visit Number: 1 2 3 4 5 6 7 8 9 10
PML checklist X X (l) X (l) X (l) X (l) X (l) X (l) X X
Provide PML wallet car d X X
Serum Pregnancy test (m) X X
Urine Pregnancy test (m) X X X X X X X
IBDQ X X X
EQ-5D X X X
Mean Likert perianal pain 
score (n)X X X X X X X X
Subject diary (n) X X X X X X X X
Review subject diary X X X X X X X
Daily  # of pads used 
(selected sites only)X X X X X X X X
Dosing (IV) (o) X X X X X X
Antibiotic dosing X X X (p)
Seton removal (q) [X (q)] [X (q)] X (q)
Concomitant medications X X X X X X X X
PTE assessment X X 
AE/SAE assessment X X X X X X X X
Long -term follow -up 
safety  questionnaireX
Access IWRS to obtain 
subject IDX
Access IWRS for 
randomizationX
Access IWRS to register 
visitX X X X X X X X
Footnotes are on t he following page.
Vedolizumab IV
Vedolizumab -4003 Page 84of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALET=early termination, tx=treatment, wk=week.
(a) Including abdominal mass assessment for CDAI calculation.
(b) Fistula(e) (perianal, enterocutaneous) will be assessed for draining or closed status at each visit .Fistula draining assessme nt will 
preferably be performed by the same qualified designee for all assessments. At Screening and Week 30, the assessment of peria nal 
fistula draining is for eligibility or primary endpoint assessment, respectively.
(c) Height collected only at the Scre ening Visit.
(d) Hematocrit results collected during Screening will be used to calculate the CDAI score to determine eligibility.
(e) CDAI score components are to be performed prior to dosing; the total CDAI score will be calculated once results are avail able 
for all components.
(f) Subjects must have safety laboratory results reviewed prior to MRI scan being performed. If a subject’s serum creatinine is >1.5 
times the ULN (>1.5x ULN), the subject should not undergo the MRI procedure. MRI will be performed at Screening and Week 30; 
MRIs will be centrally read.
(g) AVA to be collected prior to dosing. If positive AVA is detected, a sample will be assessed for neutralizing AVA.
(h) The 18 -week postdose AVA sample should be collected for all subjects who stoppe d vedolizumab during study (ie, not for those 
who continue on commercial supply vedolizumab therapy post -study).
(i) PK samples to be collected at predose on Day 1, Weeks 6, 10, 14 and 22 and at Week 30. One additional PK sample will be 
collected at Week 1 0 postdose (as close to the end of the infusion as feasible, and must be obtained within 30 minutes after the end 
of the infusion).
(j) CRP will be measured from the hematology/serum chemistry blood draw at all weeks except Week 14. Week 14 will require a 
separate blood draw as hematology and serum chemistry are not taken at this time.
(k) Stool sample to be collected and sent to central laboratory for evaluation of fecal calprotectin.
(l) PML checklist must be administered prior to dosing at every dosing v isit.
(m) Women of childbearing potential only. Urine pregnancy testing will be conducted at the site and serum pregnancy testing w ill 
be conducted by the central laboratory. At visits with study drug dosing, testing to be performed before any study drug dosing.
(n) Subject electronic diary to be completed as per training instruction during screening interval. Subject electronic diary (CDAI 
and perianal pain) to be completed daily from Screening to Week 30.
(o) Subjects should be observed for 2 hours follow ing the first 2 infusions, at a minimum, and 1 hour after each subsequent infusion 
for monitoring for potential hypersensitivity reactions.
(p) Antibiotic companion medication that was started (or continued if subject already taking antibiotics) from Day 1 , must be 
stopped at Week 6. Additional courses of antibiotics may be allowed, as needed, and in consultation with the medical monitor.
(q) Applicable for subjects who had a seton at study enrollment. Setons may be removed at or after Week 6 at the discret ion of the 
investigator, provided that significant reduction in fistula drainage has occurred . All setons must be removed by Week 14.
Vedolizumab IV
Vedolizumab -4003 Page 85of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALSchedule of Samples With Dosing Sequence Requirements 
Visit 1, 
ScreeningVisit 2, 
Day 1Visit 3, 
Wk 2Visit 4, 
Wk 6Visit 5, 
Wk10Visit 6, 
Wk 14Visit 7, 
Wk 22Visit 8
Wk 30Visit 9 
Wk 40
PK sample Within 30 
min before 
doseWithin 30 
min before 
doseWithin 30 
min before 
dose AND 
Immedi -
ately  after 
infusion 
(within 30 
minutes of 
end of 
infusion)Within 30 
min befor e 
doseWithin 30 
min 
before 
doseAnytime during 
visit (before any 
commercial 
supply 
vedolizumab 
dose, if 
applicable)
AVA testing Within 30 
min before 
doseWithin 30 
min before 
doseWithin 30 
min before 
doseWithin 30 
min before 
doseWithin 30 
min 
befor e 
doseAnytime during 
visit (before any 
commercial 
supply 
vedolizumab 
dose, if 
applicable)(Anytime 
during visit 
[only for 
subjects who 
stopped 
vedolizumab 
during study])
Pregnancy 
testAnytime 
during visitBefore 
doseBefore 
doseBefore 
doseBefore dose Before 
doseBefore 
doseAnytime during 
visitAnytime during 
visit
Vedolizumab IV
Vedolizumab -4003 Page 86of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALAppendix BResponsibilities of the Investigator
Clinical research studies sponsored by  the sponsor are subject to ICH GCP and all the applicable 
local laws a nd regulat ions. The responsibilit ies imposed on Invest igators fro m the FDA are 
summarized in the “Statement of Invest igator” (Form FDA 1572) which must be completed and 
signed before the Invest igator may participate in this study.
The invest igator agrees t o assume the fo llowing responsibilit ies:
1.Conduct the study  in accordance wit h the protocol.
2.Personally conduct or supervise the staff who will assist in the protocol.
3.Ensure that study -related procedures, including study  specific (non routine/non standard 
panel) screening assessments are NOT performed on potential subjects, prior to the receipt of 
written approval  from relevant governing bodies/authorities.
4.Ensure that all co lleagues and emplo yees assist ing in the conduct of the study are informed of 
these obligat ions.
5.Secure prior approval o f the study and any changes by an appropriate IRB/IEC that conform to 
ICH, and l ocal regul atory  requi rements.
6.Ensure that the IRB/IEC will be responsible for init ial review, continuing review, and approva l 
of the protoco l. Prom ptly report to the IRB/IEC all changes in research act ivity and all 
anticipated risks to subjects. Make at least y early reports on the progress of the study  to the 
IRB/IEC, and issue a final report within 3 months of study  com pletion.
7.Ensure that re quirements for informed consent, as outlined in ICH and local regulations, are 
met.
8.Obtain valid informed consent from each subject who participates in the study , and docum ent 
the date of consent in the subject’s medical chart. Valid informed consent is th e most current 
versio n approved by the IRB/IEC. Each informed consent form should contain a subject 
authori zation sect ion that describes the uses and disclosures of a subject’s personal 
inform ation (including personal health informat ion) that will take pla ce in connect ion wit h the 
study . If an informed consent form does not include such a subject authorization, then the 
investigator must obtain a separate subject authorization form from each subject or the 
subject’s legally acceptable representative.
9.Prepar e and maintain adequate case histories of all persons entered into the study , incl uding 
eCRFs, hospital records, laboratory  resul ts, etc, and maintain these data for a minimum o f 
2years fo llowing notificat ion by the sponsor that all invest igations have be en discont inued or 
that the regulatory  authori ty has approved the marketing applicat ion. The invest igator should 
contact and receive written approval fro m the sponsor before disposing o f any such 
docum ents.
10. Allow possible inspection and copying by the regu latory  authori ty of GCP -specified essent ial 
docum ents.
Vedolizumab IV
Vedolizumab -4003 Page 87of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL11.Maintain current records of the receipt, administratio n, and disposit ion of sponsor -supplied 
drugs, and return all unused sponsor -supplied drugs to the sponsor.
12.Report adverse reactions to the sponsor prompt ly. In the event of an SAE, notify the sponsor 
within 24 hours.
13.If the invest igator/institution retains the services of any individual or party to perform 
trial-related duti es and funct ions, the invest igator/inst itution shoul d ensure that this indiv idual 
or party  is qualified to perform those trial -related duti es and funct ions and should implement 
procedures to ensure the integrit y of the tri al-related duti es and funct ions performed and any 
data generated.
Vedolizumab IV
Vedolizumab -4003 Page 88of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALAppendix CElements of the Subject Informed Consent 
In seeking informed consent, the fo llowing information shall be provided to each subject:
1.A statement that the study  involves research.
2.An explanat ion of the purposes of the research.
3.The expected duration of the sub ject’s participat ion.
4.A descript ion of the procedures to be fo llowed, including invasive procedures.
5.The i dentificat ion of any  procedures that are experimental.
6.The est imated number of subjects invo lved in the study .
7.A descript ion of the subject’s responsi bilities.
8.A descript ion of the conduct of the study .
9.A statement describing the treatment(s) and the probabilit y for random  assignment to each 
treatm ent.
10.A descript ion of the possible side effects of the treatment that the subject may receive.
11.A descript ion of any  reasonably  foreseeable ri sks or di scomf orts to the subject and, when 
applicable, to an embry o, fetus, or nursing infant.
12.A descript ion of any  benefi ts to the subject or to others that reasonably  may be expected from  
the research. When there is no intended clinical benefit to the subject, the subject should be 
made aware of this.
13.Disclosures o f appropriate alternat ive procedures or courses of treatment, if any, that might be 
advantageous to the subject and their important potent ial risks and benefit s.
14.A statement describing the extent to which confident iality of records i dentifying the subject 
will be maintained, and a note of the possibilit y that regul atory  agencies, auditor(s), IRB/IEC, 
and the monitor may inspect the records. By  signing a written informed consent form, the 
subject or the subject’s legally acceptable representative is authorizing such access.
15.For research invo lving more than minimal risk, an explanat ion as to whether any co mpensatio n 
and an explanat ion as to whether any  medical trea tments are available if injury  occurs and, if 
so, what they  consist of or where further informat ion may be obtained.
16.The ant icipated prorated payment(s), if any, to the subject for participat ing in the study.
17.The ant icipated expenses, if any , to the subjec t for parti cipat ing in the study.
18.An explanat ion of whom to contact for answers to pertinent questions about the research 
(invest igator), subject’s rights, and IRB/IEC and who m to contact i n the event of a 
research -related inj ury to the subject.
Vedolizumab IV
Vedolizumab -4003 Page 89of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL19.A statemen t that participation is vo luntary, that refusal to participate will invo lve no penalt y or 
loss of benefits to which the subject otherwise is entit led, and that the subject may discont inue 
participat ion at any  time wi thout penal ty or loss of benefits to whi ch the subject is otherwise 
entitled.
20.The consequences of a subject’s decisio n to wi thdraw from  the research and procedures for 
orderly terminat ion of part icipation by the subject.
21.A statement that the subject or the subject’s legally acceptable representa tive will be informed 
in a timely  manner if informat ion beco mes available that may be relevant to the subject’s 
willingness to continue participat ion in the study .
22.A statement that results of pharmacogenomic analysis will not be disclosed to an individual,
unless prevailing laws require the sponsor to do so.
23.The foreseeable circumstances or reasons under which the subject’s participat ion in the study  
may be terminated.
24.A wr itten subject authorization (eit her contained within the informed consent form or pro vided 
as a separate document) describing to the subject the contemplated and permissible uses and 
disclosures of the subject’s personal information (including personal health informat ion) for 
purposes of conduct ing the study. The subject authorizat ion mustcontain the fo llowing 
statements regarding the uses and disclosures of the subject’s personal informat ion:
a)that personal information (including personal healt h informat ion) may be processed by  or 
transferred to other parties in other countries for clinica l research and safet y reporti ng 
purposes, including, without limitat ion, to the fo llowing: (1) Takeda, its affiliates, and 
licensing partners; (2) business partners assist ing Takeda, its affiliates, and licensing 
partners; (3) regulatory  agencies and other healt h authorities; and (4) IRBs/IECs;
b)it is possible that personal informat ion (including personal healt h informat ion) may be 
processed and transferred to countries that do not have data protection laws that offer 
subjects the same level o f protecti on as the data protection laws wit hin this country; 
however, Takeda will make every  effort to keep y our personal  information confident ial, 
and y our name will not be di sclosed outsi de the clinic unless required by law;
c)that personal information (including person al heal th informat ion) may be added to 
Takeda’s research databases for purposes of developing a better understanding of the 
safet y and effect iveness o f the study  drug(s), studying other therapies for patients, 
developing a better understanding of disease, and improving the efficiency of future 
clinical studies;
d)that subjects agree not to restrict the use and disclo sure of their personal informat ion 
(including personal healt h informat ion) upon withdrawal fro m the study  to the extent that 
the restricted use o r disclosure of such informat ion may  impact the scient ific integrity of 
the research; and
Vedolizumab IV
Vedolizumab -4003 Page 90of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALe)that the subject’s ident ity will remain confident ial in the event that study  resul ts are 
published.
25. Female subjects of childbearing potential (eg, nonsterilized, prem enopausal  female subjects) 
who are sexually  active m ust use highly  effect ive contraception (as defined in the informed 
consent) fro m Screening throughout the duration of the study. Regular pregnancy tests will be 
perform ed throughout the study for all fema le subjects of childbearing potential. If a subject is 
found to be pregnant during study , study  drug will  be discont inued and the invest igator will 
offer the subject the choice to receive unblinded treatment informat ion.
26.Male subjects must use highly effec tive contraceptio n (as defined in the informed consent) 
from signing the informed consent throughout the duration of the study . If the partner or wife 
of the subject is found to be pregnant during the study, the invest igator will offer the subject the 
choice to receive unblinded treatment informat ion.
27.A statem ent that clinical trial informat ion fro m this trial will be publicly disclo sed in a publicly 
accessible website, such as ClinicalTrials.gov.
Vedolizumab IV
Vedolizumab -4003 Page 91of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALAppendix DInvestigator Conse nt to Use of Personal Information 
Takeda will co llect and retain personal information of invest igator, including his or her name, 
address, and other personally identifiable informat ion. In addit ion, invest igator’s personal 
inform ation may be transferred t o other parties located in countries throughout the world (eg, the 
United Kingdom, United States, and Japan), including the following:
Takeda, its affiliates, and licensing partners.
Business partners assist ing Takeda, its affiliates, and licensing partner s.
Regulatory  agencies and other health authorit ies.
IRBs and IECs.
Invest igator’s personal informat ion may be retained, processed, and transferred by  Takeda and 
these other parties for research purposes including the fo llowing:
Assessment of the suitabili ty of invest igator for the study  and/or other clinical studies.
Management, monitoring, inspect ion, and audit of the study .
Analysis, review, and verificat ion of the study  results.
Safety reporti ng and pharmacovigilance relat ing to the study .
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies rel ating to the study .
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies relat ing to other medications used in other clinical studies that may contain 
the sam e chemical com pound present in the study  drug.
Inspect ions and invest igations by regulatory  authorit ies relat ing to the study.
Self-inspect ion and internal audit within Takeda, its affiliates, and lice nsing partners.
Archiving and audit of study  records.
Posting investigator site contact informat ion, study details and results on publicly accessible 
clinical trial registries, databases, and websites.
Invest igator’s personal informat ion may be transferred to other countries that do not have data 
protecti on laws that offer the same level of protection as data protection laws in invest igator’s own 
country .
Invest igator acknowledges and consents to the use of his or her personal information by Takeda 
and othe r parti es for the purposes described above.
Vedolizumab IV
Vedolizumab -4003 Page 92of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALAppendix EPDAI

Vedolizumab IV
Vedolizumab -4003 Page 93of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL

Vedolizumab IV
Vedolizumab -4003 Page 94of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALAppendix FCDAI
Category Count Initial TotalMultiplication 
Factor Total
Number of liquid or very 
soft stools7-day total number of liquid or very soft stools 
(reported on the 7 days immediately prior to 
the study  visit)x 2
Abdominal pain 7-day total of daily abdominal pain scores on a 
3-point scale: 0=none, 1=mild, 2=moderate, 
3=severe (reported on the 7 days immediately 
prior to the study visit)x 5
General well being 7-day total of daily general well -being scores 
on a 4 -point scale: 0=generally well, 
1=slightly under par, 2=poor, 3=very poor, 
4=terrible (reported on the 7 days immediately 
prior to the study visit)x 7
Extra-intestinal 
manifestations of Crohn’s 
DiseaseTotal number of checked boxes (check all that 
apply ):
Arthritis/arthralgia
Iritis/uveitis
Erythema nodosum/pyoderma 
gangrenosum/aphthous stomatitis
Anal fissure, fistula, or abscess
Other fistula
Fever over 37.8°C during past weekx 20
Lom otil/Imodium/opiates 
for diarrheaYes = 1
No = 0x 30
Abdominal mass None = 0
Questionable = 2
Definite = 5x 10
Hematocrit (%) (a) Males: subtract value from 47
Females: subtract value from 42x 6
Body Weight (b) (1 –(Body weight/
Standard Weight)) × 100x 1
Final Score Add totals:
Source: Adapted from: Best WR, Becktel JM, Singleton JW, Kern F, Jr. Development of a Crohn’s disease activity 
index. National Cooperative Crohn’s Disease Study. G astroenterology 1976; 70 (3):439 -44. 
(a) If hematocrit subtotal <0, enter 0. (b) If body weight subtotal < -10, enter -10.
Vedolizumab IV
Vedolizumab -4003 Page 95of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALAppendix GTable for Determining Standard Body Weight (CDAI Variable)

Vedolizumab IV
Vedolizumab -4003 Page 96of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALAppendix HIBDQ

Vedolizumab IV
Vedolizumab -4003 Page 97of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL

Vedolizumab IV
Vedolizumab -4003 Page 98of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL

Vedolizumab IV
Vedolizumab -4003 Page 99of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL

Vedolizumab IV
Vedolizumab -4003 Page 100of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL

Vedolizumab IV
Vedolizumab -4003 Page 101of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL

Vedolizumab IV
Vedolizumab -4003 Page 102of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL

Vedolizumab IV
Vedolizumab -4003 Page 103of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL

Vedolizumab IV
Vedolizumab -4003 Page 104of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL

Vedolizumab IV
Vedolizumab -4003 Page 105of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIAL

Vedolizumab IV
Vedolizumab -4003 Page 106of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALAppendix IEQ-5D
EQ-5D-3L PDA version
English (USA)
Health Questionnaire
English version for the USA
On the following screens please tap the statement that best describes your health 
TODAY.
Your mobility TODAY
I have no problems in walking about
I have some problems in walking about
I am confined to bed
Your self -care TODAY
I have no problems with self -care
I have some problems washing or dressing myself
I am unable to wash or dress myself
Your usual activities TODAY (e.g. work, study, housework, family or leisure activities)
I have no problems with performing my usual activities
I have some problems with performing my usual activities
I am unable to perform my usual activities
Your pain / discomfort TODAY
I have no pain or discomfort
I have moderate pain or discomfort
I have extreme pain or discomfort
Your anxiety / depression TODAY
I am not anxious or depressed
I am moderately anxious or depressed
Vedolizumab IV
Vedolizumab -4003 Page 107of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALI am extre mely anxious or depressed
We would like to know how good or bad your health is TODAY.
On the next screen you will see a scale numbered 0 to 100.
100 means the best health you can imagine.
0 means the worst health you can imagine.
Please tap on the sca le to indicate how your health is TODAY.
The best health you can imagine
The worst health you can imagine
YOUR HEALTH TODAY
© EuroQol Research Foundation. EQ -5D™ is a trade mark of the EuroQol Research Foundation
Disclaimer: This is a preview of the EQ-5D instrument. It demonstrates the text, questions and response 
options included in this version. This preview does not represent the final product and should not be used 
as an official EQ -5D instrument.
Vedolizumab IV
Vedolizumab -4003 Page 108of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALAppendix JLiker t Scale for Perianal Pain
This 11 -point Likert rating scale will be used by subjects to assess their perianal pain each day, as 
below. Likert scale for perianal pain will be completed as part of the subject diary.
“How woul d you rate y our peri anal pain in the last 24 hours?”
0 1 2 3 4 5 6 7 8 9 10
No 
painWorst 
possible 
pain
Source: Adapted from: Likert, R. A technique for the measurement of attitudes. Archives of Psychology 
1932;140:1–55.
Vedolizumab IV
Vedolizumab -4003 Page 109of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALAppendix KDetailed Desc ription of Amendments to Text
The primary sect ion(s) of the protocol affected by the changes in Amendment No. 05 are indicated. 
The corresponding text has been revised throughout the protocol. 
Change 1: Removed the requirement for perianal seton placement as part of standard of care 
before rando mizat ion.
The primary  change occurs in Section 7.1Inclusio n Cri teria: 
Initial 
wording:The subject h ad noncutting perianal seton placement as part of standard care within 1 
to 4 weeks prior to randomizat ion.
Amended 
or new 
wording:IfTthe subject had noncutting perianal seton placement as part of standard care within 
1 to 4 weeks prior to randomizat ion, seton must be removed by Week 14 of the 
study.
Rationale for Change:
Study  popul ation modified to allow subjects with or without seton.
The fo llowing sect ions also contain this change:
Secti on 2.0STUDY SUMMARY .
Secti on 4.2Rationale for the Proposed Study .
Secti on 6.1Study  Design . 
Appendix ASchedule o f Study  Procedures ,
 footnote q.
Change 2: Change d the requi rements for seton remo val, if applicable, fro m 10 to 22 weeks after 
rando mizat ion to 6 to 14 weeks after randomizat ion.
The p rimary  change occurs in Section 6.1Study  Design :
Initial 
wording:In both groups, setons may be removed at or after Week 10 at the discret ion of the 
investigator, provided that significant reduction in fistul a drainage has occurred . All 
setons are recommended to be removed by Week 14 and must be removed by Week 
22.
Amended 
or new 
wording:In both groups , for subjects with a seton at study entry, setons may be removed at or 
after Week 106at the disc retion of the invest igator, provided that significant reduction 
in fistul a drainage has occurred . All setons are recommended to be removed by Week 
14 and must be removed by Week 2214.
Vedolizumab IV
Vedolizumab -4003 Page 110of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALRationale for Change:
Updated the text to apply only to subjects who ha ve a seton at study entry, as setons are no longer 
requi red in thi s amendment; updated the window for seton removal so they are removed earlier in 
the study  and do not confound endpo int assessment.
Appendix ASchedule o f Study  Procedures also contains this change.
Change 3: Added a secondary endpoint to evaluate fistulas healed at both Week 22 and Week 30.
The primary  change occurs in Section 5.2.2 Secondary Endpo ints:
Added text: The proportion of subjects with a reduction of at least 50% from Day 1 in the 
number of draining perianal fistulae at both Week 22 and Week 30 (where 
closed fistulae a re no longer draining despite gentle finger compression).
Rationale for Change:
New endpo int added that is considered clinically  relevant
The fo llowing sect ions also contain this change:
Secti on 2.0STUDY SUMMARY .
Secti on 13.1.3 Analysis o f Fistula Healing.
Change 4: Modified inclusio n criterion 6 such that both France -specific and global language is 
presented.
The primary  change occurs in Section 7.1Inclusio n Cri teria:
Added text: 6. All countries except France: The subject, hi storically, had an inadequa te response 
with, lost response to, or was i ntolerant to ei ther convent ional therapy  or a TNF -α 
antagonist for their underlying CD (does not require treatment failure for currently 
active draining fistula) . 
France only: The subject, historically, failed ( ie, had an inadequate response 
with, lost response to, or was i ntolerant to) infliximab for treatment of their 
underlying CD or fistulizing CD.
Rationale for Change:
To conso lidate pri or regi on-specific protocols into a single global protocol amendment.
The fo llowing sect ions also contain this change:
Secti on 2.0STUDY SUMMARY .
Secti on 6.1Study  Design .
Vedolizumab IV
Vedolizumab -4003 Page 111of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALChange 5: Modified inclusio n and exclusio n criteria to allow addit ional types o f antibiotic to 
reduce the incidence of abscess.
The primary  changes occur in Section 7 .1Inclusio n Cri teriaand Secti on 7.2Exclusio n Cri teria:
Initial 
wording:7.1 Inclusion Criteria
…
9. The subject is willing and able to take antibiot ic treatment (metronidazo le or 
ciprofl oxacin, as per l ocal label) from Day 1 through study  Week 6.
…
7.2 Exclusion Criteria
…
12. The subject has allergies to and/or contraindications for metronidazo le and 
ciprofl oxacin (including interact ing drugs such as tizanidine).
13. In the opinion o f the invest igator, the subject is li kely to requi re greater than 6 
weeks of treatment after Day  1 wi th metroni dazo le or ci profl oxacin for the 
treatm ent of abscess.
Amended 
or new 
wording:7.1 Inclusion Criteria
…
9. The subject is willing and able to take antibiot ic treatment (metronidazo le,or
ciprofl oxacin, amoxicillin clavulanate ,or tinidazole, as per local label) fro m 
Day 1 through study  Week 6.
…
7.2 Exclusion Criteria
…
12. The subject has allergies to and/or contraindications for metronidazo le and 
ciprofl oxacin and amoxicillin clavul anate and tinidazole (including interacting 
drugs such as t izanidine).
13. In the opinion o f the invest igator, the subject is likely to require greater than 6 
weeks of treatment after Day  1 wi th metroni dazo le,orcipro floxacin , amoxicillin 
clavulanate ,or tinidazole for the treatm ent of abscess.
Rationale for Change:
To allow addit ional options for antibiot ics (amoxicillin clavulanate 875 mg BID, or tinidazo le 500 
mg QD)
Vedolizumab IV
Vedolizumab -4003 Page 112of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALThe fo llowing sect ions also contain this change:
Secti on 7.3Excluded Medications .
Secti on 7.3.1 Permitted Medications and Treatments .
Secti on 8.1.1.2 Com panion Medicat ion.
Section
 8.1.3 Dose and Regimen .
Appendix ASchedule o f Study  Procedures .
Change 6: Modified inclusio n criteria 10 and 11 per updated safety  language.
The primary  change occurs in Section 7.1Inclusio n Cri teria:
Initial 
wording:10. A male subject who is nonsterilized* and sexually act ive with a female partner of 
childbearing potential* agrees to use adequate contraception* fro m signing of  
inform ed consent throughout the duration of the study and for 18 weeks after last dose.
11. A female subject of childbearing potential* who is sexually act ive with a 
nonsterilized* male partner agrees to use routinely  adequate contraception* from 
signing of informed consent throughout the duration of the study and for 18 weeks 
after last dose. 
*Definit ions and acceptable methods of contraceptio n are defined in 
Secti on9.1.25 Contraception and Pregnancy Avo idance Procedure 
and reporting responsibilit ies are defined in Sect ion 9.1.26
Pregnancy.
Amended 
or new 
wording:10. A male subject who is nonsterilized* and sexually act ive with a female partner of 
childbea ring potenti al* agrees to use adequate a barrier metho d of contraception
(eg,condom with spermicide) * from signing of informed consent throughout the 
durati on of  the study  and f or 18 weeks after last dose. The female partner of a 
male subject should also b e advised to use a highly effective method of 
contraception*.
11. A female subject of childbearing potential* who is sexually act ive with a 
nonsterilized* male partner agrees to use routinely adequate a highly effective 
method of contraception* from signin g of informed consent throughout the 
durati on of  the study  and f or 18 weeks after last dose. 
*Definit ions and acceptable highly effective methods of 
contraception are defined in Sect ion9.1.25 Contraception and 
Pregnancy Avoidance Procedure and reporting responsibilit ies are 
defined in Sect ion 9.1.26 Pregnancy.
Vedolizumab IV
Vedolizumab -4003 Page 113of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALRationale for Change:
To cl arify study  inclusio n criteria per current safety  requirements.
Change 7: Modified exclusi on criteria 6 and 7 per updated safet y language.
The primary  change occurs in Section 7.2Exclusio n Cri teria:
Initial 
wording:6. The subject has act ive or latent tuberculosis (TB), regardless of treatment 
history , as evi denced by any of the f ollowing:
a.History  ofTB.
b.A diagnostic TB test performed during Screening that is posit ive, as 
defined by:
i.A posit ive test for tuberculosis (QuantiFERON) or 2 successive 
indeterminate QuantiFERON tests OR
ii.A tuberculin skin test reactio n≥10 mm (≥5 mm in subjects 
receiving the equivalent of >15 mg/day predniso ne)
Note: if the subject has a documented negat ive diagnostic TB test in the 
previous 3 months, screening testing does not need to be repeated provided 
subject has no risk factors for exposure .
7. The subject has a known history  of infect ion with human immunodeficiency  
virus (HIV), hepatit is B (HBV) or hepatit is C (HCV) or is found to be 
seroposi tive at Screening.
Amended 
or new 
wording:6. The subject has act ive or latent tuberculosi s (TB), regardless of treatment 
history , as evidenced by any of the f ollowing:
a.History  ofTB.
a.A diagnostic TB test performed during Screening that is posit ive, as 
defined by:
iii.A posit ive test for tuberculosis (QuantiFERON) or 2 successive 
indeterminate Quan tiFERON tests OR
iv.A tuberculin skin test reaction ≥10 mm (≥5 mm in subjects 
receiving the equivalent of >15 mg/day predniso ne)
b.Chest X -ray within 3 months prior to Day 1 that is suspicious for 
pulmonary TB, and a positive or 2 successive indeterminate 
Quant iFERON test within 30 days prior to Screening or during 
the Screening Period.
Note: if the subject has a documented negat ive diagnostic TB test in the 
previous 3 months, screening testing does not need to be repeated provided 
Vedolizumab IV
Vedolizumab -4003 Page 114of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALsubject has no risk factors fo r exposure .
7.  The subject has chronic hepatitis B virus (HBV) infection* or chronic 
hepatitis C virus (HCV) infection** or a known history  of infect ion 
withhuman immunodeficiency virus (HIV) , hepat itis B (HBV) or hepatit is C 
(HCV) infection ( or is found to be seroposit ive at Screening ) or subject is 
immunodeficient (eg, due to organ transplantation, history of common 
variable immunodeficiency). 
*Subjects who are positive for hepatitis B virus surface antigen (HBsAg) will 
be excluded. For subjects who are negative for HBsAg but are positive for 
either surface antibodies and/or core antibodies, HBV DNA polymerase 
chain reaction will be performed ,and if any test result meets or exceeds 
detection sensitivity, the subject will be excluded.
** If the subject is HCV antibody positive, then a viral load test will be 
performed. If the viral load test is positive ,then the subject will be excluded.
Rationale for Change:
To cl arify exclusi on criteria per preferred safety  wording.
Change 8: Modified exclusio n criterion 17 to remove the option of 5 half lives as washout 
window.
The primary  change occurs in Section 7.2Exclusio n Cri teria:
Deleted 
text:17. T he subject has received any invest igational or approved bio logic or bi osimilar 
agent wi thin 60 days or 5 half lives (whichever is longer) of rando mizat ion.
Rationale for Change:
To cl arify that 60 days is considered a sufficient washout period.
The fo llowing sect ions also contain this change:
Secti on 2.0STUDY SUMMARY .
Secti on 7.3Excluded Medications .
Change 9: Modified exclusio n criterion 19 to al so exclude subjects with prior exposure to 
etrolizumab or anti -mucosal addressin c ell adhesi on molecule -1 therapy  therapy .
The primary  change occurs in Section 7.2Exclusio n Cri teria:
Initial 
wording:19. The subject has any  prior exposure to vedolizumab, natalizumab, efalizumab, or 
rituximab.
Amended 
or new 
wording:19. The subject has any  prior exposure to vedolizumab, natalizumab, efalizuma b,or
rituximab ,etrolizumab, or anti -MAdCAM -1 therapy .
Vedolizumab IV
Vedolizumab -4003 Page 115of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALRationale for Change:
To exclude subjects with exposures to etrolizumab or anti -MAdCAM -1 therapy
Secti on 2.0STUDY SUMMARY also contain this ch ange.
Change 10: Reduced the study sample size fro m 126 (63 per group) to 100 (50 per group).
The primary  change occurs in Section 13.3 Determinat ion of Sample Size :
Initial 
wording:A sample size of 126 subjects (63 per group) will generate 95% CIs for fistula closure 
rate with a half width no wider than 12.4%; in additio n, the 95% CIs for the difference 
in fistula closure rates between the 2 gr oups will be no wider than 17.6%. The sample 
size was not based on statist ical power considerations but on an estimate of precision.
Amended 
or new 
wording:A sample size o f 126100subjects ( 6350per group) will generate 95% CIs for fistula 
closure rate w ith a half width no wider than 12.413.9 %; in addit ion, the 95% CIs for 
the difference in fistula closure rates between the 2 groups will be no wider than 
17.619.6%. The sample size was not based on statistical power considerat ions but on 
an est imate of pr ecision.
Rationale for Change:
To m odify the study  sample size.
The fo llowing sect ions also contain this change:
Secti on 2.0STUDY SUMMARY .
Secti on 6.1Study  Design .
Change 11: Increased the number of study  sites from 30 to 40.
The primary  change occurs in Section 2.0STUDY SUMMARY :
Initial 
wording:Approximately  30 si tes in North America and Europe
Amended 
or new 
wording:Approximately  3040sites in North America and Europe
Rationale for Change:
To increase study  recrui tment
Vedolizumab IV
Vedolizumab -4003 Page 116of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALChange 12: Added a stratificat ion factor for seton or no seton at randomizat ion.
The primary  change occurs in Section 8.3Rando mizat ion Code Creation and Storage :
Added text: Randomizatio n will  be stratified by TNF naïve versus TNF non -naïve (TNF failed) 
and by seton or no seton at Baseline .
Rationale for Change:
To bal ance groups by  seton use, given that setons are no longer required as of this amendment.
Change 13: Added a futilit y analysis after 25 subjects complete the primary  endpoint assessment 
(Week 30).
The primary  change occurs in Section 13.2 Futilit y Analysis and Criteria for Early Termination :
Initial 
wording:13.2 Interim Analysis and Criteria for Early Termination
No interim analysis, nor criteria for early termination of the study  are planned.
Amended 
or new 
wording:13.2 Interim Futility Analysis and Criteria for Early Termination
Nointerim analysis, nor criteria for early termination of the study are planned. A 
futility analysi s will be performed after 25 patients per treatment arm compl ete 
to Week 30. There is no intention to stop for efficacy at this point .
Rationale for Change:
To add a fut ility analysis 
The fo llowing sect ions also contain this change:
Secti on 6.3.1 Criteria for Premature Terminat ion or Suspensio n ofStudy  Sites.
Secti on 13.2 Futilit y Analysis and Criteria for Early  Terminati on.
Change 14: Updated background informat ion per the current Invest igator’s Brochure.
Theprimary  change occurs in Section 4.1.2.2 Human Experience :
Initial 
wording:In the clinical development program more than 3400 subjects have received at least 1 
dose of vedo lizumab (see Invest igator’ s Brochure [IB], Edition 17). 
Amended 
or new 
wording:In the clinical development program more than 3400 4200 subjects have received at 
least 1 dose of vedo lizumab (see Invest igator’s Brochure [IB], Edit ion 1719).
Rationale for Change:
Updated per Inves tigator’s Brochure Edi tion 19.
Vedolizumab IV
Vedolizumab -4003 Page 117of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALChange 15: Revised the rationale for the proposed study given that perianal seton replacement no 
longer required.
The primary  change occurs in Section 4.2Rationale for the Proposed Study :
Deleted 
text:Treatment in both arms will be combined wit h standard of care surgical intervent ion 
(seton) based on recent literature, which suggests benefit of a combined surgical and 
medical approach for patients with CD perianal fistulae [8,17,45] .
Rationale for Change:
Updated on the basis of changes to the study  populati on as of this amendment.
Change 16: Revised the benefit -risk assessment given that perianal seton replacement no longer 
requi red.
The primary  change occurs in Section 4.3Benefit:R isk Assessment :
Deleted 
text:Treatment in both arms will be combined w ith standard of care surgical intervent ion 
(seton) based on recent literature, which suggests benefit of a combined surgical and 
medical approach for pat ients with CD perianal fistulae [8,17,45] .The combinat ion of 
vedo lizumab therapy wit h surgical standar d of care is intended to minimize the risk o f 
treatm ent failure.
Rationale for Change:
Updated on the basis of changes to the study  populati on as of this amendment.
Change 17: Modified the Schemat ic of Study Design given the changes in this amendment.
The primary  change occurs in Figure 6.a Schemat ic of Study  Design :
Descript ion 
of Change:Removed standard care seton before randomizat ion.
Modified sample size to 100 subject s rando mized.
Clarified that “If baseline seton” then removal beween Weeks 6 and 14.
Added endpo int assessment at Week 22.
Rationale for Change:
Updated the figure on the basis of changes to the study  design as of this amendment
Change 18: Changed the maximum dose of oral corticosteroids fro m 30 to 20 m g/day  and 
clarified that tapering schedule provided is an example of one schedule; allowed for return to 
baseline corticosteroid dose.
The primary  change occurs in Section 7.3.1.1 Oral Corticosteroid Dosing and Tapering :
Initial 
wording:Themaximum dose oforalcorticosteroi dsforthetreatm entofCDthatmay be
coadministered with vedolizumab IV is30mg/day predniso neor 9mg/day 
budesonide (or equivalent) as long as the corticosteroid dose has been stable for at 
Vedolizumab IV
Vedolizumab -4003 Page 118of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALleast 4weeks prior to randomization.
Itisrequi red that subjects receiving oral corticosteroids begin a tapering regimen 
by Week 4. T he tapering schedule is as fo llows:
Forprednisone at doses >10 mg/day (or equivalent), the dose should be reduced at 
a rate of 5 mg/week untila 10 m g/day is reached.
For predni sone at doses ≤10 m g/day  (or equivalent) or once a 10 mg/day dose (or 
equivale nt) isachieved by tapering, the dose should be reduced at a rate of 2.5 
mg/week unt ildiscont inuat ion.
Budesonide should be reduced at a rate of 3 mg every  3 weeks unt il 
discontinuat ion.
Amended 
or new 
wording:Themaximum dose oforalcorticosteroi dsforthetreatm entofCDthatmay be
coadministered with vedolizumab IV is 3020mg/day  prednisone or 9mg/day 
budesonide (or equivalent) as long as the corticosteroid dose has been stable for at 
least 4weeks prior to randomization.
Itisrequi red that subjec ts receiving oral corticosteroids begin a tapering regimen 
by Week 4. TheAn example tapering schedule is as follows:
Forprednisone at doses >10 mg/day (or equivalent), the dose should be reduced at 
a rate of 5 mg/week untila 10 m g/day is reached.
For pre dnisone at doses ≤10 m g/day  (or equivalent) or once a 10 mg/day dose (or 
equivalent) is achieved by tapering, the dose should be reduced at a rate of 2.5 
mg/week unt ildiscont inuat ion.
Budesonide should be reduced at a rate of 3 mg every  3 weeks unt il 
discontinuat ion.
For patients who could not tolerate the corticosteroid taper without recurrence 
of clinical symptoms, corticosteroids may have been increased up to the original 
dose at the start of study (should not exceed baseline dose). In such cases, the 
tapering regimen must be reinitiated within 2 weeks.
Rationale for Change:
To reduce m aximum  dose of concomitant corticosteroid, to allow sites to follow their standard 
tapering schedule, and to clarify  that that steroi ds can be increased back to the basel ine dose if 
needed.
Vedolizumab IV
Vedolizumab -4003 Page 119of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALChange 19: Modified the criteria for discont inuat ion or withdrawal to add monitoring for 
leukopenia and lymphopenia and to clarify  other cri teria.
The primary change occurs in Sec tion 7.4Criteria for Discont inuat ion or Withdrawal of a Subject : 
Initial 
wording:1. Pretreatment event (PTE) or AE. The subject has experienced a PTE or AE that 
requi res early termination because cont inued participat ion imposes an 
unacceptable risk to the subject’s healt h or the subject is unwilling to continue 
because of the PTE or AE.
Liver Funct ion Test (LFT) Abnormalit ies.
Study  medicati on shoul d be discont inued immediately with appropriate 
clinical fo llow-up (including repeat laboratory  tests, until a subject’s 
laboratory  profile has returned to normal/baseline status, see Section 9.1.20), if 
the following ci rcumstances occur at any  time during study  medicati on 
treatm ent:
–ALT or AST >8 × ULN, or
–ALT or AST >5 × ULN and persists for more than 2 weeks, or
–ALT or AST >3 × ULN in conjunct ion with elevated total  bilirubin >2 × 
ULN or internat ional normalized rat io (INR) >1.5, or
–ALT or AST >3 × ULN with appearance of fatigue, nausea, vo miting, right 
upper quadrant pain or tenderness, fever, rash and/or eosinophilia (>5%).
…
3. Lost to follow-up. The subject did not return to the clinic and attempts to contact the 
subject were unsuccessful. Attempts to con tact the subject must be documented.
4. Vol untary withdrawal. The subject (or subject’s legally acceptable representative) 
wishes to withdraw fro m the study. The reason for withdrawal, if provided, should 
be recorded in the eCRF.
Note: All attempts should be made to determine the underlying reason for the 
withdrawal  and, where possible, the primary underlying reason should be recorded 
(eg, wi thdrawal  due to an AE or lack of  efficacy).
Amended 
or new 
wording:1. Pretreatment event (PTE) or AE. The subject has experienced a PTE or AE that 
requi res early terminati on because cont inued participat ion imposes an 
unacceptable risk to the subject’s healt h or the subject is unwilling to continue 
because of the PTE or AE.
Liver Funct ion Test (LFT) Abnormalit ies.
Study  medicationdrugshoul d be di scontinued immediat ely with appropriate 
clinical fo llow-up (including repeat laboratory  tests, until a subject’s 
Vedolizumab IV
Vedolizumab -4003 Page 120of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALlaboratory  profile has returned to normal/baseline status, see Section 9.1.20), if 
the following ci rcumstances occur at any  time during study  medicationdrug
treatment:
–ALT or AST >8 × ULN, or
–ALT or AST >5 × ULN and persists for more than 2 weeks, or
–ALT or AST >3 × ULN in conjunct ion with elevated total  bilirubin >2 × 
ULN or internat ional normalized rat io (INR) >1.5, or
–ALT or AST >3 × ULN with appearance of fatig ue, nausea, vo miting, right 
upper quadrant pain or tenderness, fever, rash and/or eosinophilia (>5%).
Leukopenia or lymphopenia: WBC and lymphocyte counts will be 
monitored for all subjects. Azathioprine, 6- MP, or methotrexate, if 
applicable, should be dis continued and the dose of vedolizumab held for 
an absolute lymphocyte count <0.5×109/L at any point in the study. The 
absolute lymphocyte count must be repeated at appropriate intervals as 
determined by the investigator. The next dose of vedolizumab can be
administered only if the absolute lymphocyte count is ≥0.5×109/L. If the 
absolute lymphocyte count remains <0.5×109/L, study drug should be 
discontinued and the subject withdrawn from the study.
…
3. Lost to follow-up. The subject did not return to the cl inic and attempts to contact the 
subject were unsuccessful. Attempts to contact the subject must be documented in 
the subject’s source documents .
4. Vol untary  withdrawal. The subject (or subject’s legally acceptable representative) 
wishes to withdraw fro mthe study. The reason for withdrawal, if provided, should 
be recorded in the eCRF.
Note: All attempts should be made to determine the underlying reason for the 
withdrawal  and, where possible, the primary underlying reason should be recorded 
(ieeg, withdrawal due to an AE should not be recorded in the voluntary 
withdrawal category . Similarly, orlack of efficacy should not be recorded in 
the voluntary withdrawal category ).
Rationale for Change:
To add m onitoring for l eukopenia and lymphopenia and to add cl arificat ions to criteria 3 and 4.
Vedolizumab IV
Vedolizumab -4003 Page 121of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALChange 20:Clarified the medical  history  collecti on of  smoking/nicotine usage status and 
collect ion of all medications for Crohn’s disease.
The prima ry change occurs in Section 9.1.2 Demographics, Medical History , and Medicat ion 
History  Procedure :
Initial 
wording:Dem ographic informat ion to be obtained will include date of birth or age, sex, 
Hispanic ethnicit y(as applicable), race as described by  thesubject, andsmoking
status ofthe subject at Screening.
Medical history  to be obtained will include determining whether the subject has 
any significant condit ionsordiseases relevant tothedisease under study  that 
stopped at or prior to signing of inform ed consent. Ongoing condit ions are 
considered concurrent medical condit ions (see Secti on 9.1.8 .)
…
In addit ion,all prior biologic m edicat ion history  forthetreatm ent of CD, including 
date of diagno sis, wi th thereason for discont inuat ionis to be collected for subjects 
where possible.
Amended 
or new 
wording:Dem ographic informat ion to be obtained will include date of birth or age, sex, 
Hispanic ethnicit y(as applicable), race as described by  thesubject, and
smoking /nicotine usage status ofthe subject at Screening.
Medical history  to be obtained will include determining whether the subject has 
any significant condit ionsordiseases relevant tothedisease under study  that 
stopped resolved at or pri or to si gning of informed consent. Ongoing condit ions 
are considered concurrent medical condit ions (see Secti on 9.1.8 .)
…
In addit ion,all pri orbiologic and/or any medication history  forthetreatment of 
CD, including date of diagnosis, with the reason for discontinuation is to be 
collected for subjects where possible.
Rationale for Change:
To capture relevant medical history  inform ation
Vedolizumab IV
Vedolizumab -4003 Page 122of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALChange 21: Clarified vital signs collection.
The primary  change occurs in Section 9.1.6 Vital Sign Procedure :
Initial 
wording:Vital signs will include body temperature (oral measurement), respiratory  rate, supine 
blood pressure (resting more than 5 minutes), and pulse (resting more than 5 minutes).
Amended 
or new 
wording:Vital signs will include body temperature (oral measurement) , respiratory  rate, supine 
blood pressure ( systolic and diastolic, resting more than 5 minutes), and pulse 
(resting more than 5 minut es).
Rationale for Change:
To allow for sites that use tympanic body temperature and to clarify that blood pressure collect ion 
includes both sy stolic and di astolic.
Change 22: Clarified that all fistula draining assessments are preferably be done by the same 
qualified designee.
The primary  change occurs in Section 9.1.11 Fistula Draining Assessment :
Added text: Fistula draining assessment will p referably be performed by the same qualified 
designee for all assessments.
Rationale for Change:
For consistency in endpo int measurement.
Appendix ASchedule o f Study  Procedures , footnote b, also contai ns this change.
Change 23: Clarified that confirmation fro m a central  reader is required for magnet ic resonance 
imaging eligibilit y.
The primary  change occurs in Section 9.1.10 MRI Procedure :
Added text: Confirmation must be obtained from a central reader to confirm MRI eligibility.
Rationale for Change:
To cl arify MRI eligibilit y requirements.
Vedolizumab IV
Vedolizumab -4003 Page 123of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALChange 24: Added the superficial category for the Parks classificat ion.
The primary  change occurs in Section 9.1.10.1 Parks Classificat ion:
Added text: Parks described a classificat ion system fo r perianal fistula [31], that will be used at 
Screening for classificat ion of act ive fistula(e) as superficial, intersphincteric, 
transsphincteric, suprasphincteric, or extrasphincteric. 
Rationale for Change:
To provi de all categori es for Parks classific ation.
Change 25: Clarified the neutralizing anti- vedo lizumab ant ibodies (AVA) analysis.
The primary  change occurs in Section 9.1.23 Anti-Vedolizumab Ant ibodies Sampling :
Added text: A sample will be assessed for neutralizing AVA if a positive AVA is detected.
Rationale for Change:
To cl arify when neutralizing AVA will be analyzed.
Change 26: Replaced the exis ting Contraception and Pregnancy Avo idance language wit h 4 new 
subsect ions containing updated language for contraception and pregnancy avo idance, and clarified 
in Appendix Cthat highly effect ive contraception must be used.
The primary change occurs in Section 9.1.25 Contraception and Pregnancy Avo idance Procedure :
Deleted 
text:For m ale subjects:
From  signing of informed consent, throughout the dura tion of  the study , and for 18 
weeks after last dose of study  medicat ion, nonsterilized** male subjects who are 
sexually  active wit h a female partner of childbearing potential* must use barrier 
contraception (eg, condom with spermicidal cream or jelly). In addition, they  must be 
advised not to donate sperm during this period.
For female subjects of childbearing potential:
From  signing of informed consent, throughout the duration of the study , and for 18 
weeks after last dose of study  medicat ion, female subje cts of  childbearing potential* 
who are sexually  active wi th a nonsterilized male partner** must use adequate 
contraception. In addit ion they  must be advised not to donate ova during this period.
*Females NOT of childbearing potential are defined as those w ho have been 
surgi cally sterilized (hysterectomy, bilateral oophorectomy  or tubal  ligat ion) or who 
are postm enopausal  (eg, defined as at l east 1 y ear since last regular menses with an 
FSH >40 IU/L or at least 5 y ears since l ast regul ar menses, confirmed be fore any 
study  medicat ion is implemented).
**Sterilized males should be at least 1 y ear post -vasectomy and have confirmed that 
Vedolizumab IV
Vedolizumab -4003 Page 124of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALthey have obtained documentation of the absence of sperm in the ejaculate.
An acceptable method of contraception is defined as o ne that has no higher than a 1% 
failure rate. In this study , where medicat ions and devices containing hormones are 
included, the only  acceptable methods of contraception are:
Barrier methods (each time 
the subject has intercourse):Intrauterine devices 
(IUDs):Hormonal 
contraceptives:
Male condom PLUS 
spermicide.
Cap (plus spermicidal crea m 
or jelly) PLUS m ale 
condom  and spermicide.
Diaphragm  (plus 
spermicidal cream or jelly) 
PLUS m ale condom  and 
spermicide.Copper T PLUS 
condom  or 
spermicide.
#Progesteron e T 
PLUS condom or 
spermicide.Implants.
Horm one 
shot/inject ion.
Combined pill.
Minipill.
Patch.
Vaginal ring PLUS 
male condo m and 
spermicide.
Subjects will be provided with informat ion on acceptable methods of contraception as 
part of the subject informe d consent process and will be asked to sign a consent form 
stating that they understand the requirements for avo idance of pregnancy, donation of 
ova, and sperm donation during the course of the study .
During the course of the study , regular urine hCG pregn ancy tests will be performed 
only for women of childbearing potential and subjects will receive cont inued guidance 
with respect to the avoidance of pregnancy  and sperm  donati on as part of the study  
procedures ( Appendix A ). In addi tion to a negat ive serum h CG pregnancy test at 
Screening, subjects also must have a negat ive urine hCG pregnancy test prior to 
receiving each IV dosing. At final study  visit or early  terminati on, subjects will have 
an addit ional serum  pregnancy  test.
Added text: 9.1.25.1 Male Subj ects and Their Female Partners
From signing of informed consent, throughout the duration of the study, and for 
18 weeks after last dose of study drug, nonsterilized** male subjects who are 
sexually active with a female partner of childbearing potential* mu st use barrier 
contraception (eg, condom with spermicidal cream or jelly). In addition, they 
must be advised not to donate sperm during this period. Women of childbearing 
potential who are partners of male subjects are also advised to use additional 
contra ception as shown in the list of highly effective contraception below.
9.1.25.2 Female Subjects and Their Male Partners
Vedolizumab IV
Vedolizumab -4003 Page 125of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALFrom signing of informed consent, throughout the duration of the study, and for 
18 weeks after last dose of study drug, female subjects o f childbearing potential* 
who are sexually active with a nonsterilized male partner** must use a highly 
effective method of contraception (from the list below). 
In addition, they must be advised not to donate ova during this period.
9.1.25.3 Definitions and Procedures for Contraception and Pregnancy Avoidance
The following definitions apply for contraception and pregnancy avoidance 
procedures.
* A woman is considered a woman of childbearing potential (ie, fertile) following 
menarche and until becoming post -menopausal unless permanently sterile. 
Permanent sterilization methods include hysterectomy, and bilateral 
oophorectomy. A post -menopausal state is defined as no menses for 12 months 
without an alternative medical cause. A high follicle -stimulating hormon e (FSH) 
level in the post -menopausal range (FSH >40 IU/L) may be used to confirm a 
post-menopausal state in younger women (ie, younger than age 45) or women 
who are not using hormonal contraception or hormonal replacement therapy. 
However, in the absence o f 12 months of amenorrhea, a single FSH measurement 
is insufficient.
** Sterilized males should be at least 1 year post -bilateral vasectomy and have 
confirmed that they have obtained documentation of the absence of sperm in the 
ejaculate or have had bilate ral orchidectomy.
The following procedures apply for contraception and pregnancy avoidance.
6.Highly effective methods of contraception are defined as “those that, alone or 
in combination, result in a low failure rate (ie, less than 1% failure rate per 
year when used consistently and correctly). In this study, where medications 
and devices containing hormones are included, the only acceptable methods 
of contraception are: 
Non-hormonal methods: 
Intrauterine device (IUD). 
Bilateral tubal occlusion. 
Vasectom ised partner (provided that partner is the sole sexual 
partner of the trial participant and that the vasectomised partner 
has received medical assessment of the surgical success. 
Hormonal methods: 
Combined (estrogen and progestogen) hormonal contraceptio n 
associated with inhibition of ovulation initiated at least 3 months 
prior to the first dose of study drug OR combined with a barrier 
method (male condom, female condom or diaphragm) if for 
shorter duration until she has been on contraceptive for 3 months ;
Vedolizumab IV
Vedolizumab -4003 Page 126of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALOral. 
Intravaginal (eg, ring).
Transdermal. 
Progestogen -only hormonal contraception associated with 
inhibition of ovulation1 initiated at least 3 months prior to the first 
dose of study drug OR combined with a barrier method (male 
condom, female condom or diaphragm) if shorter till she has been 
on contraceptive for 3 months;
Oral. 
Injectable.
Implantable.
7.Unacceptable methods of contraception are:
Periodic abstinence (eg, calendar, ovulation, symptothermal, 
post-ovulation methods).
Spermicides only.
Withdrawal.
No method at all.
Use of female and male condoms together.
Cap/diaphragm/sponge without spermicide and without condom.
Sexual abstinence is NOT an acceptable method of contraception.
8.Subjects will be provided with information on highly effective methods of 
contraception as part of the subject informed consent process and will be 
asked to sign a consent form stating that they understand the requirements 
for avoidance of pregnancy, donat ion of ova, and sperm donation during the 
course of the study.
9.During the course of the study, regular urine human chorionic gonadotropin 
(hCG) pregnancy tests will be performed only for women of childbearing 
potential and all subjects (male and female) wi ll receive continued guidance 
with respect to the avoidance of pregnancy and sperm donation as part of the 
study procedures. Such guidance should include a reminder of the following:
a.Contraceptive requirements of the study
b.Reasons for use of barrier method s (ie, condom) in males with 
pregnant partners
c.Assessment of subject compliance through questions such as
i.Have you used the contraception consistently and correctly 
since the last visit?
ii.Have you forgotten to use contraception since the last 
visit?
iii.Are yo ur menses late (even in women with irregular or 
infrequent menstrual cycles a pregnancy test must be 
performed if the answer is “yes”)?
Vedolizumab IV
Vedolizumab -4003 Page 127of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALiv.Is there a chance you could be pregnant?
10.In addition to a negative serum hCG pregnancy test at Screening, female 
subject s of childbearing potential must also have confirmed menses in the 
month before first dosing (no delayed menses) and a negative urine hCG 
pregnancy test prior to receiving each IV dosing.
9.1.25.4 General Guidance With Respect to the Avoidance of Pregnancy
Such guidance should include a reminder of the following:
Contraceptive requirements of the study.
Reasons for use of barrier methods (ie, condom) in males with pregnant 
partners.
Assessment of subject compliance through questions such as:
–Have you used t he contraception consistently and correctly since the last 
visit?
–Have you forgotten to use contraception since the last visit? 
–Are your menses late (even in women with irregular or infrequent 
menstrual cycles a pregnancy test must be performed if the ans wer is 
“yes”)?
–Is there a chance you could be pregnant?
Rationale for Change: 
To add updated language for contraception and pregnancy avo idance to clarify 
acceptable/unacceptable forms of contraception and appropriate guidance for patients with regard 
topregnancy avo idance during course of study  and to clarify that hi ghly effect ive contraception 
must be used in Appendix C.
Appendix CElements of the Subject Informed Consent also contains this change.
Change 27:Clarified the pregnancy form requirement for female partners of male subjects.
The primary  change occurs in Section 9.1.26 Pregnancy :
Added text: All pregnancies in subjects , including female partners of male subjects, on active 
study  drug including comparator will be followed up to final outcome, using the 
pregnancy form.
Rationale for Change:
To cl arify that pregnancy  is followed f or female partners of male subjects
Change 28: Added a requirement to document missed doses of ant ibiotic companio n medication.
The primary  change occurs in Se ction 9.2Moni toring Subject Treatment Compliance :
Added text: The site will also document missed doses of antibiotic companion medication.
Vedolizumab IV
Vedolizumab -4003 Page 128of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALRationale for Change:
To cl arify that missed doses of compani on medicatio n shoul d be docum ented.
Change 29: Changed wording in the safet y section from severity tointensity .
The primary  change occurs in Section 10.1.3 Additio nal Po ints to Consider for PTEs and AEs :
Initial 
wording:Changes in severit yof AEs /Seri ous PTEs:
If the subject experiences changes in severi tyof an AE/seri ous PTE, the event 
shoul d be captured once with the m aximum  severity is recorded.
Amended 
or new 
wording:Changes in severit yintensity of AEs/Serious PTEs:
If the subject experiences changes in severi tyintensity of an AE/serious PTE, the 
event should be captured once with the maximum severit yinten sityis recorded.
Rationale for Change:
Update to preferred safet y language
The fo llowing sect ions also contain this change:
Secti on 10.1.6 Intensity of PTEs and AEs .
Secti on 10.2.1.2 PTE and AE Reporting.
Secti on 13.1.6 Safet y Analysis .
Change 30: Added frequency to list of pretreatm ent event and adverse event reporting.
The primary  change occurs in Section 10.2.1.2 PTE and AE Reporting:
Added text: 3. Frequency
Rationale for Change:
Added per preferred safet y language.
Change 31: Clarified that AVA t iters are analyzed.
The primary  change occurs in Section 13.1.5 Anti-vedo lizumab Ant ibodies Analysis :
Added text: The propo rtion of subjects with posit ive and titers of AVA (transient and persistent), 
and proportion of subjects with positive neutralizing AVA during the study  will be 
summarized.
Rationale for Change:
To cl arify that ti ters of  AVA are included in analysis.
Change 32: Clarified that the subject diary for Crohn’s Disease Act ivity Index is el ectroni c.
Vedolizumab IV
Vedolizumab -4003 Page 129of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALThe primary  change occurs in Appendix ASchedule of Study  Procedures, footnote n:
Added text: (n) Subject electronic diary to be completed as per training instruction during screening 
interval. Subject electronic diary (CDAI and perianal pain) to be completed daily from 
Screening to Week 30.
Rationale for Change:
To cl arify that footno te (n) in Appendix A refers to electronic diary.
Secti on 9.1.15 CDAI Diary Co mpletionalso contains this change.
Change 33: Clarified when serum versus urine pregnancy testing done.
The primary change occurs in Appendix A Schedule of Study  Procedures:
Descript ion
of change:Row for “Pregnancy Testing” split into two rows to depict serum versus urine 
pregnancy testing. 
Serum  pregnancy  testing not e at Screening and Final Visit/Early Terminat ion.
Urine pregnancy  testing noted at Day  1, Weeks 2, 6, 10, 14, 22 and 40.
Rationale for Change:
To cl arify when serum or urine testing is required in the table instead of in the footn otes.
Change 34: Clarified that pregnancy testing is perform ed before study  drug dosing at dosing 
visits.
The primary change occurs in Appendix A Schedule of Study  Procedures, footnote m:
Initial 
wording:(m) Women of child bearing potential only. Urine pregnancy test ing will be conducted 
at the site and serum pregnancy  testing will  be conducted by  the central  laboratory . 
Serum  pregnancy co mpleted at Screening and Week 30/Early  Terminat ion; urine 
pregnancy to be completed at other visits.
Amended 
or new 
wording:(m) Women of childbearing potential only. Urine pregnancy test ing will be conducted 
at the site and serum pregnancy  testing will  be conducted by  the central  laboratory .
Serum  pregnancy co mpleted at Screening and Week 30/Early Terminat ion; urine 
pregnancy to be completed at other visits. At visits with study drug dosing, to be 
performed before any study drug dosing.
Rationale for Change:
To cl arify in footnote (m) that pregnancy  testing must be perform ed before study  drug dosing.
Change 35: Added an investigator responsibilit y per updated International Conference on 
Harm onisat ionguideline .
The primary  change occurs in Appendix BResponsibilit ies o f the Invest igator :
Vedolizumab IV
Vedolizumab -4003 Page 130of 130
Protocol Incorporating Amendment 05 20April2017
CONFIDENTIALAdded text: 13.  If the investigator/institution retains the services of any individual or party 
to perform trial -related duties and functions, the investigator/institution should 
ensure that this ind ividual or party is qualified to perform those trial -related 
duties and functions and should implement procedures to ensure the integrity of 
the trial -related duties and functions performed and any data generated.
Rationale for Change:
Added anew invest igator responsibilit y per update in ICH guideline
 䢢
䢢䢢䢢
䢢
䢢䢢
䢢
(/(&7521,& 6,*1$785(6 
Signed by Meaning of Signature Server Date 
(dd-MMM-yyyy HH:mm ‘UTC’) 

  

  

  

  

   


   


   


   


   


   


   


   


   


   


   


   


   


   


   



GGHH䣃䣯䣧䣰䣦䣯䣧䣰䣶䢢䢲䢷䢢䣶䣱䢢䣃䢢䣔䣣䣰䣦䣱䣯䣫䣼䣧䣦䢢䣆䣱䣷䣤䣮䣧䢯䣄䣮䣫䣰䣦䢢䣒䣪䣣䣵䣧䢢䢶䢢䣕䣶䣷䣦䣻䢢䣶䣱䢢䣇䣸䣣䣮 䣷䣣䣶䣧䢢䣶䣪䣧䢢䣕䣣䣨䣧䣶䣻䢢䣣䣰䣦䢢䣒䣴䣱䣲䣱䣴䣶䣫䣱䣰䢢䣱䣨䢢䣕䣷䣤䣬䣧䣥䣶䣵
䣙䣫䣶䣪䢢䣈䣫䣵䣶䣷䣮䣣䢢䣊䣧䣣䣮䣫䣰䣩䢢䣫䣰䢢䢴䢢䣆䣱䣵䣧䢢䣔䣧䣩䣫䣯䣧䣰䣵䢢䣱䣨䢢䣇䣰䣶䣻䣸䣫䣱䢢䢪䣘䣧䣦䣱䣮䣫䣼䣷䣯䣣䣤 䢢䣋䣘䢫䢢䣫䣰䢢䣶䣪䣧䢢䣖䣴䣧䣣䣶䣯䣧䣰䣶䢢䣱䣨䢢䣈䣫䣵䣶䣷䣮䣫䣼䣫䣰䣩䢢䣅䣴䣱䣪䣰䯑䣵
䣆䣫䣵䣧䣣䣵䣧䢢䢪䣇䣐䣖䣇䣔䣒䣔䣋䣕䣇䢫
3KDUPDFRYLJLODQFH$SSURYDO $SU87&
%LRVWDWLVWLFV$SSURYDO $SU87&
4XDOLW\&RQWURO$SSURYDO $SU87&
0HGLFDO$IIDLUV$SSURYDO $SU87&PPD